|
G |
CAPN1 |
calpain 1 |
multiple interactions |
EXP |
aloxistatin inhibits the reaction [CAPN1 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr11:65,181,373...65,212,006
Ensembl chr11:65,180,566...65,212,006
|
|
G |
CAPN7 |
calpain 7 |
multiple interactions |
EXP |
aloxistatin inhibits the reaction [CAPN7 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr 3:15,206,246...15,252,916
Ensembl chr 3:15,206,152...15,252,916
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP ISO |
[aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein] [Swainsonine co-treated with aloxistatin] results in increased cleavage of CASP3 protein |
CTD |
PMID:26853465 PMID:33186601 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of CASP9 protein] |
CTD |
PMID:34523043 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CTSB |
cathepsin B |
multiple interactions |
EXP |
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; aloxistatin inhibits the reaction [CTSB protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 PMID:32186374 |
|
NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533
|
|
G |
CTSD |
cathepsin D |
multiple interactions |
EXP |
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein |
CTD |
PMID:32186374 |
|
NCBI chr11:1,752,755...1,763,927
Ensembl chr11:1,752,752...1,764,573
|
|
G |
CTSL |
cathepsin L |
multiple interactions |
EXP |
aloxistatin inhibits the reaction [CTSL protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469
|
|
G |
DDX3X |
DEAD-box helicase 3 X-linked |
multiple interactions |
EXP |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein] |
CTD |
PMID:30821613 |
|
NCBI chr X:41,333,308...41,364,472
Ensembl chr X:41,333,348...41,364,472
|
|
G |
EIF4A1 |
eukaryotic translation initiation factor 4A1 |
multiple interactions |
EXP |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein] |
CTD |
PMID:30821613 |
|
NCBI chr17:7,572,825...7,579,006
Ensembl chr17:7,572,824...7,579,006
|
|
G |
EIF4H |
eukaryotic translation initiation factor 4H |
multiple interactions |
EXP |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein] |
CTD |
PMID:30821613 |
|
NCBI chr 7:74,174,356...74,197,096
Ensembl chr 7:74,174,231...74,197,122
|
|
G |
GAPDH |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
EXP |
aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of GAPDH protein] |
CTD |
PMID:34523043 |
|
NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374
|
|
G |
LAMP2 |
lysosomal associated membrane protein 2 |
multiple interactions |
EXP |
[aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein |
CTD |
PMID:32186374 |
|
NCBI chr X:120,426,148...120,469,349
Ensembl chr X:120,426,148...120,469,365
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions increases lipidation |
ISO EXP |
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in increased expression of MAP1LC3B protein aloxistatin results in increased lipidation of MAP1LC3B protein [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [ABTL0812 results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form; aloxistatin promotes the reaction [indatraline results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:26483381 PMID:27635674 PMID:32397857 PMID:33124469 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
SMN2 |
survival of motor neuron 2, centromeric |
multiple interactions |
EXP |
aloxistatin inhibits the reaction [CAPN1 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]; aloxistatin inhibits the reaction [CAPN7 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]; aloxistatin inhibits the reaction [CTSB protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]; aloxistatin inhibits the reaction [CTSL protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr 5:70,049,523...70,090,528
Ensembl chr 5:70,049,638...70,078,522 Ensembl chr 5:70,049,638...70,078,522
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions increases expression |
EXP ISO |
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; aloxistatin promotes the reaction [indatraline results in increased expression of SQSTM1 protein]; aloxistatin promotes the reaction [Sertraline results in increased expression of SQSTM1 protein] aloxistatin results in increased expression of SQSTM1 protein [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein |
CTD |
PMID:26483381 PMID:32186374 PMID:32773031 PMID:33124469 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]] |
CTD |
PMID:31348943 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:31348943 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased secretion of APP protein modified form] |
CTD |
PMID:22115781 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of BAX protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of BAX protein]] |
CTD |
PMID:21209419 PMID:34897970 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of BCL2 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in decreased expression of BCL2 protein]] |
CTD |
PMID:21209419 PMID:34897970 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BMP6 |
bone morphogenetic protein 6 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA] |
CTD |
PMID:23566955 |
|
NCBI chr 6:7,726,099...7,881,728
Ensembl chr 6:7,726,099...7,881,728
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP3 protein modified form]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of and results in increased activity of CASP3 protein |
CTD |
PMID:21209419 PMID:34897970 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP9 protein modified form]] |
CTD |
PMID:34897970 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CCND1 |
cyclin D1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of CCND1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CDH1 |
cadherin 1 |
multiple interactions |
EXP |
[N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester co-treated with 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one] inhibits the reaction [polyhexamethyleneguanidine results in decreased expression of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased secretion of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased cleavage of CDH1 protein] |
CTD |
PMID:18791180 PMID:31348943 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CDH2 |
cadherin 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of CDH2 protein] |
CTD |
PMID:23876460 |
|
NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946
|
|
G |
CSF1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of CSF1 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
|
|
G |
ENO2 |
enolase 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of ENO2 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr12:6,914,580...6,923,697
Ensembl chr12:6,913,745...6,923,698
|
|
G |
FLT1 |
fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of FLT1 protein] |
CTD |
PMID:21843347 |
|
NCBI chr13:28,300,346...28,495,128
Ensembl chr13:28,300,346...28,495,145
|
|
G |
FOXO3 |
forkhead box O3 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein] |
CTD |
PMID:25108166 |
|
NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774
|
|
G |
HES1 |
hes family bHLH transcription factor 1 |
multiple interactions decreases expression |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased expression of HES1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of HES1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HES1 mRNA] |
CTD |
PMID:19160421 PMID:24223152 PMID:25005833 PMID:25108166 PMID:32041402 PMID:36988346 More...
|
|
NCBI chr 3:194,136,148...194,138,732
Ensembl chr 3:194,136,148...194,138,732
|
|
G |
HEY1 |
hes related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 8:79,764,010...79,767,767
Ensembl chr 8:79,762,371...79,767,857
|
|
G |
HEY2 |
hes related family bHLH transcription factor with YRPW motif 2 |
multiple interactions |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Niclosamide results in increased expression of HEY2 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 PMID:32041402 |
|
NCBI chr 6:125,749,632...125,761,269
Ensembl chr 6:125,747,664...125,761,269
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein] |
CTD |
PMID:25108166 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HMGB1 |
high mobility group box 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of HMGB1 protein] |
CTD |
PMID:21843347 |
|
NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597
|
|
G |
IL10 |
interleukin 10 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL10 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Diethylhexyl Phthalate results in increased expression of IL1B protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA] |
CTD |
PMID:21843347 PMID:24223152 PMID:36988346 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL6 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] |
CTD |
PMID:21843347 PMID:24223152 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
ITGAM |
integrin subunit alpha M |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of ITGAM protein] |
CTD |
PMID:28130038 |
|
NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892
|
|
G |
IVL |
involucrin |
decreases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL protein |
CTD |
PMID:18633435 |
|
NCBI chr 1:152,908,546...152,911,886
Ensembl chr 1:152,908,546...152,911,886
|
|
G |
JAG1 |
jagged canonical Notch ligand 1 |
decreases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 protein |
CTD |
PMID:18633435 |
|
NCBI chr20:10,637,684...10,673,999
Ensembl chr20:10,637,684...10,673,999
|
|
G |
KRT1 |
keratin 1 |
multiple interactions decreases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT1 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT1 mRNA |
CTD |
PMID:18633435 PMID:23566955 |
|
NCBI chr12:52,674,736...52,680,407
Ensembl chr12:52,674,736...52,680,407
|
|
G |
KRT10 |
keratin 10 |
multiple interactions decreases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT10 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 protein |
CTD |
PMID:18633435 PMID:23566955 |
|
NCBI chr17:40,818,117...40,822,614
Ensembl chr17:40,818,117...40,822,614
|
|
G |
LGR5 |
leucine rich repeat containing G protein-coupled receptor 5 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of LGR5 mRNA] |
CTD |
PMID:32041402 |
|
NCBI chr12:71,439,129...71,586,310
Ensembl chr12:71,439,798...71,586,310
|
|
G |
MAP2 |
microtubule associated protein 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of MAP2 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr 2:209,424,047...209,734,112
Ensembl chr 2:209,424,047...209,734,147
|
|
G |
MDM2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
EXP |
Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of MDM2 protein] |
CTD |
PMID:25005833 |
|
NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544
|
|
G |
MIR141 |
microRNA 141 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in decreased expression of BCL2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of BAX protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP3 protein modified form]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP9 protein modified form]] |
CTD |
PMID:34897970 |
|
NCBI chr12:6,964,097...6,964,191
Ensembl chr12:6,964,097...6,964,191
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,552...38,143,024
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOTCH1 |
notch receptor 1 |
multiple interactions decreases expression |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [phenethyl isothiocyanate results in increased cleavage of and results in increased activity of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NOTCH1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of NOTCH1 protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Oxygen deficiency results in increased expression of NOTCH1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH1 protein modified form |
CTD |
PMID:18633435 PMID:22039516 PMID:22115781 PMID:24223152 PMID:25108166 PMID:25118938 PMID:28130038 PMID:31348943 PMID:36988346 More...
|
|
NCBI chr 9:136,494,433...136,546,048
Ensembl chr 9:136,494,433...136,546,048
|
|
G |
NOTCH2 |
notch receptor 2 |
multiple interactions decreases expression |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH2 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NOTCH2 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH2 protein |
CTD |
PMID:22039516 PMID:36988346 |
|
NCBI chr 1:119,911,553...120,069,662
Ensembl chr 1:119,911,553...120,100,779
|
|
G |
NOTCH3 |
notch receptor 3 |
decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH3 protein |
CTD |
PMID:36988346 |
|
NCBI chr19:15,159,038...15,200,995
Ensembl chr19:15,159,038...15,200,995
|
|
G |
NOTCH4 |
notch receptor 4 |
decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH4 protein |
CTD |
PMID:36988346 |
|
NCBI chr 6:32,194,843...32,224,067
Ensembl chr 6:32,194,843...32,224,067
|
|
G |
NUMB |
NUMB endocytic adaptor protein |
increases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of NUMB protein |
CTD |
PMID:25005833 |
|
NCBI chr14:73,275,216...73,458,546
Ensembl chr14:73,275,107...73,458,617
|
|
G |
PML |
PML nuclear body scaffold |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr15:73,994,716...74,047,827
Ensembl chr15:73,994,673...74,047,827
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of PPARA protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of PPARA protein] |
CTD |
PMID:36988346 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased expression of PTGS2 mRNA] |
CTD |
PMID:18791180 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RARA |
retinoic acid receptor alpha |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr17:40,309,180...40,357,643
Ensembl chr17:40,309,180...40,357,643
|
|
G |
RBPJ |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions increases expression |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RBPJ mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of RBPJ protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 PMID:24223152 |
|
NCBI chr 4:26,105,449...26,435,131
Ensembl chr 4:26,163,455...26,435,131
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of RELA protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RELA protein] |
CTD |
PMID:24223152 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TGFB1 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TLR4 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TP53 |
tumor protein p53 |
decreases expression multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein] |
CTD |
PMID:25005833 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
TRAF6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr11:36,483,769...36,510,272
Ensembl chr11:36,483,769...36,510,272
|
|
G |
TUBB3 |
tubulin beta 3 class III |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of TUBB3 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr16:89,921,925...89,936,097
Ensembl chr16:89,921,392...89,938,761
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein] |
CTD |
PMID:21843347 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VIL1 |
villin 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of VIL1 mRNA] |
CTD |
PMID:32041402 |
|
NCBI chr 2:218,419,123...218,453,295
Ensembl chr 2:218,419,121...218,453,295
|
|
|
G |
A4GALT |
alpha 1,4-galactosyltransferase (P1PK blood group) |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of A4GALT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr22:42,692,121...42,721,301
Ensembl chr22:42,692,121...42,721,298
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (JR blood group) |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
ADAMTS1 |
ADAM metallopeptidase with thrombospondin type 1 motif 1 |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein affects the expression of ADAMTS1 mRNA] |
CTD |
PMID:33316053 PMID:37552060 |
|
NCBI chr21:26,835,755...26,845,409
Ensembl chr21:26,835,755...26,845,409
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of ADIPOQ mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
ADRB3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of ADRB3 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 8:37,962,990...37,966,599
Ensembl chr 8:37,962,990...37,966,599
|
|
G |
AK5 |
adenylate kinase 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of AK5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:77,282,019...77,559,966
Ensembl chr 1:77,282,019...77,559,966
|
|
G |
ALDH1A1 |
aldehyde dehydrogenase 1 family member A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:30768133 |
|
NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442
|
|
G |
ALDH2 |
aldehyde dehydrogenase 2 family member |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of ALDH2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532
|
|
G |
ALDOC |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ALDOC mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDOC protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr17:28,573,120...28,576,895
Ensembl chr17:28,573,115...28,576,948
|
|
G |
AMHR2 |
anti-Mullerian hormone receptor type 2 |
increases expression |
ISO |
diisobutyl phthalate results in increased expression of AMHR2 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr12:53,423,855...53,431,672
Ensembl chr12:53,423,855...53,431,672
|
|
G |
AR |
androgen receptor |
affects binding multiple interactions |
ISO EXP |
diisobutyl phthalate binds to AR protein diisobutyl phthalate inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; diisobutyl phthalate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein] |
CTD |
PMID:14565775 PMID:15840436 PMID:28571686 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
ARNT2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:80,404,382...80,597,933
Ensembl chr15:80,404,350...80,597,933
|
|
G |
ASTN1 |
astrotactin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:176,857,321...177,164,712
Ensembl chr 1:176,857,302...177,164,973
|
|
G |
ASTN2 |
astrotactin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:116,423,112...117,415,057
Ensembl chr 9:116,423,112...117,415,070
|
|
G |
ATP1A3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:41,966,582...41,994,230
Ensembl chr19:41,966,582...41,997,497
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BAX mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BAX mRNA |
CTD |
PMID:28013214 PMID:37021957 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCAT1 |
branched chain amino acid transaminase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:24,810,024...24,949,340
Ensembl chr12:24,810,024...24,949,101
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BCL2 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of BCL2 mRNA |
CTD |
PMID:28013214 PMID:35762964 PMID:37021957 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L10 |
BCL2 like 10 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BCL2L10 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr15:52,109,263...52,112,775
Ensembl chr15:52,109,263...52,112,775
|
|
G |
BEND6 |
BEN domain containing 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BEND6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:56,955,107...57,027,346
Ensembl chr 6:56,955,107...57,027,346
|
|
G |
BPGM |
bisphosphoglycerate mutase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BPGM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:134,646,853...134,679,816
Ensembl chr 7:134,646,811...134,679,816
|
|
G |
CACNG7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CACNG7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:53,909,278...53,943,950
Ensembl chr19:53,909,278...53,943,950
|
|
G |
CADM3 |
cell adhesion molecule 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADM3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:159,171,615...159,203,313
Ensembl chr 1:159,171,609...159,203,313
|
|
G |
CADPS |
calcium dependent secretion activator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADPS mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:62,398,348...62,875,416
Ensembl chr 3:62,398,346...62,875,416
|
|
G |
CAMK4 |
calcium/calmodulin dependent protein kinase IV |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:111,223,583...111,494,886
Ensembl chr 5:111,223,653...111,494,886
|
|
G |
CASP2 |
caspase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CASP2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CASP3 mRNA |
CTD |
PMID:37839492 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAT mRNA |
CTD |
PMID:28013214 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CCL2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CCL5 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CCND2 |
cyclin D2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CCND2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353
|
|
G |
CDK4 |
cyclin dependent kinase 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CDK4 mRNA |
CTD |
PMID:35762964 |
|
NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CDKN1A mRNA |
CTD |
PMID:33316053 PMID:35762964 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:37839492 |
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369
|
|
G |
CDKN2A |
cyclin dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 9:21,967,752...21,995,324
Ensembl chr 9:21,967,752...21,995,301
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CEBPA mRNA |
CTD |
PMID:37021957 |
|
NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534
|
|
G |
CELSR3 |
cadherin EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CELSR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:48,636,463...48,662,886
Ensembl chr 3:48,636,463...48,662,886
|
|
G |
CGA |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein affects the expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CXCR4 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CYP11A1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of HSD3B2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PTX3 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of RGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of STAR mRNA]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] |
CTD |
PMID:33316053 PMID:37552060 |
|
NCBI chr 6:87,085,498...87,095,106
Ensembl chr 6:87,085,498...87,095,106
|
|
G |
CHGA |
chromogranin A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGA mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:92,922,664...92,935,285
Ensembl chr14:92,923,150...92,935,285
|
|
G |
CHGB |
chromogranin B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGB mRNA |
CTD |
PMID:31199487 |
|
NCBI chr20:5,911,510...5,925,353
Ensembl chr20:5,911,510...5,925,353
|
|
G |
CITED1 |
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CITED1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:72,301,646...72,307,157
Ensembl chr X:72,301,638...72,307,187
|
|
G |
CLSTN3 |
calsyntenin 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:7,129,093...7,158,945
Ensembl chr12:7,129,698...7,158,945
|
|
G |
CNTNAP1 |
contactin associated protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CNTNAP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:42,682,531...42,699,993
Ensembl chr17:42,682,531...42,699,993
|
|
G |
CRMP1 |
collapsin response mediator protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:5,820,764...5,893,086
Ensembl chr 4:5,748,084...5,893,086
|
|
G |
CXCR4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CXCR4 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr 2:136,114,349...136,118,149
Ensembl chr 2:136,114,349...136,119,177
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
decreases expression multiple interactions |
ISO EXP |
diisobutyl phthalate results in decreased expression of CYP11A1 mRNA; diisobutyl phthalate results in decreased expression of CYP11A1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CYP11A1 mRNA] [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11A1 mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:30802670 PMID:33983380 PMID:34597818 PMID:37552060 PMID:37788136 More...
|
|
NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646
|
|
G |
CYP11B1 |
cytochrome P450 family 11 subfamily B member 1 |
decreases expression multiple interactions |
ISO |
diisobutyl phthalate results in decreased expression of CYP11B1 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:22112501 PMID:33983380 |
|
NCBI chr 8:142,872,357...142,879,825
Ensembl chr 8:142,872,356...142,879,846
|
|
G |
CYP11B2 |
cytochrome P450 family 11 subfamily B member 2 |
multiple interactions decreases expression |
ISO |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11B2 mRNA diisobutyl phthalate results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 8:142,910,559...142,917,843
Ensembl chr 8:142,910,559...142,917,843
|
|
G |
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
decreases expression multiple interactions |
ISO |
diisobutyl phthalate results in decreased expression of CYP17A1 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP17A1 mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:22112501 PMID:28655647 PMID:30802670 PMID:33983380 PMID:37788136 |
|
NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472
|
|
G |
CYP19A1 |
cytochrome P450 family 19 subfamily A member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP19A1 mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:28013214 PMID:34597818 |
|
NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601
|
|
G |
CYP26B1 |
cytochrome P450 family 26 subfamily B member 1 |
multiple interactions |
ISO |
[diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in increased expression of CYP26B1 mRNA |
CTD |
PMID:37788136 |
|
NCBI chr 2:72,129,238...72,147,862
Ensembl chr 2:72,129,238...72,147,862
|
|
G |
CYP51A1 |
cytochrome P450 family 51 subfamily A member 1 |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of CYP51 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 7:92,112,153...92,134,803
Ensembl chr 7:92,084,987...92,134,803
|
|
G |
DCLK3 |
doublecortin like kinase 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DCLK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:36,712,421...36,764,553
Ensembl chr 3:36,712,421...36,764,553
|
|
G |
DDC |
dopa decarboxylase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DDC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:50,458,442...50,565,405
Ensembl chr 7:50,458,436...50,565,405
|
|
G |
DHCR7 |
7-dehydrocholesterol reductase |
multiple interactions decreases expression |
ISO |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of DHCR7 mRNA diisobutyl phthalate results in decreased expression of DHCR7 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr11:71,434,411...71,448,393
Ensembl chr11:71,428,193...71,452,868
|
|
G |
DOCK3 |
dedicator of cytokinesis 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DOCK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:50,674,927...51,384,198
Ensembl chr 3:50,674,927...51,384,198
|
|
G |
DPF1 |
double PHD fingers 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DPF1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:38,211,006...38,229,695
Ensembl chr19:38,211,006...38,229,714
|
|
G |
DYNC1I1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:95,772,554...96,110,322
Ensembl chr 7:95,772,506...96,110,322
|
|
G |
EBP |
EBP cholestenol delta-isomerase |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of EBP mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:48,521,808...48,528,716
Ensembl chr X:48,521,799...48,528,716
|
|
G |
ECE2 |
endothelin converting enzyme 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ECE2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:184,276,022...184,293,031
Ensembl chr 3:184,276,011...184,293,031
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
EDN2 |
endothelin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 1:41,478,775...41,484,683
Ensembl chr 1:41,478,775...41,484,683
|
|
G |
ELMOD1 |
ELMO domain containing 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:107,591,147...107,666,779
Ensembl chr11:107,591,091...107,666,779
|
|
G |
EMX2 |
empty spiracles homeobox 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EMX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:117,542,746...117,549,546
Ensembl chr10:117,542,445...117,549,546
|
|
G |
EPDR1 |
ependymin related 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EPDR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:37,920,640...37,951,936
Ensembl chr 7:37,920,640...37,951,936
|
|
G |
ESPN |
espin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESPN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:6,424,776...6,461,370
Ensembl chr 1:6,424,776...6,461,367
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions increases activity |
EXP ISO |
diisobutyl phthalate binds to and results in increased activity of ESR1 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Tamoxifen inhibits the reaction [diisobutyl phthalate binds to and results in increased activity of ESR1 protein] diisobutyl phthalate results in increased activity of ESR1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESR1 mRNA |
CTD |
PMID:15840436 PMID:27633901 PMID:28013214 PMID:28571686 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
multiple interactions increases activity |
EXP |
diisobutyl phthalate binds to and results in increased activity of ESR2 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] diisobutyl phthalate results in increased activity of ESR2 protein |
CTD |
PMID:27633901 PMID:28571686 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
FABP5 |
fatty acid binding protein 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FABP5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:81,280,536...81,284,775
Ensembl chr 8:81,280,536...81,284,777
|
|
G |
FAM163A |
family with sequence similarity 163 member A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FAM163A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:179,727,776...179,816,198
Ensembl chr 1:179,743,291...179,816,198
|
|
G |
FDPS |
farnesyl diphosphate synthase |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of FDPS mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 1:155,308,866...155,320,665
Ensembl chr 1:155,308,748...155,320,666
|
|
G |
FEZ1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:125,442,881...125,496,265
Ensembl chr11:125,442,881...125,592,568
|
|
G |
FGF2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of FGF2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236
|
|
G |
FKBP1B |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FKBP1B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:24,033,206...24,063,681
Ensembl chr 2:24,049,701...24,063,681
|
|
G |
FLG |
filaggrin |
multiple interactions |
EXP |
[FLG gene polymorphism affects the susceptibility to diisobutyl phthalate] which affects the abundance of mono-isobutyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 1:152,302,165...152,325,239
Ensembl chr 1:152,302,165...152,325,239
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
[Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of FSHB protein |
CTD |
PMID:34597818 |
|
NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261
|
|
G |
FSHR |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FSHR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 2:48,962,157...49,154,515
Ensembl chr 2:48,962,157...49,154,527
|
|
G |
FXYD7 |
FXYD domain containing ion transport regulator 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FXYD7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:35,143,255...35,154,302
Ensembl chr19:35,143,250...35,154,302
|
|
G |
GFRA3 |
GDNF family receptor alpha 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:138,252,380...138,274,621
Ensembl chr 5:138,252,380...138,274,621
|
|
G |
GFRA4 |
GDNF family receptor alpha 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr20:3,659,248...3,663,399
Ensembl chr20:3,659,248...3,663,399
|
|
G |
GGTA1 |
glycoprotein alpha-galactosyltransferase 1 (inactive) |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GGTA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:121,444,990...121,499,844
Ensembl chr 9:121,444,991...121,499,844
|
|
G |
GNG2 |
G protein subunit gamma 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GNG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:51,826,174...51,969,795
Ensembl chr14:51,826,195...51,979,342
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of GPX1 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:28013214 PMID:37021957 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of HMGCR mRNA |
CTD |
PMID:28655647 PMID:33983380 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMGCS1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:28655647 PMID:33983380 |
|
NCBI chr 5:43,287,470...43,313,412
Ensembl chr 5:43,287,470...43,313,512
|
|
G |
HOXB8 |
homeobox B8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXB8 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:48,612,346...48,615,292
Ensembl chr17:48,611,377...48,615,292
|
|
G |
HOXD3 |
homeobox D3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXD3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:176,152,529...176,173,098
Ensembl chr 2:176,136,612...176,173,102
|
|
G |
HSD17B3 |
hydroxysteroid 17-beta dehydrogenase 3 |
increases expression |
ISO |
diisobutyl phthalate results in increased expression of HSD17B3 mRNA |
CTD |
PMID:28655647 |
|
NCBI chr 9:96,235,306...96,302,176
Ensembl chr 9:96,235,306...96,302,176
|
|
G |
HSD3B1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSD3B1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of HSD3B1 mRNA |
CTD |
PMID:28013214 PMID:35762964 |
|
NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054
|
|
G |
HSD3B2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr 1:119,414,931...119,423,034
Ensembl chr 1:119,414,931...119,423,035
|
|
G |
HSPA12A |
heat shock protein family A (Hsp70) member 12A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSPA12A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:116,671,192...116,850,747
Ensembl chr10:116,671,192...116,850,251
|
|
G |
IDO2 |
indoleamine 2,3-dioxygenase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of IDO2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:39,934,651...40,016,392
Ensembl chr 8:39,934,614...40,016,392
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of IL1B mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INHA |
inhibin subunit alpha |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of INHA mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 2:219,572,310...219,575,711
Ensembl chr 2:219,569,162...219,575,711
|
|
G |
INSIG1 |
insulin induced gene 1 |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of INSIG1 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
|
|
G |
INSL3 |
insulin like 3 |
decreases expression multiple interactions |
ISO |
diisobutyl phthalate results in decreased expression of INSL3 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of INSL3 mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of INSL3 mRNA |
CTD |
PMID:22112501 PMID:33983380 PMID:37788136 |
|
NCBI chr19:17,816,512...17,821,519
Ensembl chr19:17,816,512...17,821,574
|
|
G |
KIF5A |
kinesin family member 5A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KIF5A protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5A mRNA |
CTD |
PMID:37690569 |
|
NCBI chr12:57,550,044...57,586,633
Ensembl chr12:57,546,026...57,586,633
|
|
G |
KIF5C |
kinesin family member 5C |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:148,875,227...149,026,759
Ensembl chr 2:148,875,227...149,026,759
|
|
G |
L1CAM |
L1 cell adhesion molecule |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of L1CAM mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of L1CAM protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr X:153,861,514...153,886,173
Ensembl chr X:153,861,514...153,886,173
|
|
G |
LCN2 |
lipocalin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LCN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453
|
|
G |
LDLR |
low density lipoprotein receptor |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of LDLR mRNA |
CTD |
PMID:33983380 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased secretion of LHB protein |
CTD |
PMID:37839492 |
|
NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091
|
|
G |
LHCGR |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of LHCGR mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 2:48,686,774...48,755,724
Ensembl chr 2:48,686,774...48,755,730
|
|
G |
LONRF2 |
LON peptidase N-terminal domain and ring finger 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LONRF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:100,271,875...100,322,501
Ensembl chr 2:100,271,875...100,322,501
|
|
G |
LPL |
lipoprotein lipase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of LPL mRNA |
CTD |
PMID:30768133 |
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
G |
LRRC4B |
leucine rich repeat containing 4B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LRRC4B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:50,516,892...50,568,435
Ensembl chr19:50,516,892...50,568,435
|
|
G |
LYNX1 |
Ly6/neurotoxin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:142,771,197...142,777,872
Ensembl chr 8:142,771,197...142,777,810
|
|
G |
MAP6 |
microtubule associated protein 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAP6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:75,586,918...75,669,038
Ensembl chr11:75,586,918...75,669,038
|
|
G |
MAPT |
microtubule associated protein tau |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAPT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334
|
|
G |
MIR141 |
microRNA 141 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR141 |
CTD |
PMID:31199487 |
|
NCBI chr12:6,964,097...6,964,191
Ensembl chr12:6,964,097...6,964,191
|
|
G |
MIR184 |
microRNA 184 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184 mRNA |
CTD |
PMID:31199487 PMID:35762964 |
|
NCBI chr15:79,209,788...79,209,871
Ensembl chr15:79,209,788...79,209,871
|
|
G |
MLLT11 |
MLLT11 transcription factor 7 cofactor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MLLT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:151,060,397...151,069,544
Ensembl chr 1:151,060,397...151,069,544
|
|
G |
MMP14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr14:22,836,585...22,847,758
Ensembl chr14:22,836,560...22,849,041
|
|
G |
MMP16 |
matrix metallopeptidase 16 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 8:88,032,011...88,327,483
Ensembl chr 8:88,032,011...88,328,025
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MVD |
mevalonate diphosphate decarboxylase |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of MVD mRNA |
CTD |
PMID:33983380 |
|
NCBI chr16:88,651,940...88,663,091
Ensembl chr16:88,651,935...88,663,161
|
|
G |
NCS1 |
neuronal calcium sensor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NCS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:130,172,404...130,237,303
Ensembl chr 9:130,172,404...130,237,303
|
|
G |
NDRG4 |
NDRG family member 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NDRG4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr16:58,463,715...58,515,387
Ensembl chr16:58,462,846...58,513,628
|
|
G |
NEFH |
neurofilament heavy chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr22:29,480,218...29,491,390
Ensembl chr22:29,480,218...29,491,390
|
|
G |
NEFL |
neurofilament light chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFL mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:24,950,955...24,956,612
Ensembl chr 8:24,950,955...24,956,721
|
|
G |
NELL1 |
neural EGFL like 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NELL1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:20,669,551...21,575,686
Ensembl chr11:20,669,551...21,575,686
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of NFE2L2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NGFR |
nerve growth factor receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NGFR mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:49,495,293...49,515,008
Ensembl chr17:49,495,293...49,515,008
|
|
G |
NR0B1 |
nuclear receptor subfamily 0 group B member 1 |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of NR0B1 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:30,304,206...30,309,390
Ensembl chr X:30,304,206...30,309,390
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
diisobutyl phthalate results in increased activity of NR1I2 protein alternative form |
CTD |
PMID:21227907 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
multiple interactions affects binding increases activity |
EXP |
[diisobutyl phthalate co-treated with Androstanols] results in increased activity of NR1I3 protein alternative form diisobutyl phthalate binds to NR1I3 protein diisobutyl phthalate results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:21227907 PMID:25938866 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
NRXN2 |
neurexin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:64,606,174...64,723,197
Ensembl chr11:64,606,174...64,723,197
|
|
G |
NSDHL |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of NSDHL mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:152,831,063...152,869,729
Ensembl chr X:152,830,967...152,869,729
|
|
G |
NSG1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:4,386,532...4,419,058
Ensembl chr 4:4,348,140...4,419,058
|
|
G |
NSG2 |
neuronal vesicle trafficking associated 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:174,045,706...174,109,179
Ensembl chr 5:174,045,706...174,243,501
|
|
G |
OLFM1 |
olfactomedin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of OLFM1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:135,075,505...135,121,184
Ensembl chr 9:135,075,422...135,121,180
|
|
G |
PCP4 |
Purkinje cell protein 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PCP4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr21:39,867,438...39,929,392
Ensembl chr21:39,867,438...39,929,397
|
|
G |
PGR |
progesterone receptor |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] |
CTD |
PMID:33316053 PMID:37552060 |
|
NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813
|
|
G |
PLAT |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 8:42,174,718...42,207,565
Ensembl chr 8:42,174,718...42,207,709
|
|
G |
PLIN1 |
perilipin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of PLIN1 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr15:89,664,367...89,679,367
Ensembl chr15:89,664,367...89,679,427
|
|
G |
PLPPR3 |
phospholipid phosphatase related 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLPPR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:812,488...823,797
Ensembl chr19:812,488...821,955
|
|
G |
PLS1 |
plastin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:142,596,393...142,713,664
Ensembl chr 3:142,596,393...142,713,664
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPARA mRNA |
CTD |
PMID:28013214 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression increases activity |
EXP |
diisobutyl phthalate binds to and results in increased activity of PPARG protein diisobutyl phthalate results in increased expression of PPARG protein diisobutyl phthalate results in increased activity of PPARG protein |
CTD |
PMID:24155963 PMID:26172262 PMID:27633901 PMID:29061543 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PPP2R2B |
protein phosphatase 2 regulatory subunit Bbeta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:146,580,742...147,081,520
Ensembl chr 5:146,580,742...147,084,784
|
|
G |
PRIMA1 |
proline rich membrane anchor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRIMA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:93,718,298...93,788,994
Ensembl chr14:93,718,298...93,788,485
|
|
G |
PRPH |
peripherin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRPH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:49,295,147...49,298,686
Ensembl chr12:49,295,147...49,298,686
|
|
G |
PTGES |
prostaglandin E synthase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGES mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042
|
|
G |
PTGR1 |
prostaglandin reductase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:111,549,722...111,599,647
Ensembl chr 9:111,549,722...111,599,893
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PTPRN |
protein tyrosine phosphatase receptor type N |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTPRN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:219,289,623...219,309,401
Ensembl chr 2:219,289,623...219,309,648
|
|
G |
PTX3 |
pentraxin 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PTX3 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr 3:157,436,850...157,443,633
Ensembl chr 3:157,436,850...157,443,633
|
|
G |
QSOX1 |
quiescin sulfhydryl oxidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of QSOX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:180,154,869...180,204,030
Ensembl chr 1:180,154,869...180,204,030
|
|
G |
RAB3B |
RAB3B, member RAS oncogene family |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 1:51,907,956...51,990,700
Ensembl chr 1:51,907,956...51,990,700
|
|
G |
RAB6B |
RAB6B, member RAS oncogene family |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 3:133,824,235...133,895,882
Ensembl chr 3:133,824,235...133,895,882
|
|
G |
RASSF4 |
Ras association domain family member 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RASSF4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:44,959,802...44,995,891
Ensembl chr10:44,959,407...44,995,891
|
|
G |
RESP18 |
regulated endocrine specific protein 18 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RESP18 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:219,327,407...219,336,656
Ensembl chr 2:219,327,407...219,333,177
|
|
G |
RGS2 |
regulator of G protein signaling 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of RGS2 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr 1:192,809,039...192,812,275
Ensembl chr 1:192,809,039...192,812,275
|
|
G |
RNF183 |
ring finger protein 183 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of RNF183 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:113,297,093...113,303,376
Ensembl chr 9:113,297,093...113,303,376
|
|
G |
RTN1 |
reticulon 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:59,595,976...59,870,776
Ensembl chr14:59,595,976...59,870,776
|
|
G |
RTN4R |
reticulon 4 receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN4R mRNA |
CTD |
PMID:31199487 |
|
NCBI chr22:20,241,415...20,268,318
Ensembl chr22:20,241,415...20,283,246
|
|
G |
RXRG |
retinoid X receptor gamma |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of RXRG mRNA |
CTD |
PMID:22112501 |
|
NCBI chr 1:165,400,922...165,445,126
Ensembl chr 1:165,400,922...165,445,355
|
|
G |
SCARB1 |
scavenger receptor class B member 1 |
decreases expression multiple interactions |
ISO |
diisobutyl phthalate results in decreased expression of SCARB1 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of SCARB1 mRNA |
CTD |
PMID:22112501 PMID:28655647 PMID:33983380 |
|
NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
|
|
G |
SCG3 |
secretogranin III |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCG3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:51,681,503...51,721,026
Ensembl chr15:51,681,492...51,721,026
|
|
G |
SCN3B |
sodium voltage-gated channel beta subunit 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCN3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:123,629,188...123,654,624
Ensembl chr11:123,629,187...123,655,244
|
|
G |
SCRN1 |
secernin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCRN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:29,920,103...29,990,289
Ensembl chr 7:29,920,104...29,990,289
|
|
G |
SERPINB2 |
serpin family B member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr18:63,887,705...63,903,888
Ensembl chr18:63,871,692...63,903,888
|
|
G |
SERPINE1 |
serpin family E member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SH3GL3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3GL3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:83,447,341...83,633,820
Ensembl chr15:83,447,228...83,618,743
|
|
G |
SH3TC2 |
SH3 domain and tetratricopeptide repeats 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3TC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:148,982,150...149,063,062
Ensembl chr 5:148,923,639...149,063,163
|
|
G |
SHC2 |
SHC adaptor protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SHC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:416,589...461,033
Ensembl chr19:416,589...461,033
|
|
G |
SLC13A2 |
solute carrier family 13 member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC13A2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:28,473,644...28,497,781
Ensembl chr17:28,473,293...28,497,781
|
|
G |
SLC29A4 |
solute carrier family 29 member 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:5,282,943...5,306,912
Ensembl chr 7:5,274,369...5,306,912
|
|
G |
SLC5A7 |
solute carrier family 5 member 7 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC5A7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:107,986,524...108,013,994
Ensembl chr 2:107,986,523...108,013,994
|
|
G |
SLCO2A1 |
solute carrier organic anion transporter family member 2A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 3:133,932,701...134,029,925
Ensembl chr 3:133,932,701...134,052,184
|
|
G |
SMIM24 |
small integral membrane protein 24 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SMIM24 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:3,473,986...3,480,525
Ensembl chr19:3,473,986...3,480,525
|
|
G |
SNHG11 |
small nucleolar RNA host gene 11 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SNHG11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr20:38,446,654...38,450,921
Ensembl chr20:38,446,343...38,450,940
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SOD1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOX9 |
SRY-box transcription factor 9 |
increases expression |
ISO |
diisobutyl phthalate results in increased expression of SOX9 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416
|
|
G |
STAR |
steroidogenic acute regulatory protein |
decreases expression multiple interactions |
ISO EXP |
diisobutyl phthalate results in decreased expression of STAR mRNA; diisobutyl phthalate results in decreased expression of STAR protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of STAR mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of STAR mRNA; [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of STAR mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in increased expression of STAR mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of STAR mRNA |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:28655647 PMID:30802670 PMID:33983380 PMID:34597818 PMID:35762964 PMID:37552060 PMID:37788136 PMID:37839492 More...
|
|
NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992
|
|
G |
STK32C |
serine/threonine kinase 32C |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STK32C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:132,207,482...132,332,235
Ensembl chr10:132,207,492...132,331,847
|
|
G |
STMN4 |
stathmin 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STMN4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:27,235,308...27,258,404
Ensembl chr 8:27,235,308...27,258,420
|
|
G |
SYT11 |
synaptotagmin 11 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:155,859,567...155,885,199
Ensembl chr 1:155,859,567...155,885,199
|
|
G |
SYT5 |
synaptotagmin 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:55,171,196...55,180,289
Ensembl chr19:55,171,196...55,180,289
|
|
G |
TBX2 |
T-box transcription factor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TBX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:61,399,843...61,409,466
Ensembl chr17:61,399,843...61,409,466
|
|
G |
TCF23 |
transcription factor 23 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCF23 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:27,149,004...27,156,974
Ensembl chr 2:27,149,004...27,156,974
|
|
G |
TCTE1 |
t-complex-associated-testis-expressed 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCTE1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:44,278,734...44,297,698
Ensembl chr 6:44,278,734...44,297,698
|
|
G |
THRB |
thyroid hormone receptor beta |
multiple interactions |
EXP |
diisobutyl phthalate binds to and results in decreased activity of THRB protein |
CTD |
PMID:27633901 |
|
NCBI chr 3:24,117,153...24,495,708
Ensembl chr 3:24,117,153...24,495,756
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
G |
TM7SF2 |
transmembrane 7 superfamily member 2 |
decreases expression |
ISO |
diisobutyl phthalate results in decreased expression of TM7SF2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr11:65,111,872...65,116,230
Ensembl chr11:65,111,845...65,116,384
|
|
G |
TMEFF2 |
transmembrane protein with EGF like and two follistatin like domains 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEFF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:191,949,046...192,194,933
Ensembl chr 2:191,949,043...192,194,933
|
|
G |
TMEM130 |
transmembrane protein 130 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM130 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:98,846,490...98,870,014
Ensembl chr 7:98,846,488...98,870,771
|
|
G |
TMEM35A |
transmembrane protein 35A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:101,078,879...101,096,367
Ensembl chr X:101,078,879...101,096,367
|
|
G |
TMEM63C |
transmembrane protein 63C |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM63C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:77,181,798...77,259,495
Ensembl chr14:77,116,568...77,259,495
|
|
G |
TRPC6 |
transient receptor potential cation channel subfamily C member 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TRPC6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:101,451,564...101,584,007
Ensembl chr11:101,451,564...101,872,562
|
|
G |
TSHB |
thyroid stimulating hormone subunit beta |
multiple interactions |
EXP |
[diisobutyl phthalate results in increased abundance of mono-isobutyl phthalate] which results in decreased secretion of TSHB protein |
CTD |
PMID:29734584 |
|
NCBI chr 1:115,029,826...115,034,309
Ensembl chr 1:115,029,826...115,034,302
|
|
G |
TTYH1 |
tweety family member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TTYH1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:54,415,464...54,436,904
Ensembl chr19:54,415,219...54,436,904
|
|
G |
TUBB2B |
tubulin beta 2B class IIb |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB2B protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB2B mRNA |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 6:3,224,277...3,227,653
Ensembl chr 6:3,223,324...3,231,730
|
|
G |
TUBB3 |
tubulin beta 3 class III |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB3 protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB3 mRNA |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr16:89,921,925...89,936,097
Ensembl chr16:89,921,392...89,938,761
|
|
G |
TUBB4A |
tubulin beta 4A class IVa |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB4A protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB4A mRNA |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr19:6,494,319...6,502,848
Ensembl chr19:6,494,319...6,502,848
|
|
G |
UBASH3B |
ubiquitin associated and SH3 domain containing B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBASH3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:122,655,722...122,814,473
Ensembl chr11:122,655,722...122,814,473
|
|
G |
UBXN11 |
UBX domain protein 11 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBXN11 mRNA |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 1:26,282,282...26,318,355
Ensembl chr 1:26,281,328...26,318,363
|
|
G |
UCP1 |
uncoupling protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of UCP1 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 4:140,559,431...140,568,961
Ensembl chr 4:140,559,431...140,568,961
|
|
G |
WNT4 |
Wnt family member 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 1:22,117,313...22,143,097
Ensembl chr 1:22,117,313...22,143,969
|
|
G |
WNT6 |
Wnt family member 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:218,859,805...218,874,233
Ensembl chr 2:218,859,805...218,874,233
|
|
G |
WNT9B |
Wnt family member 9B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT9B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:46,833,189...46,886,738
Ensembl chr17:46,833,201...46,886,730
|
|
G |
WT1 |
WT1 transcription factor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:32,387,775...32,435,539
Ensembl chr11:32,387,775...32,435,564
|
|
G |
ZCCHC12 |
zinc finger CCHC-type containing 12 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZCCHC12 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:118,823,824...118,826,968
Ensembl chr X:118,823,824...118,826,968
|
|
G |
ZFAT |
zinc finger and AT-hook domain containing |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ZFAT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:134,477,788...134,832,339
Ensembl chr 8:134,477,788...134,713,049
|
|
G |
ZP2 |
zona pellucida glycoprotein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZP2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr16:21,197,450...21,214,510
Ensembl chr16:21,197,450...21,214,510
|
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of ABCA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
decreases activity |
ISO |
fenpyroximate results in decreased activity of ACHE protein |
CTD |
PMID:35580743 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
AKR1B1 |
aldo-keto reductase family 1 member B |
decreases expression |
EXP |
fenpyroximate results in decreased expression of AKR1B1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284
|
|
G |
AKR7A2 |
aldo-keto reductase family 7 member A2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,144
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of AKT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ALDH9A1 |
aldehyde dehydrogenase 9 family member A1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ALDH9A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:165,662,216...165,698,562
Ensembl chr 1:165,662,216...165,698,562
|
|
G |
AMER1 |
APC membrane recruitment protein 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of AMER1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:64,185,117...64,205,708
Ensembl chr X:64,185,117...64,205,708
|
|
G |
ANO10 |
anoctamin 10 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ANO10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:43,365,848...43,691,594
Ensembl chr 3:43,354,859...43,691,594
|
|
G |
AP3M1 |
adaptor related protein complex 3 subunit mu 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of AP3M1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:74,120,255...74,150,828
Ensembl chr10:74,120,255...74,150,842
|
|
G |
APEX1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of APEX1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:20,455,226...20,457,767
Ensembl chr14:20,455,191...20,457,772
|
|
G |
ARG1 |
arginase 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ARG1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 6:131,573,226...131,584,329
Ensembl chr 6:131,470,832...131,584,332
|
|
G |
ARHGAP9 |
Rho GTPase activating protein 9 |
increases expression |
EXP |
fenpyroximate results in increased expression of ARHGAP9 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:57,472,269...57,488,824
Ensembl chr12:57,472,264...57,488,814
|
|
G |
ARRDC4 |
arrestin domain containing 4 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ARRDC4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:97,960,703...97,973,833
Ensembl chr15:97,960,703...97,973,833
|
|
G |
ASNS |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
EXP |
fenpyroximate results in increased expression of ASNS mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:97,851,677...97,928,441
Ensembl chr 7:97,851,677...97,872,542
|
|
G |
ASS1 |
argininosuccinate synthase 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of ASS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:130,444,707...130,501,274
Ensembl chr 9:130,444,961...130,501,274
|
|
G |
ATF4 |
activating transcription factor 4 |
increases expression |
EXP |
fenpyroximate results in increased expression of ATF4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683
|
|
G |
ATF5 |
activating transcription factor 5 |
increases expression |
EXP |
fenpyroximate results in increased expression of ATF5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:49,928,906...49,933,935
Ensembl chr19:49,928,702...49,933,935
|
|
G |
ATMIN |
ATM interactor |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ATMIN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:81,035,842...81,047,350
Ensembl chr16:81,035,842...81,047,350
|
|
G |
ATP5F1B |
ATP synthase F1 subunit beta |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ATP5F1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:56,638,175...56,645,984
Ensembl chr12:56,638,175...56,645,984
|
|
G |
ATP5F1C |
ATP synthase F1 subunit gamma |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ATP5F1C mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:7,788,177...7,807,801
Ensembl chr10:7,788,147...7,807,815
|
|
G |
ATP6V1B2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ATP6V1B2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:20,197,381...20,221,696
Ensembl chr 8:20,197,381...20,226,819
|
|
G |
AURKA |
aurora kinase A |
increases expression |
EXP |
fenpyroximate results in increased expression of AURKA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:56,369,390...56,392,215
Ensembl chr20:56,369,389...56,392,337
|
|
G |
B2M |
beta-2-microglobulin |
increases expression |
EXP |
fenpyroximate results in increased expression of B2M mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:44,711,517...44,718,145
Ensembl chr15:44,711,358...44,718,851
|
|
G |
B3GALT6 |
beta-1,3-galactosyltransferase 6 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of B3GALT6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:1,232,237...1,235,041
Ensembl chr 1:1,232,237...1,235,041
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
fenpyroximate results in increased expression of BAX mRNA |
CTD |
PMID:36933581 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
EXP |
fenpyroximate results in decreased expression of BCL2 mRNA |
CTD |
PMID:36933581 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L13 |
BCL2 like 13 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of BCL2L13 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr22:17,628,877...17,730,855
Ensembl chr22:17,628,855...17,730,855
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
increases expression |
EXP |
fenpyroximate results in increased expression of BIRC5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
BMF |
Bcl2 modifying factor |
decreases expression |
EXP |
fenpyroximate results in decreased expression of BMF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:40,087,890...40,108,879
Ensembl chr15:40,087,890...40,108,892
|
|
G |
BPHL |
biphenyl hydrolase like |
decreases expression |
EXP |
fenpyroximate results in decreased expression of BPHL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:3,118,376...3,153,578
Ensembl chr 6:3,118,374...3,153,578
|
|
G |
BZW1 |
basic leucine zipper and W2 domains 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of BZW1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:200,811,589...200,827,338
Ensembl chr 2:200,810,594...200,827,338
|
|
G |
C2CD5 |
C2 calcium dependent domain containing 5 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of C2CD5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:22,448,583...22,544,542
Ensembl chr12:22,448,583...22,544,546
|
|
G |
CANX |
calnexin |
increases expression |
EXP |
fenpyroximate results in increased expression of CANX mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:179,678,656...179,731,641
Ensembl chr 5:179,678,628...179,731,641
|
|
G |
CARS1 |
cysteinyl-tRNA synthetase 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of CARS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:3,000,929...3,057,423
Ensembl chr11:3,000,922...3,057,613
|
|
G |
CASP3 |
caspase 3 |
increases activity multiple interactions |
EXP |
fenpyroximate results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [fenpyroximate results in increased activity of CASP3 protein] |
CTD |
PMID:35580743 PMID:36933581 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP9 |
caspase 9 |
increases activity |
EXP |
fenpyroximate results in increased activity of CASP9 protein |
CTD |
PMID:36933581 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
increases activity affects activity |
EXP ISO |
fenpyroximate results in increased activity of CAT protein fenpyroximate affects the activity of CAT protein |
CTD |
PMID:35580743 PMID:36933581 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CBR1 |
carbonyl reductase 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CBR1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166
|
|
G |
CBX4 |
chromobox 4 |
increases expression |
EXP |
fenpyroximate results in increased expression of CBX4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:79,833,156...79,839,440
Ensembl chr17:79,833,156...79,839,440
|
|
G |
CCNB1 |
cyclin B1 |
increases expression |
EXP |
fenpyroximate results in increased expression of CCNB1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245
|
|
G |
CCNB2 |
cyclin B2 |
increases expression |
EXP |
fenpyroximate results in increased expression of CCNB2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:59,105,146...59,125,045
Ensembl chr15:59,105,126...59,125,045
|
|
G |
CD24 |
CD24 molecule |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CD24 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:106,969,831...106,976,855
Ensembl chr 6:106,969,831...106,975,627
|
|
G |
CDH10 |
cadherin 10 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CDH10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:24,487,100...24,644,978
Ensembl chr 5:24,487,100...24,644,978
|
|
G |
CDH2 |
cadherin 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CDH2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of CDK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
|
|
G |
CDK5R1 |
cyclin dependent kinase 5 regulatory subunit 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CDK5R1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:32,486,993...32,491,253
Ensembl chr17:32,486,993...32,491,253
|
|
G |
CDK6 |
cyclin dependent kinase 6 |
increases expression |
EXP |
fenpyroximate results in increased expression of CDK6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:92,604,921...92,836,573
Ensembl chr 7:92,604,921...92,836,573
|
|
G |
CDKN3 |
cyclin dependent kinase inhibitor 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of CDKN3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:54,397,007...54,420,218
Ensembl chr14:54,396,849...54,420,218
|
|
G |
CEBPB |
CCAAT enhancer binding protein beta |
increases expression |
EXP |
fenpyroximate results in increased expression of CEBPB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,830...50,192,668
|
|
G |
CEL |
carboxyl ester lipase |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CEL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:133,061,981...133,071,861
Ensembl chr 9:133,061,981...133,071,861
|
|
G |
CFL2 |
cofilin 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CFL2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:34,709,113...34,714,593
Ensembl chr14:34,709,113...34,714,823
|
|
G |
CHAC1 |
ChaC glutathione specific gamma-glutamylcyclotransferase 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of CHAC1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:40,953,471...40,956,512
Ensembl chr15:40,952,962...40,956,512
|
|
G |
CHEK1 |
checkpoint kinase 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of CHEK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:125,625,136...125,681,124
Ensembl chr11:125,625,163...125,676,255
|
|
G |
CHKA |
choline kinase alpha |
increases expression |
EXP |
fenpyroximate results in increased expression of CHKA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:68,052,859...68,121,388
Ensembl chr11:68,052,859...68,121,444
|
|
G |
CKS1B |
CDC28 protein kinase regulatory subunit 1B |
increases expression |
EXP |
fenpyroximate results in increased expression of CKS1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:154,974,681...154,979,251
Ensembl chr 1:154,974,653...154,979,251
|
|
G |
CKS2 |
CDC28 protein kinase regulatory subunit 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of CKS2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:89,311,195...89,316,703
Ensembl chr 9:89,311,195...89,316,703
|
|
G |
CLIC4 |
chloride intracellular channel 4 |
increases expression |
EXP |
fenpyroximate results in increased expression of CLIC4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:24,745,447...24,844,321
Ensembl chr 1:24,745,382...24,844,321
|
|
G |
CNPY3 |
canopy FGF signaling regulator 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of CNPY3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:42,928,002...42,939,294
Ensembl chr 6:42,929,480...42,939,294
|
|
G |
CNTN1 |
contactin 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of CNTN1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:40,692,439...41,072,415
Ensembl chr12:40,692,439...41,072,415
|
|
G |
COA6 |
cytochrome c oxidase assembly factor 6 |
increases expression |
EXP |
fenpyroximate results in increased expression of COA6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:234,373,456...234,385,080
Ensembl chr 1:234,373,456...234,385,080
|
|
G |
COL16A1 |
collagen type XVI alpha 1 chain |
increases expression |
EXP |
fenpyroximate results in increased expression of COL16A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:31,652,263...31,704,017
Ensembl chr 1:31,652,263...31,704,319
|
|
G |
COPS5 |
COP9 signalosome subunit 5 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of COPS5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:67,043,079...67,062,133
Ensembl chr 8:67,043,079...67,083,783
|
|
G |
CREBRF |
CREB3 regulatory factor |
increases expression |
EXP |
fenpyroximate results in increased expression of CREBRF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:173,056,352...173,139,284
Ensembl chr 5:173,056,352...173,139,284
|
|
G |
CREG1 |
cellular repressor of E1A stimulated genes 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of CREG1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:167,541,013...167,553,762
Ensembl chr 1:167,529,117...167,553,805
|
|
G |
CRELD2 |
cysteine rich with EGF like domains 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of CRELD2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr22:49,918,634...49,927,537
Ensembl chr22:49,918,167...49,927,540
|
|
G |
CRTAP |
cartilage associated protein |
increases expression |
EXP |
fenpyroximate results in increased expression of CRTAP mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:33,114,014...33,147,773
Ensembl chr 3:33,114,014...33,147,773
|
|
G |
CTNNAL1 |
catenin alpha like 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of CTNNAL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:108,942,577...109,013,499
Ensembl chr 9:108,942,569...109,013,522
|
|
G |
CTNND1 |
catenin delta 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CTNND1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:57,761,802...57,819,540
Ensembl chr11:57,753,243...57,819,546
|
|
G |
CTPS1 |
CTP synthase 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CTPS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:40,979,696...41,012,565
Ensembl chr 1:40,979,300...41,012,565
|
|
G |
CTTN |
cortactin |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CTTN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:70,398,529...70,436,575
Ensembl chr11:70,398,404...70,436,584
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of CYP1A1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
increases expression |
EXP |
fenpyroximate results in increased expression of CYP3A5 mRNA |
CTD |
PMID:34642769 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of CYP7A1 mRNA; fenpyroximate results in decreased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
|
|
G |
DAAM1 |
dishevelled associated activator of morphogenesis 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of DAAM1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:59,188,667...59,371,405
Ensembl chr14:59,188,646...59,371,405
|
|
G |
DAXX |
death domain associated protein |
decreases expression |
EXP |
fenpyroximate results in decreased expression of DAXX mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:33,318,558...33,322,959
Ensembl chr 6:33,318,558...33,323,016
|
|
G |
DCK |
deoxycytidine kinase |
decreases expression |
EXP |
fenpyroximate results in decreased expression of DCK mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:70,993,649...71,030,914
Ensembl chr 4:70,992,538...71,030,914
|
|
G |
DDC |
dopa decarboxylase |
decreases expression |
EXP |
fenpyroximate results in decreased expression of DDC mRNA |
CTD |
PMID:34642769 |
|
NCBI chr 7:50,458,442...50,565,405
Ensembl chr 7:50,458,436...50,565,405
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of DDIT3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DEPDC1B |
DEP domain containing 1B |
increases expression |
EXP |
fenpyroximate results in increased expression of DEPDC1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:60,596,912...60,700,166
Ensembl chr 5:60,596,912...60,700,190
|
|
G |
DFFB |
DNA fragmentation factor subunit beta |
decreases expression |
EXP |
fenpyroximate results in decreased expression of DFFB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:3,857,476...3,885,429
Ensembl chr 1:3,857,267...3,885,429
|
|
G |
DLGAP5 |
DLG associated protein 5 |
increases expression |
EXP |
fenpyroximate results in increased expression of DLGAP5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:55,148,135...55,191,585
Ensembl chr14:55,148,112...55,191,608
|
|
G |
DNAJB14 |
DnaJ heat shock protein family (Hsp40) member B14 |
increases expression |
EXP |
fenpyroximate results in increased expression of DNAJB14 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:99,896,248...99,946,618
Ensembl chr 4:99,896,248...99,946,618
|
|
G |
DNTTIP2 |
deoxynucleotidyltransferase terminal interacting protein 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of DNTTIP2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:93,866,284...93,879,206
Ensembl chr 1:93,866,284...93,879,918
|
|
G |
DRD2 |
dopamine receptor D2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of DRD2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691
|
|
G |
DUSP4 |
dual specificity phosphatase 4 |
increases expression |
EXP |
fenpyroximate results in increased expression of DUSP4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:29,333,064...29,350,684
Ensembl chr 8:29,333,064...29,350,684
|
|
G |
EEF1G |
eukaryotic translation elongation factor 1 gamma |
decreases expression |
EXP |
fenpyroximate results in decreased expression of EEF1G mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:62,559,596...62,573,891
Ensembl chr11:62,559,596...62,574,086
|
|
G |
EGR1 |
early growth response 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of EGR1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
EIF2S2 |
eukaryotic translation initiation factor 2 subunit beta |
increases expression |
EXP |
fenpyroximate results in increased expression of EIF2S2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:34,088,309...34,112,243
Ensembl chr20:34,088,309...34,112,243
|
|
G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365
|
|
G |
ELMOD1 |
ELMO domain containing 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:107,591,147...107,666,779
Ensembl chr11:107,591,091...107,666,779
|
|
G |
EP300 |
E1A binding protein p300 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of EP300 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,592...41,180,077
|
|
G |
EPHB2 |
EPH receptor B2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of EPHB2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:22,710,838...22,921,500
Ensembl chr 1:22,710,839...22,921,500
|
|
G |
ERO1A |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
EXP |
fenpyroximate results in increased expression of ERO1A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:52,639,915...52,695,558
Ensembl chr14:52,639,915...52,695,900
|
|
G |
ERO1B |
endoplasmic reticulum oxidoreductase 1 beta |
increases expression |
EXP |
fenpyroximate results in increased expression of ERO1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:236,215,101...236,281,958
Ensembl chr 1:236,214,681...236,282,019
|
|
G |
ESR2 |
estrogen receptor 2 |
multiple interactions |
EXP |
fenpyroximate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:30818834 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
ESRRA |
estrogen related receptor alpha |
multiple interactions |
EXP |
fenpyroximate inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; fenpyroximate inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr11:64,305,524...64,316,743
Ensembl chr11:64,305,497...64,316,743
|
|
G |
EXOSC4 |
exosome component 4 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of EXOSC4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:144,064,056...144,080,648
Ensembl chr 8:144,078,648...144,080,648
|
|
G |
EXOSC8 |
exosome component 8 |
increases expression |
EXP |
fenpyroximate results in increased expression of EXOSC8 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:37,000,786...37,009,614
Ensembl chr13:36,998,816...37,025,881
|
|
G |
FAM72A |
family with sequence similarity 72 member A |
increases expression |
EXP |
fenpyroximate results in increased expression of FAM72A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:206,186,179...206,205,773
Ensembl chr 1:206,186,179...206,204,414
|
|
G |
FAM72C |
family with sequence similarity 72 member C |
increases expression |
EXP |
fenpyroximate results in increased expression of FAM72C mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:143,955,287...143,973,564
Ensembl chr 1:143,955,287...143,971,986
|
|
G |
FBL |
fibrillarin |
increases expression |
EXP |
fenpyroximate results in increased expression of FBL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:39,834,458...39,846,379
Ensembl chr19:39,834,458...39,846,379
|
|
G |
FBXO7 |
F-box protein 7 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of FBXO7 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr22:32,474,811...32,498,829
Ensembl chr22:32,474,676...32,498,829
|
|
G |
FGF2 |
fibroblast growth factor 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of FGF2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236
|
|
G |
FTH1 |
ferritin heavy chain 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of FTH1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634
|
|
G |
FTL |
ferritin light chain |
increases expression |
EXP |
fenpyroximate results in increased expression of FTL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:48,965,309...48,966,879
Ensembl chr19:48,965,309...48,966,879
|
|
G |
G6PC1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
decreases expression |
EXP |
fenpyroximate results in decreased expression of G6PD mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
GADD45B |
growth arrest and DNA damage inducible beta |
increases expression |
EXP |
fenpyroximate results in increased expression of GADD45B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:2,476,127...2,478,257
Ensembl chr19:2,476,122...2,478,259
|
|
G |
GADD45G |
growth arrest and DNA damage inducible gamma |
increases expression |
EXP |
fenpyroximate results in increased expression of GADD45G mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:89,605,012...89,606,555
Ensembl chr 9:89,605,012...89,606,555
|
|
G |
GAP43 |
growth associated protein 43 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of GAP43 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:115,623,510...115,721,483
Ensembl chr 3:115,623,510...115,721,490
|
|
G |
GCLM |
glutamate-cysteine ligase modifier subunit |
increases expression |
EXP |
fenpyroximate results in increased expression of GCLM mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456
|
|
G |
GDF15 |
growth differentiation factor 15 |
increases expression |
EXP |
fenpyroximate results in increased expression of GDF15 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:18,386,158...18,389,176
Ensembl chr19:18,374,731...18,389,176
|
|
G |
GFUS |
GDP-L-fucose synthase |
increases expression |
EXP |
fenpyroximate results in increased expression of GFUS mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:143,612,618...143,618,048
Ensembl chr 8:143,612,618...143,618,048
|
|
G |
GLDC |
glycine decarboxylase |
decreases expression |
EXP |
fenpyroximate results in decreased expression of GLDC mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:6,532,467...6,645,729
Ensembl chr 9:6,532,467...6,645,729
|
|
G |
GLI3 |
GLI family zinc finger 3 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of GLI3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:41,960,949...42,264,268
Ensembl chr 7:41,960,949...42,264,100
|
|
G |
GLRX |
glutaredoxin |
decreases expression |
EXP |
fenpyroximate results in decreased expression of GLRX mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:95,813,849...95,822,726
Ensembl chr 5:95,751,319...95,822,726
|
|
G |
GNAI2 |
G protein subunit alpha i2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of GNAI2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:50,227,068...50,263,358
Ensembl chr 3:50,226,292...50,259,362
|
|
G |
GRB10 |
growth factor receptor bound protein 10 |
increases expression |
EXP |
fenpyroximate results in increased expression of GRB10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:50,590,068...50,793,453
Ensembl chr 7:50,590,063...50,793,462
|
|
G |
GRM4 |
glutamate metabotropic receptor 4 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of GRM4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:34,018,643...34,155,622
Ensembl chr 6:34,018,643...34,155,622
|
|
G |
GSTM2 |
glutathione S-transferase mu 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of GSTM2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
|
|
G |
H1-2 |
H1.2 linker histone, cluster member |
increases expression |
EXP |
fenpyroximate results in increased expression of H1-2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:26,055,740...26,056,470
Ensembl chr 6:26,055,740...26,056,470
|
|
G |
H2AC11 |
H2A clustered histone 11 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2AC11 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:27,133,043...27,133,535
Ensembl chr 6:27,133,043...27,133,535
|
|
G |
H2AC15 |
H2A clustered histone 15 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2AC15 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:27,837,880...27,838,375
Ensembl chr 6:27,837,880...27,838,375
|
|
G |
H2AC19 |
H2A clustered histone 19 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2AC19 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:149,851,061...149,851,594
Ensembl chr 1:149,851,061...149,851,594
|
|
G |
H2AC6 |
H2A clustered histone 6 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2AC6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:26,124,172...26,124,690
Ensembl chr 6:26,124,145...26,139,116
|
|
G |
H2AC8 |
H2A clustered histone 8 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2AC8 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:26,216,921...26,217,437
Ensembl chr 6:26,216,921...26,217,437
|
|
G |
H2BC13 |
H2B clustered histone 13 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2BC13 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:27,807,479...27,807,929
Ensembl chr 6:27,807,479...27,807,929
|
|
G |
H2BC14 |
H2B clustered histone 14 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2BC14 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:27,815,022...27,815,489
Ensembl chr 6:27,815,022...27,815,489
|
|
G |
H2BC15 |
H2B clustered histone 15 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2BC15 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:27,838,569...27,839,110
Ensembl chr 6:27,838,545...27,855,709
|
|
G |
H2BC3 |
H2B clustered histone 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2BC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:26,043,227...26,043,713
Ensembl chr 6:26,043,227...26,043,713
|
|
G |
H2BC5 |
H2B clustered histone 5 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2BC5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:26,158,121...26,171,349
Ensembl chr 6:26,158,122...26,171,349
|
|
G |
H2BC9 |
H2B clustered histone 9 |
increases expression |
EXP |
fenpyroximate results in increased expression of H2BC9 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:26,251,614...26,252,075
Ensembl chr 6:26,251,614...26,252,075
|
|
G |
H3C10 |
H3 clustered histone 10 |
increases expression |
EXP |
fenpyroximate results in increased expression of H3C10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:27,810,051...27,810,536
Ensembl chr 6:27,810,051...27,811,300
|
|
G |
H3C2 |
H3 clustered histone 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of H3C2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:26,031,589...26,032,099
Ensembl chr 6:26,031,589...26,032,099
|
|
G |
H3C3 |
H3 clustered histone 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of H3C3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:26,045,384...26,045,869
Ensembl chr 6:26,045,384...26,045,869
|
|
G |
H3C4 |
H3 clustered histone 4 |
increases expression |
EXP |
fenpyroximate results in increased expression of H3C4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:26,196,784...26,199,293
Ensembl chr 6:26,196,784...26,197,286
|
|
G |
HAPSTR1 |
HUWE1 associated protein modifying stress responses |
increases expression |
EXP |
fenpyroximate results in increased expression of HAPSTR1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:9,091,644...9,121,635
Ensembl chr16:9,091,644...9,121,635
|
|
G |
HCST |
hematopoietic cell signal transducer |
increases expression |
EXP |
fenpyroximate results in increased expression of HCST mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:35,902,529...35,904,377
Ensembl chr19:35,902,529...35,904,377
|
|
G |
HDAC2 |
histone deacetylase 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of HDAC2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:113,933,028...113,971,148
Ensembl chr 6:113,933,028...114,011,308
|
|
G |
HERPUD1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of HERPUD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
|
|
G |
HES1 |
hes family bHLH transcription factor 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of HES1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:194,136,148...194,138,732
Ensembl chr 3:194,136,148...194,138,732
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of HMOX1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HNRNPM |
heterogeneous nuclear ribonucleoprotein M |
decreases expression |
EXP |
fenpyroximate results in decreased expression of HNRNPM mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:8,444,975...8,489,114
Ensembl chr19:8,444,767...8,489,114
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of HSP90B1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:103,930,410...103,947,926
Ensembl chr12:103,930,107...103,953,931
|
|
G |
HSPA1B |
heat shock protein family A (Hsp70) member 1B |
increases expression |
EXP |
fenpyroximate results in increased expression of HSPA1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:31,827,738...31,830,254
Ensembl chr 6:31,827,738...31,830,254
|
|
G |
HSPE1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of HSPE1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:197,500,379...197,503,449
Ensembl chr 2:197,500,140...197,503,449
|
|
G |
HTATSF1 |
HIV-1 Tat specific factor 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of HTATSF1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:136,497,229...136,512,346
Ensembl chr X:136,497,079...136,512,346
|
|
G |
ID1 |
inhibitor of DNA binding 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ID1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:31,605,289...31,606,510
Ensembl chr20:31,605,283...31,606,515
|
|
G |
ID2 |
inhibitor of DNA binding 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of ID2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:8,682,056...8,684,461
Ensembl chr 2:8,678,845...8,684,461
|
|
G |
IFRD1 |
interferon related developmental regulator 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of IFRD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:112,423,174...112,477,203
Ensembl chr 7:112,422,887...112,481,017
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
decreases expression |
EXP |
fenpyroximate results in decreased expression of IGF1R mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530
|
|
G |
IGFBP2 |
insulin like growth factor binding protein 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of IGFBP2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:216,632,828...216,664,436
Ensembl chr 2:216,632,828...216,664,436
|
|
G |
INA |
internexin neuronal intermediate filament protein alpha |
decreases expression |
EXP |
fenpyroximate results in decreased expression of INA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:103,277,138...103,290,346
Ensembl chr10:103,277,138...103,290,346
|
|
G |
IPO5 |
importin 5 |
increases expression |
EXP |
fenpyroximate results in increased expression of IPO5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:97,953,675...98,024,296
Ensembl chr13:97,953,658...98,024,296
|
|
G |
ITPR2 |
inositol 1,4,5-trisphosphate receptor type 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ITPR2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:26,335,352...26,833,194
Ensembl chr12:26,335,352...26,833,194
|
|
G |
JMJD6 |
jumonji domain containing 6, arginine demethylase and lysine hydroxylase |
increases expression |
EXP |
fenpyroximate results in increased expression of JMJD6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:76,712,836...76,726,606
Ensembl chr17:76,712,832...76,726,799
|
|
G |
KDM3A |
lysine demethylase 3A |
decreases expression |
EXP |
fenpyroximate results in decreased expression of KDM3A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:86,437,044...86,492,716
Ensembl chr 2:86,440,647...86,492,716
|
|
G |
KDM5B |
lysine demethylase 5B |
decreases expression |
EXP |
fenpyroximate results in decreased expression of KDM5B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:202,724,495...202,808,421
Ensembl chr 1:202,724,495...202,808,487
|
|
G |
KIF15 |
kinesin family member 15 |
increases expression |
EXP |
fenpyroximate results in increased expression of KIF15 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:44,761,794...44,868,687
Ensembl chr 3:44,761,721...44,873,376
|
|
G |
KIF20A |
kinesin family member 20A |
increases expression |
EXP |
fenpyroximate results in increased expression of KIF20A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:138,179,112...138,187,723
Ensembl chr 5:138,178,719...138,187,723
|
|
G |
KIF5C |
kinesin family member 5C |
decreases expression |
EXP |
fenpyroximate results in decreased expression of KIF5C mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:148,875,227...149,026,759
Ensembl chr 2:148,875,227...149,026,759
|
|
G |
KLHL24 |
kelch like family member 24 |
increases expression |
EXP |
fenpyroximate results in increased expression of KLHL24 mRNA |
CTD |
PMID:34642769 |
|
NCBI chr 3:183,635,623...183,684,519
Ensembl chr 3:183,635,610...183,684,519
|
|
G |
KNL1 |
kinetochore scaffold 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of KNL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:40,594,249...40,664,342
Ensembl chr15:40,594,020...40,664,342
|
|
G |
KYAT3 |
kynurenine aminotransferase 3 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of KYAT3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:88,921,044...88,992,960
Ensembl chr 1:88,935,773...88,992,953
|
|
G |
LOXL1 |
lysyl oxidase like 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of LOXL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:73,926,462...73,952,136
Ensembl chr15:73,925,989...73,952,137
|
|
G |
LRRC41 |
leucine rich repeat containing 41 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of LRRC41 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:46,277,462...46,303,616
Ensembl chr 1:46,261,196...46,303,616
|
|
G |
MANF |
mesencephalic astrocyte derived neurotrophic factor |
increases expression |
EXP |
fenpyroximate results in increased expression of MANF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:51,385,291...51,389,397
Ensembl chr 3:51,385,291...51,389,397
|
|
G |
MAP1B |
microtubule associated protein 1B |
decreases expression |
EXP |
fenpyroximate results in decreased expression of MAP1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:72,107,475...72,209,565
Ensembl chr 5:72,107,234...72,209,565
|
|
G |
MAP6 |
microtubule associated protein 6 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of MAP6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:75,586,918...75,669,038
Ensembl chr11:75,586,918...75,669,038
|
|
G |
MCM7 |
minichromosome maintenance complex component 7 |
increases expression |
EXP |
fenpyroximate results in increased expression of MCM7 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:100,092,728...100,101,397
Ensembl chr 7:100,092,233...100,101,940
|
|
G |
MDK |
midkine |
increases expression |
EXP |
fenpyroximate results in increased expression of MDK mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:46,380,784...46,383,837
Ensembl chr11:46,380,756...46,383,837
|
|
G |
ME1 |
malic enzyme 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of ME1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:83,210,402...83,431,051
Ensembl chr 6:83,210,402...83,431,051
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
increases expression |
EXP |
fenpyroximate results in increased expression of MKI67 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
MLLT11 |
MLLT11 transcription factor 7 cofactor |
decreases expression |
EXP |
fenpyroximate results in decreased expression of MLLT11 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:151,060,397...151,069,544
Ensembl chr 1:151,060,397...151,069,544
|
|
G |
MNAT1 |
MNAT1 component of CDK activating kinase |
decreases expression |
EXP |
fenpyroximate results in decreased expression of MNAT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:60,734,761...60,969,965
Ensembl chr14:60,734,742...60,969,965
|
|
G |
MORN2 |
MORN repeat containing 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of MORN2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:38,875,976...38,882,709
Ensembl chr 2:38,875,976...38,929,072
|
|
G |
MSI2 |
musashi RNA binding protein 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of MSI2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:57,255,851...57,701,581
Ensembl chr17:57,255,851...57,684,689
|
|
G |
MTA1 |
metastasis associated 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of MTA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:105,419,827...105,470,729
Ensembl chr14:105,419,820...105,470,729
|
|
G |
MTHFD2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
increases expression |
EXP |
fenpyroximate results in increased expression of MTHFD2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:74,198,615...74,217,565
Ensembl chr 2:74,186,172...74,217,565
|
|
G |
NAV1 |
neuron navigator 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NAV1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:201,539,127...201,826,969
Ensembl chr 1:201,539,127...201,826,969
|
|
G |
NCAN |
neurocan |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NCAN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:19,211,958...19,252,233
Ensembl chr19:19,211,958...19,252,233
|
|
G |
NDUFA1 |
NADH:ubiquinone oxidoreductase subunit A1 |
increases expression |
EXP |
fenpyroximate results in increased expression of NDUFA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:119,871,832...119,876,662
Ensembl chr X:119,871,832...119,876,662
|
|
G |
NEK2 |
NIMA related kinase 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of NEK2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:211,658,256...211,675,621
Ensembl chr 1:211,658,657...211,675,630
|
|
G |
NFATC3 |
nuclear factor of activated T cells 3 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NFATC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:68,085,370...68,229,259
Ensembl chr16:68,084,751...68,229,259
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
increases activity |
EXP |
fenpyroximate results in increased activity of NFE2L2 protein |
CTD |
PMID:30818834 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NFIL3 |
nuclear factor, interleukin 3 regulated |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NFIL3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:91,409,045...91,483,497
Ensembl chr 9:91,409,045...91,423,832
|
|
G |
NFKBIB |
NFKB inhibitor beta |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NFKBIB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:38,899,666...38,908,889
Ensembl chr19:38,899,700...38,908,893
|
|
G |
NIT1 |
nitrilase 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NIT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:161,118,105...161,125,445
Ensembl chr 1:161,118,086...161,125,445
|
|
G |
NMNAT3 |
nicotinamide nucleotide adenylyltransferase 3 |
decreases response to substance |
ISO |
NMNAT3 protein results in decreased susceptibility to fenpyroximate |
CTD |
PMID:18463239 |
|
NCBI chr 3:139,560,180...139,678,050
Ensembl chr 3:139,560,180...139,678,017
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of NOS3 mRNA |
CTD |
PMID:34642769 |
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
NOTCH3 |
notch receptor 3 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NOTCH3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:15,159,038...15,200,995
Ensembl chr19:15,159,038...15,200,995
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of NQO1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR2F1 |
nuclear receptor subfamily 2 group F member 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NR2F1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:93,583,222...93,594,611
Ensembl chr 5:93,583,222...93,594,611
|
|
G |
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of NR3C1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512
|
|
G |
NR5A1 |
nuclear receptor subfamily 5 group A member 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NR5A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420
|
|
G |
NRCAM |
neuronal cell adhesion molecule |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NRCAM mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:108,147,649...108,456,720
Ensembl chr 7:108,147,623...108,456,717
|
|
G |
NRXN1 |
neurexin 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NRXN1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:49,918,503...51,032,132
Ensembl chr 2:49,918,503...51,225,575
|
|
G |
NTRK1 |
neurotrophic receptor tyrosine kinase 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of NTRK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:156,815,750...156,881,850
Ensembl chr 1:156,815,636...156,881,850
|
|
G |
OAZ1 |
ornithine decarboxylase antizyme 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of OAZ1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:2,269,486...2,273,488
Ensembl chr19:2,269,509...2,273,490
|
|
G |
OLFML2B |
olfactomedin like 2B |
decreases expression |
EXP |
fenpyroximate results in decreased expression of OLFML2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:161,983,192...162,023,869
Ensembl chr 1:161,983,192...162,023,869
|
|
G |
OSTC |
oligosaccharyltransferase complex non-catalytic subunit |
increases expression |
EXP |
fenpyroximate results in increased expression of OSTC mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:108,650,599...108,667,820
Ensembl chr 4:108,650,585...108,667,820
|
|
G |
PAFAH1B3 |
platelet activating factor acetylhydrolase 1b catalytic subunit 3 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PAFAH1B3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:42,297,033...42,302,800
Ensembl chr19:42,297,033...42,303,546
|
|
G |
PARK7 |
Parkinsonism associated deglycase |
decreases response to substance |
ISO |
PARK7 protein results in decreased susceptibility to fenpyroximate |
CTD |
PMID:21219333 |
|
NCBI chr 1:7,961,711...7,985,505
Ensembl chr 1:7,954,291...7,985,505
|
|
G |
PARP2 |
poly(ADP-ribose) polymerase 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of PARP2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:20,343,635...20,357,904
Ensembl chr14:20,343,615...20,357,904
|
|
G |
PDIA6 |
protein disulfide isomerase family A member 6 |
increases expression |
EXP |
fenpyroximate results in increased expression of PDIA6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:10,783,391...10,837,712
Ensembl chr 2:10,783,391...10,837,977
|
|
G |
PEBP1 |
phosphatidylethanolamine binding protein 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PEBP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:118,136,124...118,145,584
Ensembl chr12:118,136,124...118,145,584
|
|
G |
PEG10 |
paternally expressed 10 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PEG10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:94,656,325...94,669,695
Ensembl chr 7:94,656,325...94,669,695
|
|
G |
PFKP |
phosphofructokinase, platelet |
increases expression |
EXP |
fenpyroximate results in increased expression of PFKP mRNA |
CTD |
PMID:34642769 |
|
NCBI chr10:3,067,548...3,136,805
Ensembl chr10:3,066,333...3,137,718
|
|
G |
PGM3 |
phosphoglucomutase 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of PGM3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:83,148,705...83,193,900
Ensembl chr 6:83,147,324...83,193,936
|
|
G |
PGR |
progesterone receptor |
multiple interactions |
EXP |
fenpyroximate inhibits the reaction [Promegestone results in increased activity of PGR protein] |
CTD |
PMID:30818834 |
|
NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813
|
|
G |
PHGDH |
phosphoglycerate dehydrogenase |
increases expression |
EXP |
fenpyroximate results in increased expression of PHGDH mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:119,711,934...119,744,215
Ensembl chr 1:119,648,411...119,744,218
|
|
G |
PHLDA1 |
pleckstrin homology like domain family A member 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:76,025,447...76,031,776
Ensembl chr12:76,025,447...76,031,776
|
|
G |
PIK3C2B |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PIK3C2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:204,422,633...204,494,805
Ensembl chr 1:204,422,628...204,494,805
|
|
G |
PINK1 |
PTEN induced kinase 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PINK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:20,633,458...20,651,511
Ensembl chr 1:20,633,458...20,651,511
|
|
G |
PIP4K2B |
phosphatidylinositol-5-phosphate 4-kinase type 2 beta |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PIP4K2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:38,765,691...38,799,556
Ensembl chr17:38,765,691...38,800,126
|
|
G |
PITPNA |
phosphatidylinositol transfer protein alpha |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PITPNA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:1,517,718...1,562,792
Ensembl chr17:1,517,718...1,562,792
|
|
G |
PLIN2 |
perilipin 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of PLIN2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:19,108,388...19,127,492
Ensembl chr 9:19,108,375...19,149,290
|
|
G |
POLE3 |
DNA polymerase epsilon 3, accessory subunit |
increases expression |
EXP |
fenpyroximate results in increased expression of POLE3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:113,407,235...113,410,749
Ensembl chr 9:113,407,235...113,410,675
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
fenpyroximate inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PPP2R1A |
protein phosphatase 2 scaffold subunit Aalpha |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PPP2R1A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:52,190,052...52,229,518
Ensembl chr19:52,170,936...52,229,518
|
|
G |
PRKAG1 |
protein kinase AMP-activated non-catalytic subunit gamma 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PRKAG1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:49,002,274...49,018,776
Ensembl chr12:49,002,274...49,018,807
|
|
G |
PRKAR1A |
protein kinase cAMP-dependent type I regulatory subunit alpha |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PRKAR1A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:68,413,623...68,551,316
Ensembl chr17:68,511,780...68,551,319
|
|
G |
PRKN |
parkin RBR E3 ubiquitin protein ligase |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PRKN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:161,347,417...162,727,766
Ensembl chr 6:161,347,417...162,727,775
|
|
G |
PRR11 |
proline rich 11 |
increases expression |
EXP |
fenpyroximate results in increased expression of PRR11 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:59,155,746...59,206,709
Ensembl chr17:59,155,732...59,206,709
|
|
G |
PSAT1 |
phosphoserine aminotransferase 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of PSAT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:78,297,125...78,330,093
Ensembl chr 9:78,297,125...78,330,093
|
|
G |
PSMA1 |
proteasome 20S subunit alpha 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of PSMA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:14,504,876...14,643,662
Ensembl chr11:14,504,874...14,643,635
|
|
G |
PTK2B |
protein tyrosine kinase 2 beta |
decreases expression |
EXP |
fenpyroximate results in decreased expression of PTK2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:27,310,506...27,459,391
Ensembl chr 8:27,311,482...27,459,391
|
|
G |
RIPK1 |
receptor interacting serine/threonine kinase 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of RIPK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,824...3,115,187
|
|
G |
RNF4 |
ring finger protein 4 |
increases expression |
EXP |
fenpyroximate results in increased expression of RNF4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:2,469,106...2,515,857
Ensembl chr 4:2,462,220...2,515,857
|
|
G |
RNPS1 |
RNA binding protein with serine rich domain 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of RNPS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:2,253,116...2,268,126
Ensembl chr16:2,253,116...2,268,397
|
|
G |
RPA3 |
replication protein A3 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPA3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:7,636,518...7,718,607
Ensembl chr 7:7,636,518...7,718,607
|
|
G |
RPL11 |
ribosomal protein L11 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPL11 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:23,691,779...23,696,835
Ensembl chr 1:23,691,742...23,696,835
|
|
G |
RPL17 |
ribosomal protein L17 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPL17 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:49,488,481...49,492,465
Ensembl chr18:49,488,453...49,492,508
|
|
G |
RPL27 |
ribosomal protein L27 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPL27 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:42,998,273...43,002,959
Ensembl chr17:42,998,273...43,002,959
|
|
G |
RPL28 |
ribosomal protein L28 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPL28 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:55,385,932...55,403,342
Ensembl chr19:55,385,932...55,403,250
|
|
G |
RPL32 |
ribosomal protein L32 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPL32 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:12,834,485...12,841,582
Ensembl chr 3:12,834,485...12,841,582
|
|
G |
RPL36 |
ribosomal protein L36 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPL36 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:5,690,295...5,691,875
Ensembl chr19:5,674,947...5,691,875
|
|
G |
RPL36AL |
ribosomal protein L36a like |
increases expression |
EXP |
fenpyroximate results in increased expression of RPL36AL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:49,618,530...49,620,626
Ensembl chr14:49,618,530...49,620,626
|
|
G |
RPL9 |
ribosomal protein L9 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPL9 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:39,454,124...39,458,922
Ensembl chr 4:39,452,587...39,458,931
|
|
G |
RPS13 |
ribosomal protein S13 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPS13 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:17,074,388...17,077,667
Ensembl chr11:17,074,388...17,077,715
|
|
G |
RPS18 |
ribosomal protein S18 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPS18 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:33,272,075...33,276,511
Ensembl chr 6:33,272,075...33,276,511
|
|
G |
RPS2 |
ribosomal protein S2 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPS2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:1,962,058...1,964,826
Ensembl chr16:1,962,058...1,964,841
|
|
G |
RPS25 |
ribosomal protein S25 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPS25 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:119,015,717...119,018,343
Ensembl chr11:119,015,712...119,018,691
|
|
G |
RPS27A |
ribosomal protein S27a |
increases expression |
EXP |
fenpyroximate results in increased expression of RPS27A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:55,231,903...55,235,853
Ensembl chr 2:55,231,903...55,235,853
|
|
G |
RPS3 |
ribosomal protein S3 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPS3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:75,399,518...75,422,302
Ensembl chr11:75,399,515...75,422,280
|
|
G |
RPS5 |
ribosomal protein S5 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPS5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:58,387,269...58,394,804
Ensembl chr19:58,386,400...58,394,806
|
|
G |
RPS7 |
ribosomal protein S7 |
increases expression |
EXP |
fenpyroximate results in increased expression of RPS7 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:3,575,260...3,580,920
Ensembl chr 2:3,575,260...3,580,920
|
|
G |
RSL24D1 |
ribosomal L24 domain containing 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of RSL24D1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:55,180,806...55,196,941
Ensembl chr15:55,180,806...55,197,049
|
|
G |
S100A13 |
S100 calcium binding protein A13 |
increases expression |
EXP |
fenpyroximate results in increased expression of S100A13 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:153,618,799...153,634,361
Ensembl chr 1:153,618,787...153,631,360
|
|
G |
S100A4 |
S100 calcium binding protein A4 |
increases expression |
EXP |
fenpyroximate results in increased expression of S100A4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:153,543,621...153,545,806
Ensembl chr 1:153,543,613...153,550,136
|
|
G |
S100P |
S100 calcium binding protein P |
increases expression |
EXP |
fenpyroximate results in increased expression of S100P mRNA; fenpyroximate results in increased expression of S100P protein |
CTD |
PMID:32194361 |
|
NCBI chr 4:6,693,878...6,697,170
Ensembl chr 4:6,693,878...6,697,170
|
|
G |
SATB1 |
SATB homeobox 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of SATB1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:18,345,377...18,445,592
Ensembl chr 3:18,345,377...18,445,621
|
|
G |
SELENOS |
selenoprotein S |
increases expression |
EXP |
fenpyroximate results in increased expression of SELENOS mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:101,270,809...101,277,485
Ensembl chr15:101,270,817...101,277,500
|
|
G |
SEMA4B |
semaphorin 4B |
decreases expression |
EXP |
fenpyroximate results in decreased expression of SEMA4B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:90,184,920...90,229,661
Ensembl chr15:90,160,604...90,229,679
|
|
G |
SEMA6D |
semaphorin 6D |
decreases expression |
EXP |
fenpyroximate results in decreased expression of SEMA6D mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:47,184,089...47,774,228
Ensembl chr15:47,184,101...47,774,228
|
|
G |
SEPTIN10 |
septin 10 |
increases expression |
EXP |
fenpyroximate results in increased expression of SEPTIN10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:109,542,799...109,613,966
Ensembl chr 2:109,542,799...109,614,143
|
|
G |
SERTAD1 |
SERTA domain containing 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of SERTAD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:40,421,589...40,425,992
Ensembl chr19:40,421,589...40,425,992
|
|
G |
SESN2 |
sestrin 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of SESN2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:28,259,518...28,282,491
Ensembl chr 1:28,259,518...28,282,491
|
|
G |
SHCBP1 |
SHC binding and spindle associated 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of SHCBP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:46,578,591...46,621,379
Ensembl chr16:46,578,591...46,621,379
|
|
G |
SLC17A6 |
solute carrier family 17 member 6 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of SLC17A6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:22,338,381...22,379,503
Ensembl chr11:22,338,381...22,379,503
|
|
G |
SLC35A5 |
solute carrier family 35 member A5 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of SLC35A5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:112,561,320...112,585,579
Ensembl chr 3:112,561,709...112,585,579
|
|
G |
SLC38A1 |
solute carrier family 38 member 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of SLC38A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:46,183,063...46,269,043
Ensembl chr12:46,183,063...46,270,017
|
|
G |
SLC3A2 |
solute carrier family 3 member 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of SLC3A2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:62,856,109...62,888,860
Ensembl chr11:62,856,004...62,888,880
|
|
G |
SLC7A5 |
solute carrier family 7 member 5 |
increases expression |
EXP |
fenpyroximate results in increased expression of SLC7A5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:87,830,023...87,869,507
Ensembl chr16:87,830,023...87,869,507
|
|
G |
SMC3 |
structural maintenance of chromosomes 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of SMC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:110,567,695...110,606,048
Ensembl chr10:110,567,684...110,606,048
|
|
G |
SMNDC1 |
survival motor neuron domain containing 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of SMNDC1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:110,290,730...110,304,920
Ensembl chr10:110,290,730...110,304,938
|
|
G |
SNAI2 |
snail family transcriptional repressor 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of SNAI2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:48,917,598...48,921,429
Ensembl chr 8:48,917,598...48,921,740
|
|
G |
SNCA |
synuclein alpha |
increases response to substance |
EXP |
SNCA protein results in increased susceptibility to fenpyroximate |
CTD |
PMID:16239214 |
|
NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315
|
|
G |
SNHG8 |
small nucleolar RNA host gene 8 |
increases expression |
EXP |
fenpyroximate results in increased expression of SNHG8 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:118,278,762...118,279,823
Ensembl chr 4:118,278,703...118,285,316
|
|
G |
SNRPD3 |
small nuclear ribonucleoprotein D3 polypeptide |
increases expression |
EXP |
fenpyroximate results in increased expression of SNRPD3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr22:24,555,650...24,574,971
Ensembl chr22:24,555,958...24,582,052
|
|
G |
SOCS2 |
suppressor of cytokine signaling 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of SOCS2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:93,569,969...93,626,236
Ensembl chr12:93,569,814...93,583,487
|
|
G |
SPAG5 |
sperm associated antigen 5 |
increases expression |
EXP |
fenpyroximate results in increased expression of SPAG5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:28,577,574...28,599,025
Ensembl chr17:28,577,565...28,599,025
|
|
G |
SPC25 |
SPC25 component of NDC80 kinetochore complex |
increases expression |
EXP |
fenpyroximate results in increased expression of SPC25 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:168,861,521...168,890,430
Ensembl chr 2:168,834,132...168,913,371
|
|
G |
SPDEF |
SAM pointed domain containing ETS transcription factor |
decreases expression |
EXP |
fenpyroximate results in decreased expression of SPDEF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:34,537,802...34,556,329
Ensembl chr 6:34,537,802...34,556,333
|
|
G |
SRSF10 |
serine and arginine rich splicing factor 10 |
increases expression |
EXP |
fenpyroximate results in increased expression of SRSF10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:23,964,347...23,980,327
Ensembl chr 1:23,964,347...23,980,927
|
|
G |
STK25 |
serine/threonine kinase 25 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of STK25 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:241,492,670...241,509,572
Ensembl chr 2:241,492,670...241,509,730
|
|
G |
SYTL1 |
synaptotagmin like 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of SYTL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:27,342,022...27,353,932
Ensembl chr 1:27,342,020...27,353,937
|
|
G |
TACC3 |
transforming acidic coiled-coil containing protein 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of TACC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:1,721,521...1,745,171
Ensembl chr 4:1,712,858...1,745,171
|
|
G |
TCF4 |
transcription factor 4 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TCF4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:55,222,185...55,635,957
Ensembl chr18:55,222,185...55,664,787
|
|
G |
TERF2IP |
TERF2 interacting protein |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TERF2IP mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:75,647,773...75,657,432
Ensembl chr16:75,647,773...75,761,872
|
|
G |
TFDP1 |
transcription factor Dp-1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TFDP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:113,584,688...113,641,473
Ensembl chr13:113,584,721...113,641,473
|
|
G |
TGFB3 |
transforming growth factor beta 3 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TGFB3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:75,958,097...75,983,011
Ensembl chr14:75,958,097...75,983,011
|
|
G |
THRA |
thyroid hormone receptor alpha |
increases activity |
EXP |
fenpyroximate results in increased activity of THRA protein |
CTD |
PMID:20143881 |
|
NCBI chr17:40,062,193...40,093,867
Ensembl chr17:40,058,290...40,093,867
|
|
G |
TLK2 |
tousled like kinase 2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TLK2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:62,470,914...62,615,481
Ensembl chr17:62,458,658...62,615,481
|
|
G |
TM9SF3 |
transmembrane 9 superfamily member 3 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TM9SF3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:96,518,110...96,587,012
Ensembl chr10:96,518,110...96,587,452
|
|
G |
TMEM185A |
transmembrane protein 185A |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TMEM185A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:149,596,556...149,631,792
Ensembl chr X:149,596,556...149,631,912
|
|
G |
TNC |
tenascin C |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TNC mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:115,019,575...115,118,157
Ensembl chr 9:115,019,575...115,118,207
|
|
G |
TOP2A |
DNA topoisomerase II alpha |
increases expression |
EXP |
fenpyroximate results in increased expression of TOP2A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:40,388,525...40,417,896
Ensembl chr17:40,388,525...40,417,896
|
|
G |
TP53 |
tumor protein p53 |
increases expression |
EXP |
fenpyroximate results in increased expression of TP53 mRNA |
CTD |
PMID:36933581 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
TPX2 |
TPX2 microtubule nucleation factor |
increases expression |
EXP |
fenpyroximate results in increased expression of TPX2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:31,739,290...31,801,800
Ensembl chr20:31,739,271...31,801,805
|
|
G |
TRIB3 |
tribbles pseudokinase 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of TRIB3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:380,760...397,559
Ensembl chr20:362,835...397,559
|
|
G |
TRIM13 |
tripartite motif containing 13 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TRIM13 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:49,997,042...50,018,467
Ensembl chr13:49,995,888...50,020,481
|
|
G |
TRPV1 |
transient receptor potential cation channel subfamily V member 1 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TRPV1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411
|
|
G |
TSC22D3 |
TSC22 domain family member 3 |
increases expression |
EXP |
fenpyroximate results in increased expression of TSC22D3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:107,713,221...107,775,988
Ensembl chr X:107,713,221...107,777,342
|
|
G |
TSG101 |
tumor susceptibility 101 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TSG101 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:18,480,311...18,526,942
Ensembl chr11:18,468,336...18,526,951
|
|
G |
TSPAN3 |
tetraspanin 3 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TSPAN3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:77,041,404...77,071,109
Ensembl chr15:77,041,404...77,083,984
|
|
G |
TST |
thiosulfate sulfurtransferase |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TST mRNA |
CTD |
PMID:33512557 |
|
NCBI chr22:37,010,859...37,020,183
Ensembl chr22:37,010,859...37,020,183
|
|
G |
TUBB2B |
tubulin beta 2B class IIb |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TUBB2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:3,224,277...3,227,653
Ensembl chr 6:3,223,324...3,231,730
|
|
G |
TXNDC5 |
thioredoxin domain containing 5 |
increases expression |
EXP |
fenpyroximate results in increased expression of TXNDC5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:7,881,517...7,910,788
Ensembl chr 6:7,881,517...7,910,788
|
|
G |
TXNIP |
thioredoxin interacting protein |
decreases expression |
EXP |
fenpyroximate results in decreased expression of TXNIP mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:145,992,435...145,996,579
Ensembl chr 1:145,992,435...145,996,579
|
|
G |
TXNRD1 |
thioredoxin reductase 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of TXNRD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307
|
|
G |
UBA52 |
ubiquitin A-52 residue ribosomal protein fusion product 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of UBA52 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:18,563,766...18,577,550
Ensembl chr19:18,571,730...18,577,550
|
|
G |
UBE2C |
ubiquitin conjugating enzyme E2 C |
increases expression |
EXP |
fenpyroximate results in increased expression of UBE2C mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:45,812,644...45,816,952
Ensembl chr20:45,812,576...45,816,957
|
|
G |
UBE2Q2 |
ubiquitin conjugating enzyme E2 Q2 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of UBE2Q2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:75,843,447...75,901,078
Ensembl chr15:75,843,307...75,901,078
|
|
G |
UQCRQ |
ubiquinol-cytochrome c reductase complex III subunit VII |
increases expression |
EXP |
fenpyroximate results in increased expression of UQCRQ mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:132,866,642...132,868,847
Ensembl chr 5:132,866,630...132,868,847
|
|
G |
VAPB |
VAMP associated protein B and C |
decreases expression |
EXP |
fenpyroximate results in decreased expression of VAPB mRNA |
CTD |
PMID:34642769 |
|
NCBI chr20:58,389,229...58,451,101
Ensembl chr20:58,389,229...58,451,101
|
|
G |
VEGFA |
vascular endothelial growth factor A |
increases expression |
EXP |
fenpyroximate results in increased expression of VEGFA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VGLL4 |
vestigial like family member 4 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of VGLL4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:11,556,067...11,721,815
Ensembl chr 3:11,556,069...11,771,350
|
|
G |
VPS72 |
vacuolar protein sorting 72 homolog |
decreases expression |
EXP |
fenpyroximate results in decreased expression of VPS72 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:151,176,304...151,190,197
Ensembl chr 1:151,176,304...151,195,321
|
|
G |
WARS1 |
tryptophanyl-tRNA synthetase 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of WARS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:100,333,790...100,376,327
Ensembl chr14:100,333,790...100,376,805
|
|
G |
XBP1 |
X-box binding protein 1 |
increases expression |
EXP |
fenpyroximate results in increased expression of XBP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597
|
|
G |
YWHAB |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta |
decreases expression |
EXP |
fenpyroximate results in decreased expression of YWHAB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:44,885,705...44,908,532
Ensembl chr20:44,885,702...44,908,532
|
|
G |
ZBTB41 |
zinc finger and BTB domain containing 41 |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ZBTB41 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:197,153,682...197,201,293
Ensembl chr 1:197,153,682...197,201,293
|
|
G |
ZFAND2A |
zinc finger AN1-type containing 2A |
increases expression |
EXP |
fenpyroximate results in increased expression of ZFAND2A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:1,148,850...1,160,196
Ensembl chr 7:1,152,071...1,160,759
|
|
G |
ZNG1E |
Zn regulated GTPase metalloprotein activator 1E |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ZNG1E mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:65,652,979...65,734,041
Ensembl chr 9:65,668,805...65,734,041
|
|
G |
ZNG1F |
Zn regulated GTPase metalloprotein activator 1F |
decreases expression |
EXP |
fenpyroximate results in decreased expression of ZNG1F mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:41,131,309...41,205,735
Ensembl chr 9:41,131,306...41,199,261 Ensembl chr 9:41,131,306...41,199,261
|
|
G |
ZRANB2 |
zinc finger RANBP2-type containing 2 |
increases expression |
EXP |
fenpyroximate results in increased expression of ZRANB2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:71,063,291...71,081,035
Ensembl chr 1:71,063,291...71,081,289
|
|
|
G |
ACAT1 |
acetyl-CoA acetyltransferase 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ACAT1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:108,116,705...108,147,603
Ensembl chr11:108,116,695...108,147,603
|
|
G |
ACSF2 |
acyl-CoA synthetase family member 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ACSF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:50,426,218...50,474,845
Ensembl chr17:50,426,158...50,474,845
|
|
G |
ACSS2 |
acyl-CoA synthetase short chain family member 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ACSS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:34,874,989...34,927,959
Ensembl chr20:34,872,146...34,927,962
|
|
G |
ADGRG1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ADGRG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:57,619,738...57,665,567
Ensembl chr16:57,610,652...57,665,580
|
|
G |
ADIRF |
adipogenesis regulatory factor |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ADIRF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:86,968,482...86,970,915
Ensembl chr10:86,968,432...86,983,934
|
|
G |
ADORA2B |
adenosine A2b receptor |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ADORA2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:15,850,362...15,975,746
Ensembl chr17:15,945,130...15,975,746
|
|
G |
AHNAK2 |
AHNAK nucleoprotein 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AHNAK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:104,937,253...104,978,374
Ensembl chr14:104,937,244...104,978,374
|
|
G |
AKAP12 |
A-kinase anchoring protein 12 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of AKAP12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:151,239,967...151,358,559
Ensembl chr 6:151,239,967...151,358,559
|
|
G |
ALDH1L2 |
aldehyde dehydrogenase 1 family member L2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:105,019,790...105,084,458
Ensembl chr12:105,019,784...105,107,643
|
|
G |
ALDH7A1 |
aldehyde dehydrogenase 7 family member A1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDH7A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:126,541,841...126,595,219
Ensembl chr 5:126,531,200...126,595,362
|
|
G |
ALDH9A1 |
aldehyde dehydrogenase 9 family member A1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDH9A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:165,662,216...165,698,562
Ensembl chr 1:165,662,216...165,698,562
|
|
G |
ALDOC |
aldolase, fructose-bisphosphate C |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDOC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:28,573,120...28,576,895
Ensembl chr17:28,573,115...28,576,948
|
|
G |
ANGPTL4 |
angiopoietin like 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:8,364,155...8,374,370
Ensembl chr19:8,363,289...8,374,370
|
|
G |
ANXA11 |
annexin A11 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ANXA11 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:80,150,889...80,205,808
Ensembl chr10:80,150,889...80,205,572
|
|
G |
ANXA2 |
annexin A2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ANXA2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:60,347,151...60,397,986
Ensembl chr15:60,347,134...60,402,883
|
|
G |
ANXA8 |
annexin A8 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ANXA8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:47,467,993...47,991,796
Ensembl chr10:47,460,162...47,484,158
|
|
G |
AOX1 |
aldehyde oxidase 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AOX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:200,586,014...200,682,241
Ensembl chr 2:200,586,014...200,677,064
|
|
G |
AP1B1 |
adaptor related protein complex 1 subunit beta 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP1B1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr22:29,327,680...29,388,570
Ensembl chr22:29,327,680...29,388,583
|
|
G |
AP1S2 |
adaptor related protein complex 1 subunit sigma 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP1S2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:15,825,806...15,854,813
Ensembl chr X:15,825,806...15,854,931
|
|
G |
AP2S1 |
adaptor related protein complex 2 subunit sigma 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP2S1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:46,838,167...46,850,846
Ensembl chr19:46,838,136...46,850,846
|
|
G |
AP3D1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of AP3D1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:2,100,988...2,164,616
Ensembl chr19:2,100,988...2,164,468
|
|
G |
APBB3 |
amyloid beta precursor protein binding family B member 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of APBB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:140,558,268...140,564,598
Ensembl chr 5:140,558,268...140,564,781
|
|
G |
ARAP3 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARAP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:141,653,402...141,682,230
Ensembl chr 5:141,653,401...141,682,230
|
|
G |
ARHGEF16 |
Rho guanine nucleotide exchange factor 16 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ARHGEF16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:3,454,665...3,481,113
Ensembl chr 1:3,454,665...3,481,113
|
|
G |
ARID5B |
AT-rich interaction domain 5B |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARID5B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:61,901,699...62,096,944
Ensembl chr10:61,901,684...62,096,944
|
|
G |
ARL4A |
ADP ribosylation factor like GTPase 4A |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARL4A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:12,686,903...12,690,958
Ensembl chr 7:12,686,856...12,690,958
|
|
G |
ARL5A |
ADP ribosylation factor like GTPase 5A |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARL5A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:151,798,797...151,828,421
Ensembl chr 2:151,788,984...151,828,492
|
|
G |
ATP5F1EP2 |
ATP synthase F1 subunit epsilon pseudogene 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5F1EP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:27,945,206...27,945,573
Ensembl chr13:27,945,260...27,945,415
|
|
G |
ATP5MG |
ATP synthase membrane subunit g |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5MG mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:118,401,606...118,409,847
Ensembl chr11:118,401,346...118,433,278
|
|
G |
ATP5PF |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5PF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr21:25,724,500...25,735,653
Ensembl chr21:25,716,503...25,735,673
|
|
G |
ATP6V0B |
ATPase H+ transporting V0 subunit b |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ATP6V0B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:43,974,960...43,978,295
Ensembl chr 1:43,974,487...43,978,295
|
|
G |
ATP6V0E1 |
ATPase H+ transporting V0 subunit e1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP6V0E1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:172,983,771...173,035,445
Ensembl chr 5:172,983,771...173,035,445
|
|
G |
ATP8B2 |
ATPase phospholipid transporting 8B2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP8B2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:154,325,525...154,351,304
Ensembl chr 1:154,325,525...154,351,304
|
|
G |
ATP9A |
ATPase phospholipid transporting 9A (putative) |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ATP9A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:51,596,514...51,768,390
Ensembl chr20:51,596,514...51,768,390
|
|
G |
B4GALT5 |
beta-1,4-galactosyltransferase 5 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of B4GALT5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:49,632,945...49,713,878
Ensembl chr20:49,632,945...49,713,878
|
|
G |
BCAR3 |
BCAR3 adaptor protein, NSP family member |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BCAR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:93,561,741...93,848,151
Ensembl chr 1:93,561,741...93,847,150
|
|
G |
BCKDK |
branched chain keto acid dehydrogenase kinase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BCKDK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:31,108,386...31,117,640
Ensembl chr16:31,106,107...31,112,791
|
|
G |
BEX1 |
brain expressed X-linked 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BEX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:103,062,651...103,064,171
Ensembl chr X:103,062,651...103,064,171
|
|
G |
BHLHE40 |
basic helix-loop-helix family member e40 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BHLHE40 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:4,979,437...4,985,323
Ensembl chr 3:4,979,437...4,985,323
|
|
G |
BIK |
BCL2 interacting killer |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of BIK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr22:43,110,750...43,129,712
Ensembl chr22:43,110,750...43,129,712
|
|
G |
BNIP3 |
BCL2 interacting protein 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BNIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967
|
|
G |
C8orf88 |
chromosome 8 open reading frame 88 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of C8ORF88 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:90,958,471...90,985,393
Ensembl chr 8:90,958,471...90,985,238
|
|
G |
CACYBP |
calcyclin binding protein |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CACYBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:174,999,435...175,012,027
Ensembl chr 1:174,999,163...175,012,027
|
|
G |
CARD10 |
caspase recruitment domain family member 10 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CARD10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr22:37,490,362...37,519,415
Ensembl chr22:37,490,362...37,519,542
|
|
G |
CASP2 |
caspase 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CASP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
|
|
G |
CAV2 |
caveolin 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CAV2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:116,499,738...116,508,541
Ensembl chr 7:116,287,380...116,508,541
|
|
G |
CCDC12 |
coiled-coil domain containing 12 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:46,921,730...46,981,994
Ensembl chr 3:46,921,726...46,982,010
|
|
G |
CCDC92 |
coiled-coil domain containing 92 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC92 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:123,935,626...123,972,831
Ensembl chr12:123,918,660...123,972,831
|
|
G |
CCDC93 |
coiled-coil domain containing 93 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC93 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:117,915,481...118,014,070
Ensembl chr 2:117,915,478...118,014,133
|
|
G |
CCN2 |
cellular communication network factor 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
|
|
G |
CCND2 |
cyclin D2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CCND2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353
|
|
G |
CD24 |
CD24 molecule |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CD24 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:106,969,831...106,976,855
Ensembl chr 6:106,969,831...106,975,627
|
|
G |
CD63 |
CD63 molecule |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CD63 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:55,723,535...55,730,041
Ensembl chr12:55,725,323...55,729,707
|
|
G |
CD99L2 |
CD99 molecule like 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CD99L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:150,766,336...150,898,668
Ensembl chr X:150,766,336...150,898,816
|
|
G |
CDC20 |
cell division cycle 20 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CDC20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:43,358,981...43,363,203
Ensembl chr 1:43,358,981...43,363,203
|
|
G |
CDH1 |
cadherin 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which affects the expression of CDH1 mRNA; [[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CDH3 |
cadherin 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDH3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:68,645,310...68,733,771
Ensembl chr16:68,636,189...68,727,468
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDKN1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CENPA |
centromere protein A |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CENPA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:26,786,056...26,794,589
Ensembl chr 2:26,764,289...26,801,067
|
|
G |
CENPF |
centromere protein F |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CENPF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:214,603,195...214,664,571
Ensembl chr 1:214,603,185...214,664,574
|
|
G |
CEP192 |
centrosomal protein 192 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CEP192 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:12,991,362...13,125,036
Ensembl chr18:12,991,362...13,125,052
|
|
G |
CFAP251 |
cilia and flagella associated protein 251 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CFAP251 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:121,918,592...122,003,919
Ensembl chr12:121,918,592...122,003,927
|
|
G |
CHCHD2P6 |
coiled-coil-helix-coiled-coil-helix domain containing 2 pseudogene 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CHCHD2P6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:15,604,528...15,605,314
Ensembl chr 1:15,604,597...15,605,043
|
|
G |
CHD9 |
chromodomain helicase DNA binding protein 9 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CHD9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:53,054,991...53,327,497
Ensembl chr16:53,054,991...53,329,150
|
|
G |
CHRNA2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
EXP |
isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr 8:27,459,756...27,479,261
Ensembl chr 8:27,459,756...27,479,883
|
|
G |
CHRNB4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
EXP |
isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr15:78,624,111...78,661,641
Ensembl chr15:78,624,111...78,727,754
|
|
G |
CHTOP |
chromatin target of PRMT1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CHTOP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:153,634,066...153,646,306
Ensembl chr 1:153,633,982...153,646,306
|
|
G |
CITED4 |
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CITED4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:40,861,054...40,862,363
Ensembl chr 1:40,861,054...40,862,363
|
|
G |
CKLF |
chemokine like factor |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CKLF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:66,552,563...66,566,287
Ensembl chr16:66,552,563...66,566,251
|
|
G |
CKS2 |
CDC28 protein kinase regulatory subunit 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CKS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:89,311,195...89,316,703
Ensembl chr 9:89,311,195...89,316,703
|
|
G |
CLCN6 |
chloride voltage-gated channel 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CLCN6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:11,806,191...11,843,130
Ensembl chr 1:11,806,096...11,848,079
|
|
G |
CLDN1 |
claudin 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CLDN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:190,305,707...190,322,446
Ensembl chr 3:190,305,707...190,322,446
|
|
G |
CNN2 |
calponin 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CNN2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:1,026,608...1,039,065
Ensembl chr19:1,026,586...1,039,068
|
|
G |
CNPY4 |
canopy FGF signaling regulator 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CNPY4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:100,119,634...100,125,508
Ensembl chr 7:100,119,634...100,125,508
|
|
G |
COA3 |
cytochrome c oxidase assembly factor 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC56 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:42,797,625...42,798,704
Ensembl chr17:42,795,147...42,798,704
|
|
G |
COMMD1 |
copper metabolism domain containing 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COMMD1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:61,888,391...62,136,058
Ensembl chr 2:61,888,724...62,147,247
|
|
G |
COQ3 |
coenzyme Q3, methyltransferase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COQ3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:99,369,401...99,394,195
Ensembl chr 6:99,369,401...99,394,195
|
|
G |
COQ5 |
coenzyme Q5, methyltransferase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COQ5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:120,503,279...120,529,158
Ensembl chr12:120,503,279...120,534,434
|
|
G |
COTL1 |
coactosin like F-actin binding protein 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of COTL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:84,565,596...84,618,078
Ensembl chr16:84,565,596...84,618,078
|
|
G |
COX16 |
cytochrome c oxidase assembly factor COX16 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COX16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:70,325,081...70,359,683
Ensembl chr14:70,325,081...70,416,984
|
|
G |
COX7C |
cytochrome c oxidase subunit 7C |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COX7C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:86,617,941...86,620,962
Ensembl chr 5:86,617,928...86,620,962
|
|
G |
CPA4 |
carboxypeptidase A4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CPA4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:130,293,161...130,324,180
Ensembl chr 7:130,293,134...130,324,180
|
|
G |
CPD |
carboxypeptidase D |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CPD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:30,378,927...30,469,989
Ensembl chr17:30,378,927...30,469,989
|
|
G |
CREB3L2 |
cAMP responsive element binding protein 3 like 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CREB3L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:137,874,979...138,002,086
Ensembl chr 7:137,874,979...138,002,086
|
|
G |
CRIPT |
CXXC repeat containing interactor of PDZ3 domain |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CRIPT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:46,617,215...46,630,176
Ensembl chr 2:46,616,416...46,630,176
|
|
G |
CRISPLD2 |
cysteine rich secretory protein LCCL domain containing 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CRISPLD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:84,819,985...84,909,508
Ensembl chr16:84,819,985...84,920,768
|
|
G |
CSK |
C-terminal Src kinase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CSK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:74,782,080...74,803,197
Ensembl chr15:74,782,080...74,803,197
|
|
G |
CSNK1E |
casein kinase 1 epsilon |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CSNK1E mRNA |
CTD |
PMID:29432896 |
|
NCBI chr22:38,290,691...38,318,084
Ensembl chr22:38,290,691...38,318,084
|
|
G |
CUL1 |
cullin 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CUL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:148,697,756...148,801,110
Ensembl chr 7:148,697,914...148,801,110
|
|
G |
CUTA |
cutA divalent cation tolerance homolog |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CUTA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:33,416,442...33,418,107
Ensembl chr 6:33,416,442...33,418,317
|
|
G |
CWC15 |
CWC15 spliceosome associated protein homolog |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CWC15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:94,962,620...94,973,556
Ensembl chr11:94,962,620...94,973,586
|
|
G |
CXXC5 |
CXXC finger protein 5 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CXXC5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:139,647,299...139,683,882
Ensembl chr 5:139,647,299...139,683,882
|
|
G |
CYBA |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYBA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:88,643,289...88,651,053
Ensembl chr16:88,643,275...88,651,083
|
|
G |
CYGB |
cytoglobin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYGB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:76,527,356...76,551,193
Ensembl chr17:76,527,356...76,551,175
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYP1A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP4X1 |
cytochrome P450 family 4 subfamily X member 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CYP4X1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:46,961,364...47,055,432
Ensembl chr 1:47,023,669...47,050,751
|
|
G |
CYSRT1 |
cysteine rich tail 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYSRT1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:137,225,174...137,226,315
Ensembl chr 9:137,225,174...137,226,315
|
|
G |
DAPK3 |
death associated protein kinase 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DAPK3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:3,958,453...3,971,099
Ensembl chr19:3,958,453...3,971,123
|
|
G |
DBI |
diazepam binding inhibitor, acyl-CoA binding protein |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DBI mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:119,366,977...119,372,543
Ensembl chr 2:119,366,924...119,372,550
|
|
G |
DBT |
dihydrolipoamide branched chain transacylase E2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DBT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:100,186,919...100,249,834
Ensembl chr 1:100,186,919...100,249,834
|
|
G |
DCAF15 |
DDB1 and CUL4 associated factor 15 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DCAF15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:13,952,509...13,961,449
Ensembl chr19:13,952,509...13,961,449
|
|
G |
DCBLD2 |
discoidin, CUB and LCCL domain containing 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCBLD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:98,795,941...98,901,695
Ensembl chr 3:98,795,941...98,901,695
|
|
G |
DCP2 |
decapping mRNA 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:112,976,798...113,022,195
Ensembl chr 5:112,976,702...113,022,195
|
|
G |
DCTN5 |
dynactin subunit 5 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCTN5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:23,641,466...23,677,472
Ensembl chr16:23,641,466...23,677,472
|
|
G |
DDIT4 |
DNA damage inducible transcript 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DDIT4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:72,273,924...72,276,036
Ensembl chr10:72,273,919...72,276,036
|
|
G |
DDR1 |
discoidin domain receptor tyrosine kinase 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DDR1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:30,880,970...30,900,156
Ensembl chr 6:30,876,421...30,900,156
|
|
G |
DECR2 |
2,4-dienoyl-CoA reductase 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DECR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:401,885...412,482
Ensembl chr16:401,858...412,487
|
|
G |
DENND1A |
DENN domain containing 1A |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DENND1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:123,379,658...123,930,126
Ensembl chr 9:123,379,654...123,930,152
|
|
G |
DKK1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DKK1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:52,314,281...52,317,657
Ensembl chr10:52,314,281...52,318,042
|
|
G |
DLEU1 |
deleted in lymphocytic leukemia 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DLEU1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:50,082,169...50,528,643
Ensembl chr13:50,082,169...50,906,856
|
|
G |
DNAAF10 |
dynein axonemal assembly factor 10 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAAF10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:68,129,805...68,157,527
Ensembl chr 2:68,122,936...68,157,549
|
|
G |
DNAJA1 |
DnaJ heat shock protein family (Hsp40) member A1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:33,025,273...33,039,907
Ensembl chr 9:33,025,273...33,039,907
|
|
G |
DNAJB6 |
DnaJ heat shock protein family (Hsp40) member B6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAJB6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:157,337,004...157,417,439
Ensembl chr 7:157,335,381...157,417,439
|
|
G |
DNASE1L1 |
deoxyribonuclease 1 like 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNASE1L1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:154,401,236...154,412,101
Ensembl chr X:154,401,236...154,412,112
|
|
G |
EBP |
EBP cholestenol delta-isomerase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:48,521,808...48,528,716
Ensembl chr X:48,521,799...48,528,716
|
|
G |
EEF1D |
eukaryotic translation elongation factor 1 delta |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EEF1D mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:143,579,728...143,597,415
Ensembl chr 8:143,579,697...143,599,541
|
|
G |
EFNB1 |
ephrin B1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EFNB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:68,829,021...68,842,160
Ensembl chr X:68,829,021...68,842,160
|
|
G |
EFNB2 |
ephrin B2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EFNB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:106,489,745...106,535,662
Ensembl chr13:106,489,745...106,535,662
|
|
G |
EGR1 |
early growth response 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EGR1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
ELOVL6 |
ELOVL fatty acid elongase 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ELOVL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:110,045,846...110,199,202
Ensembl chr 4:110,045,846...110,199,199
|
|
G |
ELP6 |
elongator acetyltransferase complex subunit 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ELP6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:47,495,640...47,513,712
Ensembl chr 3:47,495,640...47,513,712
|
|
G |
ERH |
ERH mRNA splicing and mitosis factor |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ERH mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:69,380,128...69,398,299
Ensembl chr14:69,380,128...69,398,299
|
|
G |
EXOC2 |
exocyst complex component 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EXOC2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:485,154...693,139
Ensembl chr 6:485,154...693,139
|
|
G |
EXOSC2 |
exosome component 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EXOSC2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:130,693,760...130,704,894
Ensembl chr 9:130,693,721...130,707,288
|
|
G |
EZR |
ezrin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EZR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:158,765,748...158,819,368
Ensembl chr 6:158,765,741...158,819,368
|
|
G |
F2RL1 |
F2R like trypsin receptor 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of F2RL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:76,819,030...76,835,315
Ensembl chr 5:76,818,933...76,835,315
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of F3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
FAM217B |
family with sequence similarity 217 member B |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FAM217B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:59,933,779...59,948,680
Ensembl chr20:59,933,764...59,948,680
|
|
G |
FAM98A |
family with sequence similarity 98 member A |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FAM98A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:33,583,660...33,599,299
Ensembl chr 2:33,532,744...33,599,347
|
|
G |
FANCE |
FA complementation group E |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FANCE mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:35,452,338...35,467,102
Ensembl chr 6:35,452,338...35,467,104
|
|
G |
FANCL |
FA complementation group L |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FANCL mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:58,159,243...58,241,380
Ensembl chr 2:58,159,243...58,241,410
|
|
G |
FBXO2 |
F-box protein 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FBXO2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:11,648,387...11,654,429
Ensembl chr 1:11,637,018...11,655,785
|
|
G |
FBXW5 |
F-box and WD repeat domain containing 5 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FBXW5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:136,940,435...136,944,738
Ensembl chr 9:136,940,435...136,944,738
|
|
G |
FEZ1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FEZ1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:125,442,881...125,496,265
Ensembl chr11:125,442,881...125,592,568
|
|
G |
FGFR3 |
fibroblast growth factor receptor 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FGFR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:1,793,293...1,808,867
Ensembl chr 4:1,793,293...1,808,872
|
|
G |
FGL1 |
fibrinogen like 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FGL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:17,864,389...17,895,538
Ensembl chr 8:17,864,380...17,910,365
|
|
G |
FNBP1 |
formin binding protein 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FNBP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:129,887,187...130,053,879
Ensembl chr 9:129,887,187...130,043,189
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FOS mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
FOSL1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FOSL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
|
|
G |
FOXJ2 |
forkhead box J2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FOXJ2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:8,032,716...8,055,517
Ensembl chr12:8,032,716...8,055,517
|
|
G |
FOXO3 |
forkhead box O3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FOXO3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774
|
|
G |
FST |
follistatin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FST mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:53,480,629...53,487,134
Ensembl chr 5:53,480,626...53,487,134
|
|
G |
FTSJ1 |
FtsJ RNA 2'-O-methyltransferase 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FTSJ1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:48,476,021...48,486,364
Ensembl chr X:48,476,021...48,486,364
|
|
G |
GADD45A |
growth arrest and DNA damage inducible alpha |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GADD45A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
|
|
G |
GALNT11 |
polypeptide N-acetylgalactosaminyltransferase 11 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GALNT11 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:152,025,674...152,122,340
Ensembl chr 7:152,025,674...152,122,340
|
|
G |
GBP1 |
guanylate binding protein 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GBP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:89,052,319...89,065,208
Ensembl chr 1:89,051,882...89,065,360
|
|
G |
GJB2 |
gap junction protein beta 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GJB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:20,187,470...20,192,938
Ensembl chr13:20,187,463...20,192,938
|
|
G |
GLDC |
glycine decarboxylase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GLDC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:6,532,467...6,645,729
Ensembl chr 9:6,532,467...6,645,729
|
|
G |
GLIPR2 |
GLI pathogenesis related 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLIPR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:36,136,536...36,163,913
Ensembl chr 9:36,136,536...36,163,913
|
|
G |
GLIS3 |
GLIS family zinc finger 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLIS3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:3,824,127...4,490,465
Ensembl chr 9:3,824,127...4,348,392
|
|
G |
GLMP |
glycosylated lysosomal membrane protein |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLMP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:156,292,688...156,295,679
Ensembl chr 1:156,290,089...156,295,689
|
|
G |
GLRX |
glutaredoxin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLRX mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:95,813,849...95,822,726
Ensembl chr 5:95,751,319...95,822,726
|
|
G |
GNG10 |
G protein subunit gamma 10 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GNG10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:111,661,605...111,670,226
Ensembl chr 9:111,661,605...111,670,226
|
|
G |
GPC1 |
glypican 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GPC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:240,435,663...240,468,076
Ensembl chr 2:240,435,663...240,468,076
|
|
G |
GPD1L |
glycerol-3-phosphate dehydrogenase 1 like |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GPD1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:32,106,620...32,168,709
Ensembl chr 3:32,105,689...32,168,709
|
|
G |
GPR137 |
G protein-coupled receptor 137 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GPR137 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:64,270,531...64,289,500
Ensembl chr11:64,270,062...64,289,494
|
|
G |
GRPEL1 |
GrpE like 1, mitochondrial |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GRPEL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:7,058,895...7,068,064
Ensembl chr 4:7,058,671...7,068,085
|
|
G |
GTF2B |
general transcription factor IIB |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTF2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:88,852,633...88,891,567
Ensembl chr 1:88,852,633...88,891,944
|
|
G |
GTF2F1 |
general transcription factor IIF subunit 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTF2F1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:6,379,572...6,393,164
Ensembl chr19:6,379,572...6,393,981
|
|
G |
GTPBP4 |
GTP binding protein 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTPBP4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:988,434...1,019,932
Ensembl chr10:988,434...1,019,932
|
|
G |
GYPC |
glycophorin C (Gerbich blood group) |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GYPC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:126,656,158...126,696,667
Ensembl chr 2:126,656,133...126,696,667
|
|
G |
H3P16 |
H3 histone pseudogene 16 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of H3P16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:139,697,626...139,698,635
Ensembl chr 4:139,698,144...139,698,554
|
|
G |
HIRIP3 |
HIRA interacting protein 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HIRIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:29,992,321...29,996,096
Ensembl chr16:29,992,330...29,996,074
|
|
G |
HMGB1P10 |
high mobility group box 1 pseudogene 10 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGB1P10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr22:26,560,428...26,561,616
Ensembl chr22:26,560,526...26,561,088
|
|
G |
HMGB3 |
high mobility group box 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:150,980,507...150,990,771
Ensembl chr X:150,980,509...150,990,771
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGCR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMGCS1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:43,287,470...43,313,412
Ensembl chr 5:43,287,470...43,313,512
|
|
G |
HNRNPA3 |
heterogeneous nuclear ribonucleoprotein A3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of HNRNPA3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:177,212,794...177,223,959
Ensembl chr 2:177,212,694...177,223,959
|
|
G |
HNRNPK |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HNRNPK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:83,968,083...83,980,615
Ensembl chr 9:83,968,083...83,980,631
|
|
G |
HOXB2 |
homeobox B2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HOXB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:48,542,655...48,545,109
Ensembl chr17:48,540,894...48,545,109
|
|
G |
HPS6 |
HPS6 biogenesis of lysosomal organelles complex 2 subunit 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HPS6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:102,065,349...102,068,036
Ensembl chr10:102,065,349...102,068,036
|
|
G |
HSD17B8 |
hydroxysteroid 17-beta dehydrogenase 8 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HSD17B8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:33,204,655...33,206,831
Ensembl chr 6:33,204,655...33,206,831
|
|
G |
HSPA8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HSPA8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230
|
|
G |
HSPB1 |
heat shock protein family B (small) member 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of HSPB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,304,295
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of IL1B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL24 |
interleukin 24 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of IL24 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:206,897,443...206,904,139
Ensembl chr 1:206,897,443...206,904,139
|
|
G |
INO80C |
INO80 complex subunit C |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of INO80C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:35,468,333...35,497,960
Ensembl chr18:35,452,230...35,497,979
|
|
G |
INSIG1 |
insulin induced gene 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of INSIG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
|
|
G |
ITGB4 |
integrin subunit beta 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ITGB4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:75,721,459...75,757,818
Ensembl chr17:75,721,328...75,757,818
|
|
G |
ITGB5 |
integrin subunit beta 5 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ITGB5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:124,761,948...124,901,418
Ensembl chr 3:124,761,948...124,901,418
|
|
G |
JAG2 |
jagged canonical Notch ligand 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of JAG2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:105,140,995...105,168,776
Ensembl chr14:105,140,982...105,168,824
|
|
G |
JMJD8 |
jumonji domain containing 8 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of JMJD8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:681,670...684,334
Ensembl chr16:681,670...684,528
|
|
G |
JUP |
junction plakoglobin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of JUP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:41,754,609...41,786,711
Ensembl chr17:41,754,604...41,786,931
|
|
G |
KAT8 |
lysine acetyltransferase 8 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KAT8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:31,117,664...31,131,393
Ensembl chr16:31,114,489...31,131,393
|
|
G |
KLF6 |
KLF transcription factor 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KLF6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281
|
|
G |
KNTC1 |
kinetochore associated 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KNTC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:122,527,249...122,626,396
Ensembl chr12:122,527,246...122,626,396
|
|
G |
KRBA1 |
KRAB-A domain containing 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KRBA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:149,714,951...149,734,575
Ensembl chr 7:149,714,781...149,734,575
|
|
G |
KRT16 |
keratin 16 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:41,609,778...41,612,767
Ensembl chr17:41,609,778...41,615,899
|
|
G |
KRT17P3 |
keratin 17 pseudogene 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT17P3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:30,567,760...30,571,815
Ensembl chr17:30,567,700...30,571,748
|
|
G |
KRT18P31 |
keratin 18 pseudogene 31 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KRT18P31 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:36,885,159...36,886,560
Ensembl chr 5:36,885,206...36,886,497
|
|
G |
KRT5 |
keratin 5 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:52,514,575...52,520,394
Ensembl chr12:52,514,575...52,520,530
|
|
G |
KRT6B |
keratin 6B |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT6B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:52,446,651...52,452,146
Ensembl chr12:52,446,651...52,452,146
|
|
G |
KRT6C |
keratin 6C |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT6C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:52,468,516...52,473,805
Ensembl chr12:52,468,516...52,473,805
|
|
G |
KRTCAP2 |
keratinocyte associated protein 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KRTCAP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:155,169,408...155,173,304
Ensembl chr 1:155,169,408...155,173,475
|
|
G |
LAMTOR4 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LAMTOR4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:100,148,918...100,154,203
Ensembl chr 7:100,148,912...100,155,944
|
|
G |
LBH |
LBH regulator of WNT signaling pathway |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LBH mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:30,231,534...30,260,028
Ensembl chr 2:30,231,534...30,323,730
|
|
G |
LDLR |
low density lipoprotein receptor |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LDLR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
G |
LGALS1 |
galectin 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LGALS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr22:37,675,636...37,679,802
Ensembl chr22:37,675,636...37,679,802
|
|
G |
LIMA1 |
LIM domain and actin binding 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of LIMA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:50,175,788...50,283,520
Ensembl chr12:50,175,788...50,283,520
|
|
G |
LITAF |
lipopolysaccharide induced TNF factor |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of LITAF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:11,547,722...11,640,317
Ensembl chr16:11,547,722...11,636,381
|
|
G |
LIX1L |
limb and CNS expressed 1 like |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LIX1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:145,933,423...145,958,017
Ensembl chr 1:145,933,423...145,958,017
|
|
G |
LMOD3 |
leiomodin 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LMOD3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:69,106,065...69,122,595
Ensembl chr 3:69,106,065...69,123,032
|
|
G |
LPIN1 |
lipin 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LPIN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:11,677,544...11,827,409
Ensembl chr 2:11,677,595...11,827,409
|
|
G |
LRRC20 |
leucine rich repeat containing 20 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LRRC20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:70,298,975...70,382,625
Ensembl chr10:70,298,970...70,382,650
|
|
G |
LUZP1 |
leucine zipper protein 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LUZP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:23,083,642...23,178,122
Ensembl chr 1:23,084,030...23,177,808
|
|
G |
LYRM2 |
LYR motif containing 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LYRM2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:89,632,224...89,638,747
Ensembl chr 6:89,568,144...89,638,749
|
|
G |
MANF |
mesencephalic astrocyte derived neurotrophic factor |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MANF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:51,385,291...51,389,397
Ensembl chr 3:51,385,291...51,389,397
|
|
G |
MAP7D1 |
MAP7 domain containing 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MAP7D1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:36,156,160...36,180,849
Ensembl chr 1:36,155,579...36,180,849
|
|
G |
MAT2B |
methionine adenosyltransferase 2 non-catalytic beta subunit |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MAT2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:163,503,064...163,519,354
Ensembl chr 5:163,503,114...163,519,558
|
|
G |
MBTPS1 |
membrane bound transcription factor peptidase, site 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MBTPS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:84,053,763...84,116,942
Ensembl chr16:84,053,761...84,116,942
|
|
G |
MCM7 |
minichromosome maintenance complex component 7 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MCM7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:100,092,728...100,101,397
Ensembl chr 7:100,092,233...100,101,940
|
|
G |
MED7 |
mediator complex subunit 7 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MED7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:157,137,424...157,142,865
Ensembl chr 5:157,137,424...157,159,019
|
|
G |
MFSD3 |
major facilitator superfamily domain containing 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MFSD3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:144,509,070...144,511,213
Ensembl chr 8:144,509,070...144,511,213
|
|
G |
MGARP |
mitochondria localized glutamic acid rich protein |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MGARP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:139,266,165...139,280,225
Ensembl chr 4:139,266,165...139,280,225
|
|
G |
MGAT2 |
alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MGAT2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:49,620,799...49,623,481
Ensembl chr14:49,620,799...49,623,481
|
|
G |
MLKL |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MLKL mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:74,671,855...74,700,862
Ensembl chr16:74,671,855...74,700,960
|
|
G |
MMACHC |
metabolism of cobalamin associated C |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MMACHC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:45,500,300...45,513,382
Ensembl chr 1:45,500,300...45,513,382
|
|
G |
MMS19 |
MMS19 homolog, cytosolic iron-sulfur assembly component |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MMS19 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:97,458,324...97,498,794
Ensembl chr10:97,458,324...97,498,794
|
|
G |
MPDZ |
multiple PDZ domain crumbs cell polarity complex component |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MPDZ mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:13,105,707...13,279,692
Ensembl chr 9:13,105,706...13,279,692
|
|
G |
MPZL2 |
myelin protein zero like 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MPZL2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:118,253,416...118,264,297
Ensembl chr11:118,253,416...118,264,536
|
|
G |
MRPL32 |
mitochondrial ribosomal protein L32 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPL32 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:42,932,376...42,937,857
Ensembl chr 7:42,932,376...42,948,958
|
|
G |
MRPL35 |
mitochondrial ribosomal protein L35 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPL35 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:86,199,433...86,213,794
Ensembl chr 2:86,199,355...86,213,790
|
|
G |
MRPS18C |
mitochondrial ribosomal protein S18C |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPS18C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:83,456,058...83,462,298
Ensembl chr 4:83,455,932...83,469,735
|
|
G |
MRPS21 |
mitochondrial ribosomal protein S21 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPS21 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:150,293,861...150,308,979
Ensembl chr 1:150,293,861...150,308,979
|
|
G |
MSH3 |
mutS homolog 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MSH3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:80,654,652...80,876,815
Ensembl chr 5:80,654,652...80,876,815
|
|
G |
MT1X |
metallothionein 1X |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MT1X mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196
|
|
G |
MT2A |
metallothionein 2A |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MT2A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497
|
|
G |
MTFR2 |
mitochondrial fission regulator 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTFR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:136,231,034...136,250,311
Ensembl chr 6:136,231,024...136,250,335
|
|
G |
MTIF3 |
mitochondrial translational initiation factor 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTIF3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:27,435,643...27,450,564
Ensembl chr13:27,435,643...27,450,591
|
|
G |
MTURN |
maturin, neural progenitor differentiation regulator homolog |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTURN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:30,134,986...30,162,762
Ensembl chr 7:30,134,986...30,162,762
|
|
G |
MVD |
mevalonate diphosphate decarboxylase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MVD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:88,651,940...88,663,091
Ensembl chr16:88,651,935...88,663,161
|
|
G |
MYADM |
myeloid associated differentiation marker |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYADM mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:53,865,628...53,876,435
Ensembl chr19:53,864,763...53,876,435
|
|
G |
MYH9 |
myosin heavy chain 9 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYH9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr22:36,281,280...36,387,967
Ensembl chr22:36,281,280...36,388,010
|
|
G |
MYL6 |
myosin light chain 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MYL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:56,158,359...56,161,579
Ensembl chr12:56,158,346...56,163,496
|
|
G |
MYL6B |
myosin light chain 6B |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MYL6B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:56,152,587...56,157,982
Ensembl chr12:56,152,256...56,159,647
|
|
G |
MYL9 |
myosin light chain 9 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYL9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:36,541,519...36,551,447
Ensembl chr20:36,541,497...36,551,447
|
|
G |
MYO1B |
myosin IB |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYO1B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:191,245,404...191,425,386
Ensembl chr 2:191,245,185...191,425,389
|
|
G |
MZF1 |
myeloid zinc finger 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MZF1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:58,561,932...58,573,573
Ensembl chr19:58,561,931...58,573,575
|
|
G |
MZT2A |
mitotic spindle organizing protein 2A |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MZT2A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:131,469,728...131,493,754
Ensembl chr 2:131,464,900...131,492,743
|
|
G |
NASP |
nuclear autoantigenic sperm protein |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NASP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:45,584,041...45,618,893
Ensembl chr 1:45,583,846...45,618,904
|
|
G |
NAV2 |
neuron navigator 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NAV2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:19,345,236...20,121,601
Ensembl chr11:19,350,724...20,121,601
|
|
G |
NCAPD2 |
non-SMC condensin I complex subunit D2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NCAPD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:6,494,102...6,531,955
Ensembl chr12:6,493,356...6,531,955
|
|
G |
NDRG1 |
N-myc downstream regulated 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NDRG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:133,237,175...133,297,252
Ensembl chr 8:133,237,175...133,302,022
|
|
G |
NDUFA12 |
NADH:ubiquinone oxidoreductase subunit A12 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFA12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:94,971,333...95,003,697
Ensembl chr12:94,895,297...95,003,748
|
|
G |
NDUFB3 |
NADH:ubiquinone oxidoreductase subunit B3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:201,072,001...201,085,750
Ensembl chr 2:201,071,433...201,085,750
|
|
G |
NDUFB4P12 |
NADH:ubiquinone oxidoreductase subunit B4 pseudogene 12 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB4P12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:43,898,938...43,899,403
Ensembl chr 4:43,898,962...43,899,351
|
|
G |
NDUFB5 |
NADH:ubiquinone oxidoreductase subunit B5 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:179,604,794...179,627,647
Ensembl chr 3:179,604,690...179,627,647
|
|
G |
NDUFB6 |
NADH:ubiquinone oxidoreductase subunit B6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NDUFB6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:32,553,001...32,573,159
Ensembl chr 9:32,553,001...32,573,184
|
|
G |
NELFE |
negative elongation factor complex member E |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NELFE mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:31,952,087...31,958,971
Ensembl chr 6:31,952,087...31,959,038
|
|
G |
NEU1 |
neuraminidase 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NEU1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:31,857,659...31,862,821
Ensembl chr 6:31,857,659...31,862,905
|
|
G |
NKIRAS2 |
NFKB inhibitor interacting Ras like 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NKIRAS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:42,017,576...42,025,641
Ensembl chr17:42,011,382...42,025,644
|
|
G |
NOL6 |
nucleolar protein 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NOL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:33,461,353...33,473,924
Ensembl chr 9:33,461,353...33,473,930
|
|
G |
NPM3 |
nucleophosmin/nucleoplasmin 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NPM3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:101,781,325...101,783,446
Ensembl chr10:101,781,325...101,783,446
|
|
G |
NPTX1 |
neuronal pentraxin 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of NPTX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:80,466,834...80,476,607
Ensembl chr17:80,466,834...80,477,843
|
|
G |
NSL1 |
NSL1 component of MIS12 kinetochore complex |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NSL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:212,726,153...212,791,777
Ensembl chr 1:212,726,153...212,791,782
|
|
G |
NUDT2 |
nudix hydrolase 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NUDT2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:34,329,569...34,343,699
Ensembl chr 9:34,329,506...34,343,711
|
|
G |
NUFIP2 |
nuclear FMR1 interacting protein 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of NUFIP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:29,255,839...29,294,148
Ensembl chr17:29,255,839...29,294,148
|
|
G |
OSBP |
oxysterol binding protein |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of OSBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:59,574,398...59,615,774
Ensembl chr11:59,574,398...59,615,774
|
|
G |
OST4 |
oligosaccharyltransferase complex subunit 4, non-catalytic |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of OST4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:27,070,472...27,071,654
Ensembl chr 2:27,070,472...27,071,654
|
|
G |
PABPC1L |
poly(A) binding protein cytoplasmic 1 like |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PABPC1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:44,910,060...44,939,316
Ensembl chr20:44,910,060...44,959,035
|
|
G |
PAK1IP1 |
PAK1 interacting protein 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PAK1IP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:10,690,865...10,709,782
Ensembl chr 6:10,694,972...10,709,782
|
|
G |
PBDC1 |
polysaccharide biosynthesis domain containing 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PBDC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:76,173,062...76,178,314
Ensembl chr X:76,173,040...76,178,314
|
|
G |
PCCB |
propionyl-CoA carboxylase subunit beta |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PCCB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:136,250,340...136,330,169
Ensembl chr 3:136,250,340...136,337,896
|
|
G |
PDIA4 |
protein disulfide isomerase family A member 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PDIA4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:149,003,051...149,028,505
Ensembl chr 7:149,003,062...149,028,662
|
|
G |
PFKFB4 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PFKFB4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:48,517,684...48,563,136
Ensembl chr 3:48,517,684...48,562,015
|
|
G |
PHACTR3 |
phosphatase and actin regulator 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PHACTR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:59,577,509...59,847,711
Ensembl chr20:59,577,509...59,847,711
|
|
G |
PHLDB2 |
pleckstrin homology like domain family B member 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PHLDB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:111,732,496...111,976,517
Ensembl chr 3:111,732,497...111,976,517
|
|
G |
PLAT |
plasminogen activator, tissue type |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLAT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:42,174,718...42,207,565
Ensembl chr 8:42,174,718...42,207,709
|
|
G |
PLEC |
plectin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLEC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:143,915,153...143,976,745
Ensembl chr 8:143,915,153...143,976,734
|
|
G |
PLK2 |
polo like kinase 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:58,453,982...58,460,086
Ensembl chr 5:58,453,982...58,460,139
|
|
G |
PLXNB2 |
plexin B2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PLXNB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr22:50,274,979...50,307,646
Ensembl chr22:50,274,979...50,307,646
|
|
G |
POC1A |
POC1 centriolar protein A |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POC1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:52,075,226...52,154,423
Ensembl chr 3:52,075,226...52,154,690
|
|
G |
POGLUT3 |
protein O-glucosyltransferase 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of POGLUT3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:108,472,116...108,498,384
Ensembl chr11:108,472,112...108,498,405
|
|
G |
POLE2 |
DNA polymerase epsilon 2, accessory subunit |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POLE2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:49,643,555...49,688,214
Ensembl chr14:49,643,555...49,688,422
|
|
G |
POLR3K |
RNA polymerase III subunit K |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POLR3K mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:46,407...53,608
Ensembl chr16:46,407...53,608
|
|
G |
POP5 |
POP5 homolog, ribonuclease P/MRP subunit |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of POP5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:120,578,764...120,581,402
Ensembl chr12:120,578,764...120,581,402
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PPIC |
peptidylprolyl isomerase C |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPIC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:123,023,250...123,036,725
Ensembl chr 5:123,023,250...123,036,725
|
|
G |
PPIL3 |
peptidylprolyl isomerase like 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPIL3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:200,870,907...200,889,291
Ensembl chr 2:200,870,907...200,889,303
|
|
G |
PPP1R14C |
protein phosphatase 1 regulatory inhibitor subunit 14C |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PPP1R14C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:150,143,044...150,250,392
Ensembl chr 6:150,143,044...150,250,392
|
|
G |
PPP6R2 |
protein phosphatase 6 regulatory subunit 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPP6R2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr22:50,330,774...50,445,090
Ensembl chr22:50,343,304...50,445,090
|
|
G |
PPWD1 |
peptidylprolyl isomerase domain and WD repeat containing 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PPWD1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:65,563,296...65,587,549
Ensembl chr 5:65,563,236...65,587,549
|
|
G |
PRICKLE1 |
prickle planar cell polarity protein 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PRICKLE1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:42,456,757...42,589,746
Ensembl chr12:42,456,757...42,590,355
|
|
G |
PSMB10 |
proteasome 20S subunit beta 10 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PSMB10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:67,934,506...67,936,850
Ensembl chr16:67,934,506...67,936,864
|
|
G |
PSMB6 |
proteasome 20S subunit beta 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PSMB6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:4,796,164...4,798,495
Ensembl chr17:4,796,144...4,798,502
|
|
G |
PSMG4 |
proteasome assembly chaperone 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PSMG4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:3,254,404...3,268,049
Ensembl chr 6:3,231,403...3,303,373
|
|
G |
PSTPIP2 |
proline-serine-threonine phosphatase interacting protein 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:45,983,536...46,072,260
Ensembl chr18:45,983,536...46,072,272
|
|
G |
PTGES |
prostaglandin E synthase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PTGES mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042
|
|
G |
PTPRE |
protein tyrosine phosphatase receptor type E |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PTPRE mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:127,907,103...128,085,855
Ensembl chr10:127,907,103...128,085,855
|
|
G |
PTTG1 |
PTTG1 regulator of sister chromatid separation, securin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of PTTG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:160,421,855...160,428,744
Ensembl chr 5:160,421,855...160,428,739
|
|
G |
PYCARD |
PYD and CARD domain containing |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of PYCARD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450
|
|
G |
QRICH1 |
glutamine rich 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of QRICH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:49,029,707...49,094,373
Ensembl chr 3:49,029,707...49,094,363
|
|
G |
RAB25 |
RAB25, member RAS oncogene family |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RAB25 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:156,061,160...156,070,504
Ensembl chr 1:156,061,160...156,070,504
|
|
G |
RAB38 |
RAB38, member RAS oncogene family |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RAB38 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:87,803,715...88,175,443
Ensembl chr11:88,113,251...88,175,443
|
|
G |
RAB8A |
RAB8A, member RAS oncogene family |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RAB8A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:16,111,889...16,134,234
Ensembl chr19:16,111,889...16,134,234
|
|
G |
RAD23B |
RAD23 homolog B, nucleotide excision repair protein |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RAD23B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:107,283,279...107,332,194
Ensembl chr 9:107,283,137...107,332,192
|
|
G |
RASIP1 |
Ras interacting protein 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RASIP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:48,720,585...48,740,610
Ensembl chr19:48,720,585...48,740,610
|
|
G |
RBCK1 |
RANBP2-type and C3HC4-type zinc finger containing 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RBCK1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:408,299...432,139
Ensembl chr20:407,498...432,139
|
|
G |
RBM33 |
RNA binding motif protein 33 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RBM33 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:155,644,661...155,781,480
Ensembl chr 7:155,644,451...155,781,485
|
|
G |
RBM5 |
RNA binding motif protein 5 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RBM5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:50,088,919...50,119,021
Ensembl chr 3:50,088,919...50,119,021
|
|
G |
RBMS1 |
RNA binding motif single stranded interacting protein 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RBMS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:160,272,151...160,493,807
Ensembl chr 2:160,272,151...160,493,807
|
|
G |
RER1 |
retention in endoplasmic reticulum sorting receptor 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RER1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:2,391,841...2,405,436
Ensembl chr 1:2,391,775...2,405,442
|
|
G |
RFXANK |
regulatory factor X associated ankyrin containing protein |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RFXANK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:19,192,258...19,201,866
Ensembl chr19:19,192,229...19,201,869
|
|
G |
RGL1 |
ral guanine nucleotide dissociation stimulator like 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RGL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:183,636,109...183,928,532
Ensembl chr 1:183,636,085...183,928,532
|
|
G |
RGS17 |
regulator of G protein signaling 17 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RGS17 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:153,004,459...153,131,282
Ensembl chr 6:153,004,459...153,131,282
|
|
G |
RGS20 |
regulator of G protein signaling 20 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RGS20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:53,851,795...53,959,303
Ensembl chr 8:53,851,795...53,959,303
|
|
G |
RHEB |
Ras homolog, mTORC1 binding |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RHEB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:151,466,012...151,519,895
Ensembl chr 7:151,466,012...151,520,120
|
|
G |
RHOB |
ras homolog family member B |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RHOB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:20,447,074...20,449,440
Ensembl chr 2:20,447,074...20,449,440
|
|
G |
RHOQ |
ras homolog family member Q |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RHOQ mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:46,542,490...46,584,688
Ensembl chr 2:46,541,806...46,584,688
|
|
G |
RIPOR2 |
RHO family interacting cell polarization regulator 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FAM65B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:24,804,284...25,042,168
Ensembl chr 6:24,804,282...25,042,170
|
|
G |
RNASET2 |
ribonuclease T2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RNASET2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:166,922,113...166,956,550
Ensembl chr 6:166,922,113...166,957,191
|
|
G |
RNF126 |
ring finger protein 126 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RNF126 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:647,526...663,214
Ensembl chr19:647,526...663,233
|
|
G |
RNF20 |
ring finger protein 20 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RNF20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:101,533,853...101,563,344
Ensembl chr 9:101,533,853...101,563,344
|
|
G |
RNH1 |
ribonuclease/angiogenin inhibitor 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RNH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:494,515...507,242
Ensembl chr11:494,512...507,300
|
|
G |
RNU1-1 |
RNA, U1 small nuclear 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RNU1-1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:16,514,122...16,514,285
Ensembl chr 1:16,514,122...16,514,285
|
|
G |
RNU6-1 |
RNA, U6 small nuclear 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RNU6-1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:67,839,940...67,840,045
Ensembl chr15:67,839,939...67,840,045
|
|
G |
RNU6-15P |
RNA, U6 small nuclear 15, pseudogene |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RNU6-15P mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:21,321,961...21,322,066
Ensembl chr10:21,321,961...21,322,067
|
|
G |
RNY1 |
RNA, Ro60-associated Y1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RNY1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:148,987,136...148,987,248
Ensembl chr 7:148,987,136...148,987,248
|
|
G |
RPL10A |
ribosomal protein L10a |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RPL10A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:35,468,401...35,470,780
Ensembl chr 6:35,468,401...35,470,785
|
|
G |
RPL10P9 |
ribosomal protein L10 pseudogene 9 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RPL10P9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:168,616,311...168,617,055
Ensembl chr 5:168,616,352...168,616,996
|
|
G |
RPL12P32 |
ribosomal protein L12 pseudogene 32 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPL12P32 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:31,948,246...31,948,871
Ensembl chr12:31,948,334...31,948,827
|
|
G |
RPL21P119 |
ribosomal protein L21 pseudogene 119 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RPL21P119 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:9,156,342...9,156,921
Ensembl chr16:9,156,402...9,156,881
|
|
G |
RPL21P16 |
ribosomal protein L21 pseudogene 16 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RPL21P16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:120,354,645...120,355,226
Ensembl chr10:120,354,701...120,355,183
|
|
G |
RPL21P28 |
ribosomal protein L21 pseudogene 28 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RPL21P28 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:212,051,486...212,052,051
Ensembl chr 1:212,051,524...212,052,006
|
|
G |
RPL27 |
ribosomal protein L27 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPL27 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:42,998,273...43,002,959
Ensembl chr17:42,998,273...43,002,959
|
|
G |
RPL29P11 |
ribosomal protein L29 pseudogene 11 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RPL29P11 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:37,016,401...37,017,034
Ensembl chr 3:37,016,523...37,017,014
|
|
G |
RPL34 |
ribosomal protein L34 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPL34 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:108,620,576...108,630,484
Ensembl chr 4:108,620,569...108,630,412
|
|
G |
RPL36AP37 |
ribosomal protein L36a pseudogene 37 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RPL36AP37 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:16,974,646...16,975,044
Ensembl chr11:16,974,693...16,975,013 Ensembl chr11:16,974,693...16,975,013
|
|
G |
RPL6P27 |
ribosomal protein L6 pseudogene 27 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of RPL6P27 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:6,462,110...6,463,029
Ensembl chr18:6,462,144...6,463,010
|
|
G |
RPL7P22 |
ribosomal protein L7 pseudogene 22 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPL7P22 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:72,725,417...72,726,154
Ensembl chr 5:72,725,419...72,726,151
|
|
G |
RPP25L |
ribonuclease P/MRP subunit p25 like |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPP25L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:34,610,495...34,612,097
Ensembl chr 9:34,610,486...34,612,104
|
|
G |
RPS26P15 |
ribosomal protein S26 pseudogene 15 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPS26P15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:58,056,062...58,056,504
Ensembl chr 1:58,056,133...58,056,480
|
|
G |
RPS26P2 |
ribosomal protein S26 pseudogene 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPS26P2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:30,831,609...30,832,249
Ensembl chr 9:30,831,878...30,832,225
|
|
G |
RPUSD2 |
RNA pseudouridine synthase domain containing 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RPUSD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:40,569,299...40,574,949
Ensembl chr15:40,569,299...40,574,949
|
|
G |
RRAGD |
Ras related GTP binding D |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of RRAGD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:89,364,616...89,412,273
Ensembl chr 6:89,364,616...89,412,273
|
|
G |
S100A10 |
S100 calcium binding protein A10 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of S100A10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:151,982,915...151,993,859
Ensembl chr 1:151,982,915...151,993,859
|
|
G |
S100A14 |
S100 calcium binding protein A14 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of S100A14 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:153,614,255...153,616,325
Ensembl chr 1:153,614,255...153,616,986
|
|
G |
S100A8 |
S100 calcium binding protein A8 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of S100A8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073
|
|
G |
S100A9 |
S100 calcium binding protein A9 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of S100A9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023
|
|
G |
SC5D |
sterol-C5-desaturase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SC5D mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:121,292,771...121,313,410
Ensembl chr11:121,292,681...121,313,410
|
|
G |
SCARA3 |
scavenger receptor class A member 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SCARA3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:27,633,463...27,734,141
Ensembl chr 8:27,633,868...27,676,776
|
|
G |
SCD |
stearoyl-CoA desaturase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SCD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826
|
|
G |
SDHAF2 |
succinate dehydrogenase complex assembly factor 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SDHAF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:61,430,124...61,446,733
Ensembl chr11:61,430,042...61,446,733
|
|
G |
SDHAP2 |
SDHA pseudogene 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SDHAP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:195,658,039...195,688,871
Ensembl chr 3:195,658,096...195,685,904
|
|
G |
SDHB |
succinate dehydrogenase complex iron sulfur subunit B |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SDHB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:17,018,722...17,054,032
Ensembl chr 1:17,018,664...17,054,032
|
|
G |
SEC13 |
SEC13 homolog, nuclear pore and COPII coat complex component |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SEC13 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:10,300,931...10,321,112
Ensembl chr 3:10,293,131...10,321,112
|
|
G |
SEC61G |
SEC61 translocon subunit gamma |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SEC61G mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:54,752,253...54,759,211
Ensembl chr 7:54,752,250...54,759,974
|
|
G |
SELENON |
selenoprotein N |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SEPN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:25,800,193...25,818,221
Ensembl chr 1:25,800,193...25,818,221
|
|
G |
SELENOS |
selenoprotein S |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SELS mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:101,270,809...101,277,485
Ensembl chr15:101,270,817...101,277,500
|
|
G |
SEM1 |
SEM1 26S proteasome subunit |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SEM1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:96,481,626...96,709,846
Ensembl chr 7:96,481,626...96,709,880
|
|
G |
SERPINB1 |
serpin family B member 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SERPINB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:2,832,332...2,841,863
Ensembl chr 6:2,832,332...2,841,959
|
|
G |
SERPINB2 |
serpin family B member 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SERPINB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:63,887,705...63,903,888
Ensembl chr18:63,871,692...63,903,888
|
|
G |
SERPINE1 |
serpin family E member 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SERPINE1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SFN |
stratifin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:26,863,149...26,864,456
Ensembl chr 1:26,863,149...26,864,456
|
|
G |
SFTA1P |
surfactant associated 1, lncRNA |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SFTA1P mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:10,784,439...10,794,914
Ensembl chr10:10,784,437...10,795,047
|
|
G |
SFXN4 |
sideroflexin 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SFXN4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:119,140,767...119,165,714
Ensembl chr10:119,140,767...119,165,714
|
|
G |
SGPP2 |
sphingosine-1-phosphate phosphatase 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SGPP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:222,423,988...222,562,621
Ensembl chr 2:222,424,543...222,562,621
|
|
G |
SH2B3 |
SH2B adaptor protein 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SH2B3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:111,404,730...111,451,623
Ensembl chr12:111,405,923...111,451,623
|
|
G |
SLC11A2 |
solute carrier family 11 member 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC11A2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:50,952,263...51,028,886
Ensembl chr12:50,979,401...51,028,566
|
|
G |
SLC26A6 |
solute carrier family 26 member 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC26A6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:48,625,723...48,635,461
Ensembl chr 3:48,625,723...48,635,493
|
|
G |
SLC43A3 |
solute carrier family 43 member 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC43A3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:57,406,954...57,427,580
Ensembl chr11:57,406,954...57,427,580
|
|
G |
SLC44A1 |
solute carrier family 44 member 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLC44A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:105,244,651...105,438,504
Ensembl chr 9:105,244,622...105,439,171
|
|
G |
SLF2 |
SMC5-SMC6 complex localization factor 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SLF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:100,912,963...100,965,134
Ensembl chr10:100,912,963...100,965,134
|
|
G |
SNHG6 |
small nucleolar RNA host gene 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNHG6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:66,921,690...66,925,541
Ensembl chr 8:66,920,561...66,926,398
|
|
G |
SNIP1 |
Smad nuclear interacting protein 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNIP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:37,534,449...37,554,293
Ensembl chr 1:37,534,449...37,554,293
|
|
G |
SNORD96A |
small nucleolar RNA, C/D box 96A |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNORD96A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:181,241,818...181,241,889
Ensembl chr 5:181,241,814...181,241,892
|
|
G |
SNRNP25 |
small nuclear ribonucleoprotein U11/U12 subunit 25 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNRNP25 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:53,828...57,669
Ensembl chr16:53,828...57,669
|
|
G |
SNX5P2 |
sorting nexin 5 pseudogene 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SNX5P2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:101,066,607...101,070,000
|
|
G |
SNX8 |
sorting nexin 8 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SNX8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:2,251,770...2,354,497
Ensembl chr 7:2,251,770...2,354,318
|
|
G |
SOX15 |
SRY-box transcription factor 15 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SOX15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:7,588,178...7,590,094
Ensembl chr17:7,588,178...7,590,094
|
|
G |
SPA17 |
sperm autoantigenic protein 17 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SPA17 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:124,673,904...124,697,518
Ensembl chr11:124,673,844...124,697,518
|
|
G |
SPATS2L |
spermatogenesis associated serine rich 2 like |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPATS2L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:200,305,879...200,482,264
Ensembl chr 2:200,305,881...200,482,264
|
|
G |
SPHK1 |
sphingosine kinase 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPHK1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:76,383,204...76,387,855
Ensembl chr17:76,376,584...76,387,860
|
|
G |
SPHK2 |
sphingosine kinase 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SPHK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:48,619,506...48,630,405
Ensembl chr19:48,619,291...48,630,717
|
|
G |
SPRY2 |
sprouty RTK signaling antagonist 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SPRY2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:80,335,976...80,341,126
Ensembl chr13:80,335,976...80,341,126
|
|
G |
SRP54 |
signal recognition particle 54 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SRP54 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:34,982,992...35,029,567
Ensembl chr14:34,981,957...35,029,686
|
|
G |
SRP9P1 |
signal recognition particle 9 pseudogene 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of SRP9P1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:91,806,064...91,807,533
Ensembl chr10:91,807,179...91,807,439
|
|
G |
ST14 |
ST14 transmembrane serine protease matriptase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ST14 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:130,159,782...130,210,362
Ensembl chr11:130,159,782...130,210,362
|
|
G |
STK26 |
serine/threonine kinase 26 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of STK26 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:132,023,302...132,075,943
Ensembl chr X:132,023,302...132,075,943
|
|
G |
STMN1 |
stathmin 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of STMN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:25,884,179...25,906,880
Ensembl chr 1:25,884,181...25,906,991
|
|
G |
STX8 |
syntaxin 8 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of STX8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:9,250,471...9,575,820
Ensembl chr17:9,250,471...9,576,591
|
|
G |
TACSTD2 |
tumor associated calcium signal transducer 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TACSTD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:58,575,433...58,577,252
Ensembl chr 1:58,575,433...58,577,252
|
|
G |
TAGLN |
transgelin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TAGLN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:117,199,294...117,207,465
Ensembl chr11:117,199,370...117,207,464
|
|
G |
TAMM41 |
TAM41 mitochondrial translocator assembly and maintenance homolog |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TAMM41 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:11,721,896...11,846,885
Ensembl chr 3:11,790,442...11,846,919
|
|
G |
TBC1D31 |
TBC1 domain family member 31 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of WDR67 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:123,072,707...123,165,173
Ensembl chr 8:123,041,968...123,152,153
|
|
G |
TBC1D32 |
TBC1 domain family member 32 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TBC1D32 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:121,079,494...121,334,729
Ensembl chr 6:121,079,494...121,334,745
|
|
G |
TCEA2 |
transcription elongation factor A2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TCEA2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:64,055,596...64,072,347
Ensembl chr20:64,049,836...64,072,347
|
|
G |
TCEAL3 |
transcription elongation factor A like 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TCEAL3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:103,607,963...103,609,927
Ensembl chr X:103,607,451...103,629,690
|
|
G |
TCEAL9 |
transcription elongation factor A like 9 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TCEAL9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:103,356,506...103,358,462
Ensembl chr X:103,356,489...103,358,462
|
|
G |
TCERG1 |
transcription elongation regulator 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TCERG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:146,447,330...146,511,961
Ensembl chr 5:146,447,311...146,511,961
|
|
G |
TENT5B |
terminal nucleotidyltransferase 5B |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FAM46B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:27,005,020...27,012,850
Ensembl chr 1:27,005,020...27,012,850
|
|
G |
TFB1M |
transcription factor B1, mitochondrial |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TFB1M mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:155,229,871...155,314,484
Ensembl chr 6:155,256,134...155,314,493
|
|
G |
TFPI |
tissue factor pathway inhibitor |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TFPI mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:187,464,230...187,554,435
Ensembl chr 2:187,464,230...187,565,760
|
|
G |
TGFA |
transforming growth factor alpha |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193
|
|
G |
TGFBR2 |
transforming growth factor beta receptor 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TGFBR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:30,606,356...30,694,142
Ensembl chr 3:30,606,601...30,694,142
|
|
G |
TGM2 |
transglutaminase 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TGM2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:38,127,385...38,168,475
Ensembl chr20:38,127,385...38,166,578
|
|
G |
THBD |
thrombomodulin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of THBD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:23,045,633...23,049,672
Ensembl chr20:23,045,633...23,049,672
|
|
G |
TIMM22 |
translocase of inner mitochondrial membrane 22 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TIMM22 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:997,129...1,003,671
Ensembl chr17:997,129...1,003,671
|
|
G |
TIMM23 |
translocase of inner mitochondrial membrane 23 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TIMM23 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:45,972,489...46,003,742
Ensembl chr10:45,972,489...46,003,742
|
|
G |
TINF2 |
TERF1 interacting nuclear factor 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TINF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:24,239,640...24,242,674
Ensembl chr14:24,238,286...24,242,663
|
|
G |
TIPARP |
TCDD inducible poly(ADP-ribose) polymerase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TIPARP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:156,674,590...156,706,770
Ensembl chr 3:156,673,235...156,706,770
|
|
G |
TMEM44 |
transmembrane protein 44 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TMEM44 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:194,587,678...194,633,419
Ensembl chr 3:194,587,673...194,633,689
|
|
G |
TMEM50B |
transmembrane protein 50B |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TMEM50B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr21:33,432,486...33,479,974
Ensembl chr21:33,432,485...33,479,974
|
|
G |
TMEM54 |
transmembrane protein 54 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TMEM54 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:32,894,595...32,901,389
Ensembl chr 1:32,894,594...32,901,438
|
|
G |
TMUB2 |
transmembrane and ubiquitin like domain containing 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TMUB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:44,186,972...44,191,929
Ensembl chr17:44,186,970...44,191,929
|
|
G |
TNC |
tenascin C |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TNC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:115,019,575...115,118,157
Ensembl chr 9:115,019,575...115,118,207
|
|
G |
TNFAIP3 |
TNF alpha induced protein 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TNFAIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:137,866,349...137,883,312
Ensembl chr 6:137,867,214...137,883,314
|
|
G |
TNFAIP8L3 |
TNF alpha induced protein 8 like 3 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TNFAIP8L3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:51,056,601...51,105,276
Ensembl chr15:51,056,598...51,105,276
|
|
G |
TOMM6 |
translocase of outer mitochondrial membrane 6 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TOMM6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:41,787,694...41,789,895
Ensembl chr 6:41,787,662...41,789,898
|
|
G |
TOMM7 |
translocase of outer mitochondrial membrane 7 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TOMM7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:22,812,974...22,822,849
Ensembl chr 7:22,812,628...22,822,849
|
|
G |
TP63 |
tumor protein p63 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TP63 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:189,596,746...189,897,276
Ensembl chr 3:189,631,389...189,897,276
|
|
G |
TPD52L1 |
TPD52 like 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TPD52L1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:125,153,773...125,264,407
Ensembl chr 6:125,119,049...125,264,407
|
|
G |
TPD52L2 |
TPD52 like 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which affects the expression of TPD52L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:63,865,270...63,891,538
Ensembl chr20:63,865,228...63,891,545
|
|
G |
TPM3P8 |
tropomyosin 3 pseudogene 8 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TPM3P8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:230,571,895...230,573,956
Ensembl chr 2:230,573,167...230,573,809
|
|
G |
TRIM33 |
tripartite motif containing 33 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TRIM33 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:114,392,790...114,511,203
Ensembl chr 1:114,392,790...114,511,203
|
|
G |
TRIM47 |
tripartite motif containing 47 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TRIM47 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:75,874,164...75,878,581
Ensembl chr17:75,874,164...75,878,581
|
|
G |
TSEN15 |
tRNA splicing endonuclease subunit 15 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TSEN15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:184,051,730...184,097,485
Ensembl chr 1:184,051,651...184,123,978
|
|
G |
TSPAN9 |
tetraspanin 9 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TSPAN9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:3,077,379...3,286,559
Ensembl chr12:3,077,355...3,286,564
|
|
G |
TSPO |
translocator protein |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TSPO mRNA |
CTD |
PMID:29432896 |
|
NCBI chr22:43,151,559...43,163,242
Ensembl chr22:43,151,547...43,163,242
|
|
G |
TUBB2A |
tubulin beta 2A class IIa |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TUBB2A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:3,153,666...3,157,544
Ensembl chr 6:3,153,497...3,157,544
|
|
G |
TWIST1 |
twist family bHLH transcription factor 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TWIST1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:19,113,047...19,117,636
Ensembl chr 7:19,020,991...19,117,636
|
|
G |
TXN |
thioredoxin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TXN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507
|
|
G |
TXNIP |
thioredoxin interacting protein |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TXNIP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:145,992,435...145,996,579
Ensembl chr 1:145,992,435...145,996,579
|
|
G |
UBE2J1 |
ubiquitin conjugating enzyme E2 J1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UBE2J1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:89,326,625...89,352,722
Ensembl chr 6:89,326,625...89,352,722
|
|
G |
UBE2N |
ubiquitin conjugating enzyme E2 N |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UBE2N mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:93,405,684...93,441,947
Ensembl chr12:93,405,673...93,441,947
|
|
G |
UIMC1 |
ubiquitin interaction motif containing 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UIMC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:176,905,005...177,022,602
Ensembl chr 5:176,905,005...177,022,633
|
|
G |
UROS |
uroporphyrinogen III synthase |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of UROS mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:125,784,980...125,823,258
Ensembl chr10:125,784,980...125,823,288
|
|
G |
USP13 |
ubiquitin specific peptidase 13 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of USP13 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:179,653,040...179,789,401
Ensembl chr 3:179,653,032...179,804,366
|
|
G |
VASN |
vasorin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of VASN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:4,371,848...4,383,538
Ensembl chr16:4,371,848...4,383,538
|
|
G |
VPS37B |
VPS37B subunit of ESCRT-I |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of VPS37B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:122,865,330...122,896,124
Ensembl chr12:122,865,330...122,896,127
|
|
G |
VPS72 |
vacuolar protein sorting 72 homolog |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of VPS72 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:151,176,304...151,190,197
Ensembl chr 1:151,176,304...151,195,321
|
|
G |
WASF2 |
WASP family member 2 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of WASF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:27,404,230...27,490,167
Ensembl chr 1:27,404,230...27,490,167
|
|
G |
XPNPEP1 |
X-prolyl aminopeptidase 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of XPNPEP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:109,864,766...109,923,511
Ensembl chr10:109,864,766...109,923,553
|
|
G |
ZC3H4 |
zinc finger CCCH-type containing 4 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ZC3H4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:47,064,187...47,113,776
Ensembl chr19:47,064,187...47,113,776
|
|
G |
ZNF185 |
zinc finger protein 185 with LIM domain |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ZNF185 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:152,898,067...152,973,481
Ensembl chr X:152,898,067...152,973,481
|
|
G |
ZSWIM1 |
zinc finger SWIM-type containing 1 |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ZSWIM1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:45,880,920...45,885,266
Ensembl chr20:45,881,227...45,885,266
|
|
G |
ZYX |
zyxin |
multiple interactions |
EXP |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ZYX mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:143,381,345...143,391,111
Ensembl chr 7:143,381,295...143,391,111
|
|
|
G |
FGF1 |
fibroblast growth factor 1 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of FGF1 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr 5:142,592,178...142,698,070
Ensembl chr 5:142,592,178...142,698,070
|
|
G |
FGF4 |
fibroblast growth factor 4 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of FGF4 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr11:69,771,022...69,775,341
Ensembl chr11:69,771,022...69,775,341
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of HMOX1 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HSPA4 |
heat shock protein family A (Hsp70) member 4 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of HSPA4 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr 5:133,052,013...133,106,449
Ensembl chr 5:133,052,013...133,106,449
|
|
G |
PF4 |
platelet factor 4 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of PF4 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr 4:73,980,811...73,982,124
Ensembl chr 4:73,980,811...73,982,027
|
|
G |
SMAD7 |
SMAD family member 7 |
increases expression |
ISO |
isobutyl nitrite results in increased expression of SMAD7 mRNA |
CTD |
PMID:16288974 |
|
NCBI chr18:48,919,853...48,950,965
Ensembl chr18:48,919,853...48,950,965
|
|
G |
VEGFA |
vascular endothelial growth factor A |
increases expression |
ISO |
isobutyl nitrite results in increased expression of VEGFA mRNA |
CTD |
PMID:16288974 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VEGFD |
vascular endothelial growth factor D |
increases expression |
ISO |
isobutyl nitrite results in increased expression of VEGFD mRNA |
CTD |
PMID:16288974 |
|
NCBI chr X:15,345,596...15,384,413
Ensembl chr X:15,345,596...15,384,413
|
|
|
G |
ATG5 |
autophagy related 5 |
multiple interactions |
ISO |
Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]] |
CTD |
PMID:31676321 |
|
NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791
|
|
G |
ATG7 |
autophagy related 7 |
multiple interactions |
ISO |
Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]] |
CTD |
PMID:31676321 |
|
NCBI chr 3:11,272,397...11,576,353
Ensembl chr 3:11,272,309...11,557,665
|
|
G |
BECN1 |
beclin 1 |
multiple interactions |
ISO |
Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein] |
CTD |
PMID:31676321 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
ISO |
Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]] |
CTD |
PMID:31676321 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine] |
CTD |
PMID:22689575 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:31676321 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:31676321 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
SLC3A2 |
solute carrier family 3 member 2 |
affects import |
EXP |
SLC3A2 protein affects the import of Leucine |
CTD |
PMID:28786956 |
|
NCBI chr11:62,856,109...62,888,860
Ensembl chr11:62,856,004...62,888,880
|
|
G |
SLC7A8 |
solute carrier family 7 member 8 |
affects import |
EXP |
SLC7A8 protein affects the import of Leucine |
CTD |
PMID:28786956 |
|
NCBI chr14:23,125,295...23,183,660
Ensembl chr14:23,125,295...23,183,674
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions |
ISO |
Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein] |
CTD |
PMID:31676321 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
|
G |
AR |
androgen receptor |
increases activity |
EXP |
lacidipine results in increased activity of AR protein |
CTD |
PMID:25257666 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
ESR1 |
estrogen receptor 1 |
increases activity |
EXP |
lacidipine results in increased activity of ESR1 protein |
CTD |
PMID:25257666 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
NCOA2 |
nuclear receptor coactivator 2 |
multiple interactions |
EXP |
lacidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]] |
CTD |
PMID:27773686 |
|
NCBI chr 8:70,109,782...70,456,446
Ensembl chr 8:70,109,782...70,403,808
|
|
G |
NR1H4 |
nuclear receptor subfamily 1 group H member 4 |
multiple interactions increases activity |
EXP |
lacidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; lacidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; lacidipine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] lacidipine results in increased activity of NR1H4 protein |
CTD |
PMID:25257666 PMID:27773686 |
|
NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
|
|
G |
PPARD |
peroxisome proliferator activated receptor delta |
increases activity |
EXP |
lacidipine results in increased activity of PPARD protein |
CTD |
PMID:25257666 |
|
NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
increases activity |
EXP |
lacidipine results in increased activity of PPARG protein |
CTD |
PMID:25257666 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
VDR |
vitamin D receptor |
increases activity |
EXP |
lacidipine results in increased activity of VDR protein |
CTD |
PMID:25257666 |
|
NCBI chr12:47,841,537...47,904,994
Ensembl chr12:47,841,537...47,943,048
|
|
|
G |
DPP3 |
dipeptidyl peptidase 3 |
multiple interactions increases cleavage |
EXP |
spinorphin inhibits the reaction [DPP3 protein results in increased cleavage of Enkephalin, Leucine]; tynorphin inhibits the reaction [DPP3 protein results in increased cleavage of Enkephalin, Leucine] |
CTD |
PMID:10873616 |
|
NCBI chr11:66,480,434...66,509,657
Ensembl chr11:66,480,013...66,509,657
|
|
G |
OPRD1 |
opioid receptor delta 1 |
increases activity |
EXP |
Enkephalin, Leucine results in increased activity of OPRD1 protein |
CTD |
PMID:26476280 |
|
NCBI chr 1:28,812,170...28,871,267
Ensembl chr 1:28,812,170...28,871,267
|
|
G |
OPRM1 |
opioid receptor mu 1 |
increases activity |
EXP |
Enkephalin, Leucine results in increased activity of OPRM1 protein |
CTD |
PMID:26476280 |
|
NCBI chr 6:154,010,496...154,246,867
Ensembl chr 6:154,010,496...154,246,867
|
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
leucine methyl ester inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:21748807 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
ADA |
adenosine deaminase |
multiple interactions |
EXP |
ADA protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides] |
CTD |
PMID:10947063 |
|
NCBI chr20:44,619,522...44,651,699
Ensembl chr20:44,584,896...44,652,252
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
EXP ISO |
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:15925284 PMID:16621998 PMID:34144024 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ALOX5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP |
[zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4]; ALOX5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of ALOX5 protein; SB 203580 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of ALOX5 protein] |
CTD |
PMID:9495842 PMID:10779545 PMID:11116075 |
|
NCBI chr10:45,374,216...45,446,117
Ensembl chr10:45,374,176...45,446,119
|
|
G |
ARF1 |
ADP ribosylation factor 1 |
affects localization |
EXP |
N-Formylmethionine Leucyl-Phenylalanine affects the localization of ARF1 protein |
CTD |
PMID:10931844 |
|
NCBI chr 1:228,082,708...228,099,212
Ensembl chr 1:228,082,708...228,099,212
|
|
G |
ARF6 |
ADP ribosylation factor 6 |
multiple interactions affects localization |
EXP |
1-Butanol inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 1-Butanol inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]; ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides] N-Formylmethionine Leucyl-Phenylalanine affects the localization of ARF6 protein |
CTD |
PMID:10931844 |
|
NCBI chr14:49,893,082...49,897,054
Ensembl chr14:49,893,079...49,897,054
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases activity |
EXP |
N-Formylmethionine Leucyl-Phenylalanine results in increased activity of BAX protein |
CTD |
PMID:20130848 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases activity |
EXP |
Melatonin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CASP3 protein] |
CTD |
PMID:20130848 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases activity |
EXP |
Melatonin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CASP9 protein] |
CTD |
PMID:20130848 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CD38 |
CD38 molecule |
increases cleavage multiple interactions |
EXP |
N-Formylmethionine Leucyl-Phenylalanine results in increased cleavage of CD38 protein SB 203580 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased cleavage of CD38 protein] |
CTD |
PMID:15494208 |
|
NCBI chr 4:15,778,328...15,853,232
Ensembl chr 4:15,778,275...15,853,232
|
|
G |
CD63 |
CD63 molecule |
multiple interactions increases expression |
EXP |
Mustard Gas promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]; Quercetin affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]; SB 203580 inhibits the reaction [Mustard Gas promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]] |
CTD |
PMID:19887118 PMID:22036725 |
|
NCBI chr12:55,723,535...55,730,041
Ensembl chr12:55,725,323...55,729,707
|
|
G |
CTSG |
cathepsin G |
multiple interactions increases secretion |
EXP |
cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CTSG protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CTSG protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CTSG protein] |
CTD |
PMID:25980585 PMID:34144024 |
|
NCBI chr14:24,573,518...24,576,250
Ensembl chr14:24,573,518...24,576,250
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
increases expression increases secretion multiple interactions |
EXP |
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CXCL8 mRNA; N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CXCL8 protein N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CXCL8 protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CXCL8 protein]; nimesulide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CXCL8 protein]; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CXCL8 mRNA]; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CXCL8 protein] |
CTD |
PMID:11566077 PMID:12946449 PMID:17459229 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYBB |
cytochrome b-245 beta chain |
multiple interactions increases activity |
ISO |
diphenyleneiodonium inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CYBB protein]; Genistein inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CYBB protein] |
CTD |
PMID:29183754 |
|
NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461
|
|
G |
ELANE |
elastase, neutrophil expressed |
multiple interactions increases secretion |
EXP |
2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of ELANE protein]; [Cytochalasin B co-treated with N-Formylmethionine Leucyl-Phenylalanine] results in increased secretion of ELANE protein; pirinixic acid analog inhibits the reaction [[Cytochalasin B co-treated with N-Formylmethionine Leucyl-Phenylalanine] results in increased secretion of ELANE protein] |
CTD |
PMID:19686721 PMID:21457779 |
|
NCBI chr19:852,303...856,243
Ensembl chr19:851,014...856,247
|
|
G |
ENPP3 |
ectonucleotide pyrophosphatase/phosphodiesterase 3 |
multiple interactions increases expression |
EXP |
Quercetin affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ENPP3 protein] |
CTD |
PMID:19887118 |
|
NCBI chr 6:131,637,302...131,747,410
Ensembl chr 6:131,628,442...131,747,418
|
|
G |
FGR |
FGR proto-oncogene, Src family tyrosine kinase |
multiple interactions increases phosphorylation |
EXP |
1-Butanol inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with dihydrocytochalasin B] results in increased activity of FGR protein] N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of FGR protein |
CTD |
PMID:11078731 PMID:25980585 |
|
NCBI chr 1:27,612,064...27,635,185
Ensembl chr 1:27,612,064...27,635,185
|
|
G |
FPR1 |
formyl peptide receptor 1 |
multiple interactions |
EXP |
N-Formylmethionine Leucyl-Phenylalanine binds to and results in increased activity of FPR1 protein |
CTD |
PMID:17520823 |
|
NCBI chr19:51,745,172...51,751,878
Ensembl chr19:51,745,172...51,804,115
|
|
G |
GUSB |
glucuronidase beta |
increases secretion multiple interactions |
ISO EXP |
N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of GUSB protein epigallocatechin gallate inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of GUSB protein] |
CTD |
PMID:9545557 PMID:11944907 |
|
NCBI chr 7:65,960,684...65,982,213
Ensembl chr 7:65,960,684...65,982,215
|
|
G |
HCK |
HCK proto-oncogene, Src family tyrosine kinase |
increases phosphorylation |
EXP |
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of HCK protein |
CTD |
PMID:25980585 |
|
NCBI chr20:32,052,242...32,101,856
Ensembl chr20:32,052,197...32,101,856
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions increases expression |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL1B protein]; nimesulide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL1B protein] |
CTD |
PMID:12946449 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL3 |
interleukin 3 |
increases response to substance |
ISO |
IL3 protein results in increased susceptibility to N-Formylmethionine Leucyl-Phenylalanine |
CTD |
PMID:11145705 |
|
NCBI chr 5:132,060,655...132,063,204
Ensembl chr 5:132,060,655...132,063,204
|
|
G |
IL6 |
interleukin 6 |
multiple interactions increases expression |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL6 protein]; nimesulide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL6 protein] |
CTD |
PMID:12946449 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
ITGA2B |
integrin subunit alpha 2b |
multiple interactions |
EXP |
ITGA2B protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein] |
CTD |
PMID:11116075 |
|
NCBI chr17:44,372,181...44,389,649
Ensembl chr17:44,372,180...44,389,649
|
|
G |
ITGAM |
integrin subunit alpha M |
multiple interactions increases expression |
EXP |
2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; dimemorfan inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; Foropafant inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; KT 5720 inhibits the reaction [2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; plaunotol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; Staurosporine inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein] fMLP increases expression of ITGAM protein on neutrophils and monocytes [N-formyl-methionyl-leucyl-phenylalanine cotreated with midazolam] decreases expression of ITGAM protein on neutrophils |
CTD RGD |
PMID:10215738 PMID:11116075 PMID:15774851 PMID:18500357 PMID:21457779 PMID:18064325 PMID:20421794 More...
|
RGD:329901666, RGD:329853762 |
NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892
|
|
G |
ITGB2 |
integrin subunit beta 2 |
increases expression multiple interactions |
ISO EXP |
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; acteoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; crenatoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; plaunotol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein] |
CTD |
PMID:10215738 PMID:16393473 PMID:21664406 |
|
NCBI chr21:44,885,953...44,928,815
Ensembl chr21:44,885,953...44,931,989
|
|
G |
ITGB3 |
integrin subunit beta 3 |
increases expression |
ISO |
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB3 protein |
CTD |
PMID:21664406 |
|
NCBI chr17:47,253,827...47,313,743
Ensembl chr17:47,253,827...47,313,743
|
|
G |
LYN |
LYN proto-oncogene, Src family tyrosine kinase |
multiple interactions increases phosphorylation |
EXP |
AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of LYN protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of LYN protein] |
CTD |
PMID:25980585 |
|
NCBI chr 8:55,879,835...56,014,169
Ensembl chr 8:55,879,835...56,014,169
|
|
G |
LYZ |
lysozyme |
increases secretion |
ISO |
N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of LYZ protein |
CTD |
PMID:9545557 |
|
NCBI chr12:69,348,381...69,354,234
Ensembl chr12:69,348,381...69,354,234
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; Grape Seed Proanthocyanidins inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pentoxifylline inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Qingdai compound inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; Resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein] N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein; resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein] RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11145705 PMID:11427526 PMID:15494208 PMID:16212921 PMID:16621998 PMID:17377739 PMID:17560994 PMID:19167369 PMID:19559779 PMID:19697996 PMID:25980585 PMID:34144024 More...
|
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK14 |
mitogen-activated protein kinase 14 |
multiple interactions increases phosphorylation |
EXP ISO |
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK14 protein; Omeprazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:16621998 PMID:17406807 |
|
NCBI chr 6:36,027,808...36,124,214
Ensembl chr 6:36,027,782...36,111,236
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; Grape Seed Proanthocyanidins inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pentoxifylline inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Qingdai compound inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; Resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein] N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein; resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein] RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11145705 PMID:11427526 PMID:15494208 PMID:16212921 PMID:16621998 PMID:17377739 PMID:17560994 PMID:19167369 PMID:19559779 PMID:19697996 PMID:25980585 PMID:34144024 More...
|
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP ISO |
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK8 protein; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK8 protein] MAPK8 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Reactive Oxygen Species]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK8 protein |
CTD |
PMID:17377739 PMID:17560994 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MMP8 |
matrix metallopeptidase 8 |
increases expression |
ISO |
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of MMP8 protein |
CTD |
PMID:32367270 |
|
NCBI chr11:102,711,796...102,724,954
Ensembl chr11:102,711,796...102,727,050
|
|
G |
MPO |
myeloperoxidase |
multiple interactions increases activity increases secretion increases expression |
ISO EXP |
carvedilol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of MPO protein] N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein Carvedilol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein]; diphenyleneiodonium inhibits the reaction [manganese chloride promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein]]; manganese chloride promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein]; Sodium Azide inhibits the reaction [manganese chloride promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein]]; Wortmannin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein] |
CTD |
PMID:16601795 PMID:17159805 PMID:18987595 PMID:22906169 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
NCF1 |
neutrophil cytosolic factor 1 |
multiple interactions affects localization |
EXP |
AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF1 protein]; bisindolylmaleimide I inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF1 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF1 protein] |
CTD |
PMID:25980585 |
|
NCBI chr 7:74,774,011...74,789,315
Ensembl chr 7:74,774,011...74,789,315
|
|
G |
PECAM1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression |
ISO |
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of PECAM1 protein |
CTD |
PMID:21664406 |
|
NCBI chr17:64,319,415...64,390,860
Ensembl chr17:64,319,415...64,413,776
|
|
G |
PLA2G4A |
phospholipase A2 group IVA |
multiple interactions |
EXP |
PLA2G4A protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased metabolism of Leukotriene B4] |
CTD |
PMID:11741884 |
|
NCBI chr 1:186,828,949...186,988,981
Ensembl chr 1:186,828,949...186,988,981
|
|
G |
PLA2G5 |
phospholipase A2 group V |
increases activity multiple interactions increases secretion |
EXP |
N-Formylmethionine Leucyl-Phenylalanine results in increased activity of PLA2G5 protein PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Arachidonic Acid]; PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4] N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of PLA2G5 protein |
CTD |
PMID:9495842 PMID:11741884 |
|
NCBI chr 1:20,028,408...20,091,911
Ensembl chr 1:20,028,179...20,091,911
|
|
G |
PLCG2 |
phospholipase C gamma 2 |
multiple interactions increases phosphorylation |
EXP |
AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein] |
CTD |
PMID:25980585 |
|
NCBI chr16:81,779,291...81,962,685
Ensembl chr16:81,779,279...81,962,685
|
|
G |
PLD1 |
phospholipase D1 |
multiple interactions |
EXP ISO |
PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein] PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:11427526 PMID:17560994 |
|
NCBI chr 3:171,600,404...171,810,483
Ensembl chr 3:171,600,404...171,810,950
|
|
G |
PTAFR |
platelet activating factor receptor |
multiple interactions |
EXP |
PTAFR protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein] |
CTD |
PMID:11116075 |
|
NCBI chr 1:28,147,166...28,193,856
Ensembl chr 1:28,147,166...28,193,936
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of PTGS2 mRNA; N-Formylmethionine Leucyl-Phenylalanine results in increased expression of PTGS2 protein |
CTD |
PMID:12946449 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RAC1 |
Rac family small GTPase 1 |
increases activity multiple interactions |
ISO |
N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein 6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]; apilimod inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]; RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein] |
CTD |
PMID:16621998 PMID:28779020 |
|
NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967
|
|
G |
RAC2 |
Rac family small GTPase 2 |
increases activity multiple interactions |
ISO |
N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein 6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein]; apilimod inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein]; RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein] |
CTD |
PMID:11145705 PMID:16621998 PMID:28779020 |
|
NCBI chr22:37,225,270...37,244,269
Ensembl chr22:37,225,270...37,259,594
|
|
G |
RHOG |
ras homolog family member G |
multiple interactions affects response to substance |
ISO |
RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]; RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein] RHOG protein affects the susceptibility to N-Formylmethionine Leucyl-Phenylalanine |
CTD |
PMID:16621998 |
|
NCBI chr11:3,826,978...3,840,959
Ensembl chr11:3,826,978...3,840,959
|
|
G |
SELL |
selectin L |
increases expression |
ISO |
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELL protein |
CTD |
PMID:21664406 |
|
NCBI chr 1:169,690,667...169,711,620
Ensembl chr 1:169,690,665...169,711,702
|
|
G |
SELP |
selectin P |
multiple interactions increases expression |
EXP |
ALOX5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; Foropafant inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; ITGA2B protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; MK-886 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; PTAFR protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; SR 121566 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; zileuton inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein] |
CTD |
PMID:11116075 |
|
NCBI chr 1:169,588,849...169,630,124
Ensembl chr 1:169,588,849...169,630,193
|
|
G |
SRC |
SRC proto-oncogene, non-receptor tyrosine kinase |
increases phosphorylation multiple interactions |
EXP |
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]; cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein] |
CTD |
PMID:25980585 PMID:34144024 |
|
NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050
|
|
G |
TEC |
tec protein tyrosine kinase |
multiple interactions affects localization |
EXP |
AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of TEC protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of TEC protein] |
CTD |
PMID:25980585 |
|
NCBI chr 4:48,135,783...48,269,838
Ensembl chr 4:48,135,783...48,269,838
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases expression |
EXP |
[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides; Cyclosporine inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides]; Tacrolimus inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides] N-Formylmethionine Leucyl-Phenylalanine results in increased expression of TNF protein |
CTD |
PMID:11121130 PMID:12946449 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFAIP6 |
TNF alpha induced protein 6 |
decreases response to substance |
EXP |
TNFAIP6 protein modified form results in decreased susceptibility to N-Formylmethionine Leucyl-Phenylalanine |
CTD |
PMID:12401803 |
|
NCBI chr 2:151,357,592...151,381,340
Ensembl chr 2:151,357,592...151,380,046
|
|
G |
VAV1 |
vav guanine nucleotide exchange factor 1 |
increases phosphorylation |
EXP |
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of VAV1 protein |
CTD |
PMID:25980585 |
|
NCBI chr19:6,772,708...6,857,361
Ensembl chr19:6,772,708...6,857,366
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions increases expression increases secretion |
EXP |
Masoprocol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA]; Masoprocol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of VEGFA protein]; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA]; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of VEGFA protein] N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA; N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA protein |
CTD |
PMID:17377739 PMID:17459229 PMID:17520823 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
|
G |
ABHD12 |
abhydrolase domain containing 12, lysophospholipase |
decreases activity |
EXP |
orlistat results in decreased activity of ABHD12 protein |
CTD |
PMID:18657971 |
|
NCBI chr20:25,294,743...25,390,835
Ensembl chr20:25,294,742...25,390,835
|
|
G |
ABHD16A |
abhydrolase domain containing 16A, phospholipase |
decreases activity |
EXP |
orlistat results in decreased activity of ABHD16A protein |
CTD |
PMID:18657971 |
|
NCBI chr 6:31,686,955...31,703,324
Ensembl chr 6:31,686,955...31,703,356
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
multiple interactions decreases expression |
EXP |
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA] Orlistat results in decreased expression of ACACA mRNA |
CTD |
PMID:32347045 PMID:33476690 |
|
NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
decreases activity |
EXP |
Orlistat results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ACOT8 |
acyl-CoA thioesterase 8 |
decreases expression |
EXP |
Orlistat results in decreased expression of ACOT8 protein |
CTD |
PMID:30667213 |
|
NCBI chr20:45,841,721...45,857,392
Ensembl chr20:45,841,721...45,857,405
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO EXP |
orlistat inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein] |
CTD |
PMID:25087745 PMID:33476690 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:32045588 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions |
EXP |
[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid] |
CTD |
PMID:28721267 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
ATF4 |
activating transcription factor 4 |
increases expression |
EXP |
orlistat results in increased expression of ATF4 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of BAX mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of BCL2 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CASP3 |
caspase 3 |
increases cleavage multiple interactions increases activity |
EXP ISO |
orlistat results in increased cleavage of CASP3 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA] orlistat results in increased activity of CASP3 protein |
CTD |
PMID:17283163 PMID:20805790 PMID:21723078 PMID:32450208 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
EXP ISO |
orlistat analog results in increased cleavage of and results in increased activity of CASP8 protein; orlistat results in increased cleavage of and results in increased activity of CASP8 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP8 mRNA] |
CTD |
PMID:18796435 PMID:20577697 PMID:32450208 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
increases activity multiple interactions |
ISO |
orlistat results in increased activity of CASP9 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP9 mRNA] |
CTD |
PMID:20805790 PMID:32450208 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions decreases expression |
ISO EXP |
Orlistat inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT mRNA]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT protein] Orlistat results in decreased expression of CAT protein |
CTD |
PMID:25087745 PMID:30667213 PMID:32450208 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCK |
cholecystokinin |
decreases secretion multiple interactions |
EXP |
orlistat results in decreased secretion of CCK protein [[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [Fats results in increased secretion of CCK protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of CCK protein] |
CTD |
PMID:11408251 PMID:18303078 PMID:18647814 |
|
NCBI chr 3:42,257,826...42,266,185
Ensembl chr 3:42,257,825...42,266,185
|
|
G |
CCNA2 |
cyclin A2 |
decreases expression |
EXP |
Orlistat results in decreased expression of CCNA2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
|
|
G |
CCND1 |
cyclin D1 |
increases expression multiple interactions |
EXP |
Orlistat results in increased expression of CCND1 protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein] |
CTD |
PMID:30667213 PMID:32045588 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCNE1 |
cyclin E1 |
increases expression |
EXP |
Orlistat results in increased expression of CCNE1 protein |
CTD |
PMID:30667213 |
|
NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312
|
|
G |
CD34 |
CD34 molecule |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein] |
CTD |
PMID:32045588 |
|
NCBI chr 1:207,880,972...207,911,125
Ensembl chr 1:207,880,972...207,911,402
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
decreases expression |
EXP |
Orlistat results in decreased expression of CDK1 protein |
CTD |
PMID:30667213 |
|
NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
decreases expression |
EXP |
Orlistat results in decreased expression of CDK2 protein |
CTD |
PMID:30667213 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CDK4 |
cyclin dependent kinase 4 |
decreases expression |
EXP |
Orlistat results in decreased expression of CDK4 protein |
CTD |
PMID:30667213 |
|
NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
EXP |
Orlistat results in increased expression of CDKN1A protein |
CTD |
PMID:30667213 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
increases expression |
EXP |
orlistat results in increased expression of CDKN1B protein |
CTD |
PMID:15138278 |
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
multiple interactions |
EXP |
Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] |
CTD |
PMID:33476690 |
|
NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534
|
|
G |
CEL |
carboxyl ester lipase |
decreases activity |
EXP |
orlistat results in decreased activity of CEL protein |
CTD |
PMID:11592731 PMID:12381337 |
|
NCBI chr 9:133,061,981...133,071,861
Ensembl chr 9:133,061,981...133,071,861
|
|
G |
CLPS |
colipase |
multiple interactions |
EXP |
orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil] |
CTD |
PMID:15158758 |
|
NCBI chr 6:35,794,982...35,797,323
Ensembl chr 6:35,794,982...35,797,344
|
|
G |
CPB2 |
carboxypeptidase B2 |
decreases expression |
EXP |
orlistat results in decreased expression of CPB2 protein |
CTD |
PMID:16959692 |
|
NCBI chr13:46,053,186...46,105,033
Ensembl chr13:46,053,186...46,105,033
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
decreases expression |
EXP |
Orlistat results in decreased expression of CPT1A protein |
CTD |
PMID:30667213 |
|
NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410
|
|
G |
CPT2 |
carnitine palmitoyltransferase 2 |
decreases expression |
EXP |
Orlistat results in decreased expression of CPT2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 1:53,196,824...53,214,197
Ensembl chr 1:53,196,792...53,214,197
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
orlistat inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA] |
CTD |
PMID:21088047 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
increases expression |
EXP |
orlistat results in increased expression of CYP3A4 mRNA; orlistat results in increased expression of CYP3A4 protein |
CTD |
PMID:20599501 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DAGLA |
diacylglycerol lipase alpha |
decreases activity |
EXP |
orlistat results in decreased activity of DAGLA protein |
CTD |
PMID:16466961 |
|
NCBI chr11:61,680,391...61,747,001
Ensembl chr11:61,680,391...61,747,001
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
EXP |
orlistat results in increased expression of DDIT3 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DDIT4 |
DNA damage inducible transcript 4 |
increases expression |
EXP |
orlistat results in increased expression of DDIT4 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr10:72,273,924...72,276,036
Ensembl chr10:72,273,919...72,276,036
|
|
G |
EIF2A |
eukaryotic translation initiation factor 2A |
increases phosphorylation multiple interactions |
ISO EXP |
orlistat results in increased phosphorylation of EIF2A protein Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein] orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein] orlistat analog results in increased phosphorylation of EIF2A protein; orlistat results in increased phosphorylation of EIF2A protein |
CTD |
PMID:17283163 PMID:20577697 |
|
NCBI chr 3:150,546,787...150,586,016
Ensembl chr 3:150,546,678...150,586,016
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases response to substance |
ISO |
orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein] EIF2AK3 gene mutant form results in increased susceptibility to orlistat |
CTD |
PMID:17283163 |
|
NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518
|
|
G |
EIF4E |
eukaryotic translation initiation factor 4E |
increases phosphorylation |
EXP |
orlistat results in increased phosphorylation of EIF4E protein |
CTD |
PMID:18796435 |
|
NCBI chr 4:98,879,276...98,929,133
Ensembl chr 4:98,879,276...98,929,133
|
|
G |
ERBB2 |
erb-b2 receptor tyrosine kinase 2 |
decreases expression affects localization affects response to substance |
EXP |
orlistat results in decreased expression of ERBB2 mRNA; orlistat results in decreased expression of ERBB2 protein orlistat affects the localization of ERBB2 protein ERBB2 protein affects the susceptibility to orlistat |
CTD |
PMID:15870086 |
|
NCBI chr17:39,688,094...39,728,658
Ensembl chr17:39,687,914...39,730,426
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA] |
CTD |
PMID:17283163 |
|
NCBI chr17:64,039,142...64,130,144
Ensembl chr17:64,039,080...64,130,819
|
|
G |
ETV4 |
ETS variant transcription factor 4 |
increases expression |
EXP |
orlistat results in increased expression of ETV4 protein |
CTD |
PMID:15870086 |
|
NCBI chr17:43,527,846...43,546,340
Ensembl chr17:43,527,844...43,579,620
|
|
G |
FABP1 |
fatty acid binding protein 1 |
decreases expression |
EXP |
Orlistat results in decreased expression of FABP1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062
|
|
G |
FAS |
Fas cell surface death receptor |
decreases expression |
EXP |
Orlistat results in decreased expression of FAS mRNA |
CTD |
PMID:32347045 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FASN |
fatty acid synthase |
multiple interactions decreases expression affects response to substance affects binding decreases activity |
ISO EXP |
[orlistat results in decreased activity of FASN protein] which affects the abundance of Fatty Acids, Nonesterified; orlistat inhibits the reaction [FASN protein results in increased chemical synthesis of Palmitic Acid] Orlistat results in decreased expression of FASN protein FASN protein affects the susceptibility to orlistat orlistat analog binds to FASN protein [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [Orlistat results in decreased activity of FASN protein] which results in decreased chemical synthesis of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein; Orlistat binds to and results in decreased activity of FASN protein; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Doxorubicin]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Mitoxantrone] orlistat analog results in decreased activity of FASN protein; orlistat results in decreased activity of FASN protein |
CTD |
PMID:15026345 PMID:15138278 PMID:15870086 PMID:17012255 PMID:17618296 PMID:17847090 PMID:18281512 PMID:18710210 PMID:18723500 PMID:20148945 PMID:20577697 PMID:21213365 PMID:30667213 PMID:32045588 PMID:33476690 More...
|
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
GCG |
glucagon |
decreases secretion multiple interactions decreases expression |
EXP |
orlistat results in decreased secretion of GCG protein orlistat inhibits the reaction [Dietary Fats results in increased secretion of GCG protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of GCG protein] orlistat results in decreased expression of GCG protein |
CTD |
PMID:12915676 PMID:18647814 PMID:19837920 |
|
NCBI chr 2:162,142,882...162,152,247
Ensembl chr 2:162,142,882...162,152,404
|
|
G |
GHRL |
ghrelin and obestatin prepropeptide |
multiple interactions |
EXP |
orlistat inhibits the reaction [Olive Oil results in decreased expression of GHRL protein]; orlistat inhibits the reaction [Triglycerides results in decreased secretion of GHRL protein] |
CTD |
PMID:15998659 PMID:17138722 |
|
NCBI chr 3:10,285,666...10,292,947
Ensembl chr 3:10,285,666...10,292,947
|
|
G |
GIP |
gastric inhibitory polypeptide |
decreases expression |
EXP |
orlistat results in decreased expression of GIP protein |
CTD |
PMID:12915676 |
|
NCBI chr17:48,958,554...48,968,596
Ensembl chr17:48,958,554...48,968,596
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein] |
CTD |
PMID:29479035 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GPX1 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
GPX8 |
glutathione peroxidase 8 (putative) |
increases expression |
EXP |
orlistat results in increased expression of GPX8 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr 5:55,160,171...55,167,297
Ensembl chr 5:55,160,167...55,167,297
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GSR protein] |
CTD |
PMID:32450208 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
HBA1 |
hemoglobin subunit alpha 1 |
decreases expression |
EXP |
orlistat results in decreased expression of HBA1 protein modified form |
CTD |
PMID:19207292 PMID:19461584 |
|
NCBI chr16:176,680...177,522
Ensembl chr16:176,680...177,522
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
orlistat inhibits the reaction [Dietary Fats results in increased expression of HMGCR protein] |
CTD |
PMID:25087745 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
orlistat results in increased expression of HSPA5 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
IL10 |
interleukin 10 |
increases expression |
ISO |
Orlistat results in increased expression of IL10 mRNA |
CTD |
PMID:32450208 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:21088047 PMID:32045588 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INS |
insulin |
increases expression multiple interactions affects expression decreases expression |
EXP |
orlistat results in increased expression of INS protein [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] orlistat affects the expression of INS protein orlistat results in decreased expression of INS protein |
CTD |
PMID:10095983 PMID:11274935 PMID:12915676 PMID:33476690 |
|
NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221
|
|
G |
INS-IGF2 |
INS-IGF2 readthrough |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of INS1 protein] |
CTD |
PMID:25087745 |
|
NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209
|
|
G |
KDELR3 |
KDEL endoplasmic reticulum protein retention receptor 3 |
increases expression |
EXP |
orlistat results in increased expression of KDELR3 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr22:38,468,096...38,483,447
Ensembl chr22:38,468,078...38,483,447
|
|
G |
KDR |
kinase insert domain receptor |
decreases expression |
EXP |
orlistat results in decreased expression of KDR protein |
CTD |
PMID:17012255 |
|
NCBI chr 4:55,078,481...55,125,595
Ensembl chr 4:55,078,481...55,125,595
|
|
G |
KRT81 |
keratin 81 |
increases expression |
EXP |
orlistat results in increased expression of KRT81 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr12:52,285,913...52,308,624
Ensembl chr12:52,285,913...52,291,534
|
|
G |
LCAT |
lecithin-cholesterol acyltransferase |
multiple interactions |
ISO |
orlistat inhibits the reaction [Dietary Fats results in decreased expression of LCAT protein] |
CTD |
PMID:25087745 |
|
NCBI chr16:67,939,750...67,944,120
Ensembl chr16:67,939,750...67,944,131
|
|
G |
LEP |
leptin |
multiple interactions |
ISO |
orlistat inhibits the reaction [Dietary Fats results in increased expression of LEP protein] |
CTD |
PMID:21332399 PMID:25087745 |
|
NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629
|
|
G |
LIPF |
lipase F, gastric type |
decreases activity |
EXP |
orlistat results in decreased activity of LIPF protein |
CTD |
PMID:11408251 PMID:12381337 |
|
NCBI chr10:88,664,442...88,678,814
Ensembl chr10:88,664,441...88,678,814
|
|
G |
LPL |
lipoprotein lipase |
multiple interactions decreases activity |
ISO EXP |
[orlistat results in decreased activity of LPL protein] which affects the uptake of Triglycerides orlistat inhibits the reaction [Dietary Fats results in decreased expression of LPL protein] orlistat inhibits the reaction [[LPL protein results in increased hydrolysis of Triglycerides] which results in increased uptake of Triglycerides]; orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]; orlistat inhibits the reaction [very low density lipoprotein triglyceride results in increased activity of LPL protein] |
CTD |
PMID:12388125 PMID:12573449 PMID:15910848 PMID:15994321 PMID:18698144 PMID:25087745 More...
|
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:32045588 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:32045588 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MET |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:32045588 |
|
NCBI chr 7:116,672,196...116,798,377
Ensembl chr 7:116,672,196...116,798,377
|
|
G |
NAPEPLD |
N-acyl phosphatidylethanolamine phospholipase D |
decreases activity |
ISO |
orlistat results in decreased activity of NAPEPLD protein |
CTD |
PMID:16466961 |
|
NCBI chr 7:103,099,776...103,150,001
Ensembl chr 7:103,099,776...103,149,560
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO EXP |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of NFE2L2 mRNA] [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:32450208 PMID:33476690 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 mRNA]; Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 protein] |
CTD |
PMID:32450208 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NPY |
neuropeptide Y |
increases expression |
EXP |
orlistat results in increased expression of NPY protein |
CTD |
PMID:15962606 |
|
NCBI chr 7:24,284,190...24,291,862
Ensembl chr 7:24,284,188...24,291,862
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
orlistat results in increased activity of NR1I2 protein |
CTD |
PMID:20599501 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
multiple interactions |
EXP |
Orlistat binds to and results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:31312845 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
NTS |
neurotensin |
multiple interactions |
EXP |
orlistat inhibits the reaction [Fats results in increased secretion of NTS protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of NTS protein] |
CTD |
PMID:18303078 |
|
NCBI chr12:85,874,295...85,882,992
Ensembl chr12:85,874,295...85,882,992
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
EXP |
orlistat results in increased cleavage of PARP1 protein [orlistat co-treated with Thapsigargin] results in increased cleavage of PARP1 protein |
CTD |
PMID:15870086 PMID:17283163 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PCNA |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein] |
CTD |
PMID:32045588 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
PLA2G7 |
phospholipase A2 group VII |
multiple interactions decreases activity |
EXP |
[orlistat co-treated with Ezetimibe] results in decreased activity of PLA2G7 protein; [orlistat co-treated with Fenofibrate] results in decreased activity of PLA2G7 protein orlistat results in decreased activity of PLA2G7 protein |
CTD |
PMID:16911813 PMID:18513463 PMID:18657971 |
|
NCBI chr 6:46,704,201...46,735,721
Ensembl chr 6:46,704,201...46,735,693
|
|
G |
PNLIP |
pancreatic lipase |
decreases secretion multiple interactions affects folding decreases activity |
EXP ISO |
orlistat results in decreased secretion of PNLIP protein [[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil] orlistat affects the folding of PNLIP protein orlistat results in decreased activity of PNLIP protein orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein] |
CTD |
PMID:11408251 PMID:11668201 PMID:12381337 PMID:15158758 PMID:19346257 |
|
NCBI chr10:116,545,931...116,567,855
Ensembl chr10:116,545,931...116,567,855
|
|
G |
PNLIPRP2 |
pancreatic lipase related protein 2 (gene/pseudogene) |
decreases activity |
EXP ISO |
orlistat results in decreased activity of PNLIPRP2 protein Orlistat results in decreased activity of PNLIPRP2 protein |
CTD |
PMID:9822688 PMID:17401110 |
|
NCBI chr10:116,620,953...116,645,143
Ensembl chr10:116,620,953...116,645,143
|
|
G |
PON1 |
paraoxonase 1 |
increases activity |
EXP |
orlistat results in increased activity of PON1 protein |
CTD |
PMID:11820148 PMID:17134960 |
|
NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532
|
|
G |
PPARD |
peroxisome proliferator activated receptor delta |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
increases expression |
EXP |
Orlistat results in increased expression of PPARG mRNA |
CTD |
PMID:32347045 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPT1 |
palmitoyl-protein thioesterase 1 |
decreases expression |
EXP |
Orlistat results in decreased expression of PPT1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 1:40,071,461...40,097,252
Ensembl chr 1:40,072,710...40,097,260
|
|
G |
PPY |
pancreatic polypeptide |
multiple interactions |
EXP |
orlistat inhibits the reaction [Triglycerides results in increased secretion of PPY protein] |
CTD |
PMID:15998659 |
|
NCBI chr17:43,940,804...43,944,215
Ensembl chr17:43,940,804...43,942,476
|
|
G |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein] orlistat inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of PRKAA1 protein] |
CTD |
PMID:18390901 PMID:19167487 |
|
NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions increases expression |
EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein] Orlistat results in increased expression of PTEN protein |
CTD |
PMID:32045588 |
|
NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein] |
CTD |
PMID:32045588 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PYY |
peptide YY |
decreases secretion multiple interactions |
EXP |
orlistat results in decreased secretion of PYY protein Orlistat inhibits the reaction [Olive Oil results in increased expression of PYY protein]; Orlistat inhibits the reaction [Triglycerides results in increased secretion of PYY protein] |
CTD |
PMID:15998659 PMID:17138722 PMID:18647814 |
|
NCBI chr17:43,952,733...44,004,445
Ensembl chr17:43,952,733...44,004,469
|
|
G |
RB1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
EXP |
orlistat results in decreased phosphorylation of RB1 protein |
CTD |
PMID:15138278 |
|
NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of RELA mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RPS6 |
ribosomal protein S6 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:32045588 |
|
NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236
|
|
G |
SEC24D |
SEC24 homolog D, COPII coat complex component |
increases expression |
EXP |
orlistat results in increased expression of SEC24D mRNA |
CTD |
PMID:18796435 |
|
NCBI chr 4:118,722,823...118,836,126
Ensembl chr 4:118,722,823...118,838,683
|
|
G |
SKP2 |
S-phase kinase associated protein 2 |
decreases expression multiple interactions |
EXP |
orlistat results in decreased expression of SKP2 protein [orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein |
CTD |
PMID:15138278 |
|
NCBI chr 5:36,152,111...36,193,530
Ensembl chr 5:36,151,989...36,196,849
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
orlistat inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
decreases expression multiple interactions |
EXP |
Orlistat results in decreased expression of SREBF1 protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein] |
CTD |
PMID:32045588 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
TF |
transferrin |
multiple interactions |
EXP |
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] |
CTD |
PMID:33476690 |
|
NCBI chr 3:133,661,998...133,796,641
Ensembl chr 3:133,746,040...133,796,641
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
EXP |
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA |
CTD |
PMID:33476690 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein] Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA] |
CTD |
PMID:15994321 PMID:32045588 PMID:32450208 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
increases response to substance |
EXP |
orlistat results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:18796435 PMID:21406729 |
|
NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of TP53 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
UCP1 |
uncoupling protein 1 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 4:140,559,431...140,568,961
Ensembl chr 4:140,559,431...140,568,961
|
|
G |
XBP1 |
X-box binding protein 1 |
multiple interactions |
EXP |
orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA] |
CTD |
PMID:17283163 |
|
NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597
|
|
|
G |
ALOX5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP |
tert-Butyl Alcohol inhibits the reaction [Calcimycin results in increased activity of and results in increased localization of ALOX5 protein] |
CTD |
PMID:18218859 |
|
NCBI chr10:45,374,216...45,446,117
Ensembl chr10:45,374,176...45,446,119
|
|
G |
CHRNA2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
EXP |
tert-Butyl Alcohol inhibits the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr 8:27,459,756...27,479,261
Ensembl chr 8:27,459,756...27,479,883
|
|
G |
CHRNB4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
EXP |
tert-Butyl Alcohol inhibits the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr15:78,624,111...78,661,641
Ensembl chr15:78,624,111...78,727,754
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
increases expression |
ISO |
tert-Butyl Alcohol results in increased expression of CYP2B10 mRNA |
CTD |
PMID:19760798 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
GABBR1 |
gamma-aminobutyric acid type B receptor subunit 1 |
multiple interactions |
EXP |
tert-Butyl Alcohol inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of GABBR1 protein] |
CTD |
PMID:10683198 |
|
NCBI chr 6:29,602,238...29,633,183
Ensembl chr 6:29,555,629...29,633,976
|
|
G |
GABRA2 |
gamma-aminobutyric acid type A receptor subunit alpha2 |
multiple interactions |
EXP |
tert-Butyl Alcohol promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA2 protein binds to GABRB1 protein]] |
CTD |
PMID:10683198 |
|
NCBI chr 4:46,243,548...46,390,300
Ensembl chr 4:46,243,548...46,475,230
|
|
G |
GABRB1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
multiple interactions |
EXP |
tert-Butyl Alcohol promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA2 protein binds to GABRB1 protein]] |
CTD |
PMID:10683198 |
|
NCBI chr 4:46,993,647...47,426,447
Ensembl chr 4:46,993,723...47,426,447
|
|
G |
GH1 |
growth hormone 1 |
affects folding |
EXP |
tert-Butyl Alcohol affects the folding of GH1 protein |
CTD |
PMID:11064379 |
|
NCBI chr17:63,917,203...63,918,839
Ensembl chr17:63,917,200...63,918,839
|
|
G |
GLRA1 |
glycine receptor alpha 1 |
multiple interactions |
EXP |
tert-Butyl Alcohol promotes the reaction [Glycine Agents results in increased activity of GLRA1 protein] |
CTD |
PMID:10683198 |
|
NCBI chr 5:151,822,513...151,924,851
Ensembl chr 5:151,822,513...151,924,851
|
|
G |
IL2 |
interleukin 2 |
multiple interactions |
EXP |
tert-Butyl Alcohol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein] |
CTD |
PMID:18423386 |
|
NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
tert-Butyl Alcohol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; tert-Butyl Alcohol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:10231168 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
SIRT1 |
sirtuin 1 |
increases expression |
ISO |
tert-Butyl Alcohol results in increased expression of SIRT1 mRNA; tert-Butyl Alcohol results in increased expression of SIRT1 protein |
CTD |
PMID:29134718 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SLC12A2 |
solute carrier family 12 member 2 |
multiple interactions |
ISO |
tert-Butyl Alcohol results in increased oxidation of and results in increased expression of SLC12A2 protein; tert-Butyl Alcohol results in increased phosphorylation of and results in increased activity of SLC12A2 protein |
CTD |
PMID:25817889 |
|
NCBI chr 5:128,083,766...128,189,677
Ensembl chr 5:128,083,766...128,189,677
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
tert-Butyl Alcohol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:10231168 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|